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I  Foreword by the EMCDDA Director
I am proud to introduce the programming document (PD) of the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) for the period 2019–21.
This is the first PD fully grounded in the EMCDDA Strategy 2025 that was unanimously adopted 
by our Management Board in December 2016; therefore, it sets a milestone in our strategic and 
operational planning framework.
At the same time, the document has been prepared at a moment of uncertainty about the 
conditions in which the agency will be operating in 2019–21.
A key influencing factor is the outcome of the fourth external evaluation of the EMCDDA, which 
has been carried out by the European Commission in 2018. The exercise may bring changes 
in the EMCDDA’s remit, which we must be prepared to implement efficiently. For that purpose, 
a strategic analysis of potential consequences on the agency’s mandate will be undertaken 
during this new programming period.
The EU multiannual financial framework for 2021–27 will also be decided in the next two years. 
This entails different possible scenarios for our available resources in the future, for which we 
will need to create the proper conditions to remain fully operational and effective. To that end, in 
2019–21 we will consolidate our internal capabilities, in line with the action areas defined under 
the new strategic business drivers. Developing our human capital will be key to that. Furthermore, 
intelligent and timely investments in our information and communication technology will be 
necessary in order to support the agency’s core business, in particular the drug information 
collection from the Member States, as well as the functioning of more efficient corporate 
processes and tools.
The most significant factor that shapes our work remains, however, the drug phenomenon, 
and this defines our activities under the two strategic goals, focused on health and security. 
The European drug situation is characterised by increasingly diverse consumption patterns 
and ever more sophisticated means of drug production and trafficking. The biggest challenge 
I see therefore is to safeguard the established EU drug monitoring system and further develop 
innovative data collection approaches, such as open source information, wastewater analysis 
or web surveys, as well as working more closely with European research networks and 
collaborations such as the European School Survey Project on Alcohol and Other Drugs (ESPAD) 
group, in order to keep pace with the evolving drug phenomenon, while resources are shrinking. 
In this context, a review of the existing tools will be carried out and a ‘futures exercise’ will take 
place for the first time, to identify future reporting needs.
An ongoing priority will be the implementation, together with our dedicated partners, of the EU 
Early Warning System on new psychoactive substances (EU EWS). In 2019–21 this will take 
place under the new legislative framework which was adopted in October 2017 and which will 
strengthen the role of the EMCDDA in the EWS and the risk assessment mechanism.
A comprehensive overview of new, changing or emerging threats will be provided by the third 
strategic analysis EU Drug Markets Report that will be launched jointly with Europol in 2019. This 
will be followed in 2020 by the second edition of Health and Social Responses to Drug Problems: 
a European Guide, providing a state-of-the-art overview of the responses to drug use and 
consequences across the EU and their effectiveness.
Maximising value from our cooperation with partners, especially with the Reitox network of 
national focal points (NFPs), our main data providers in the Member States, will be key to the 
successful delivery of our services in 2019–21. Two new frameworks will guide our work in this 
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area, namely the Reitox Development Framework, for our activities with the NFPs, and the new 
International Cooperation Framework, for our initiatives with third countries and international 
organisations.
I am fully confident that in 2019–21 the EMCDDA, guided by our Strategy 2025, will successfully 
rise to the challenges ahead, including the uncertainties in our external environment, by 
becoming a more efficient, innovation-driven, and overall robust organisation. This will allow us, 
with support from our partners, to maintain the EU drug information system fit for purpose and 
thereby to strengthen the national and EU preparedness and response to health and security 
challenges posed by drugs.
Alexis Goosdeel 
Director, EMCDDA
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I  List of abbreviations
AHCC Authority authorised to conclude the contract
BCP business continuity plan
BPP Best Practice Portal
CA contract agent
CADAP Central Asia Drug Action Programme
CC candidate countries
CEOS Conditions of employment of other servants of the EU
CEPOL European Union Agency for Law Enforcement Training
CHAFEA Consumer, Health, Agriculture and Food Executive Agency
CICAD Inter-American Drug Abuse Control Commission
CND Commission on Narcotics Drugs
COM Communication Unit
COPOLAD Cooperation Programme between Latin America, the Caribbean and the EU on Drugs 
Policies
COSI Standing Committee on Operational Cooperation on Internal Security
DG Directorate-General
DG HOME Directorate-General for Migration and Home Affairs
DG NEAR Directorate-General for Neighbourhood and Enlargement Negotiations
DG SANTÉ Directorate-General for Health and Food Safety
DRD drug-related deaths (indicator)
DRID drug-related infectious diseases (indicator)
EC European Commission
ECDC European Centre for Disease Prevention and Control
ECHA European Chemicals Agency
EDMR European Drug Markets Report
EDND European Database on New Drugs
EDR European Drug Report
EFSA European Food Safety Authority
ELDD European Legal Database on Drugs
EMA European Medicines Agency
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EMPACT European Multidisciplinary Platform against Criminal Threats
EMSA European Maritime Safety Agency
ENP European Neighbourhood Policy
EPSO European Personnel Selection Office
ERISSP European Reporting Instrument on Sites related to Synthetic Production
ESPAD European School Survey Project on Alcohol and Other Drugs
EU European Union
EU4MD EU 4 Monitoring Drugs project
Euro-DEN European Drug Emergencies Network
EU-ANSA EU Agencies Network on Scientific Advice
Eurojust the European Union’s Judicial Cooperation Unit
Europol the European Union Agency for Law Enforcement Cooperation
EWS Early Warning System
EXO Executive Office
FG function group
FRA European Union Agency for Fundamental Rights
FTE full-time equivalent
GPS general population survey
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HCV hepatitis C virus
HCIN Heads of Communication and Information Network
HDG horizontal working party on drugs
HEA Public Health Unit
HFP heads of national focal points
HIV human immunodeficiency virus
HR human resources
IAS Internal Audit Service
ICT information and communications technology
ICTAC Information and Communication Technologies Advisory Committee
IPA Instrument for Pre-accession Assistance
JHA Justice and Home Affairs
KI key indicator
KPI key performance indicator
MASP multiannual strategic plan
MFF multiannual financial framework
MIS management information system
MoU Memorandum of Understanding
NEWS national early warning systems
NFP national focal point
NPS new psychoactive substances
OAP operational action plan
OSI open source information
PCC potential candidate countries
PD programming document
PDN Performance Development Network
PDU problem drug use (indicator)
PhV pharmacovigilance
PM-P project management programme
PWID people who inject drugs
RA risk assessment
RDF Reitox Development Framework
Reitox European Information Network on Drugs and Drug Addiction
SAS Risks to Public Safety and Security Unit
SCORE Sewage analysis CORe group Europe
SIENA Secure Information Exchange Network Application
SNE Seconded national expert
SOCTA Serious and Organised Crime Threat Assessment
SR Staff Regulations
SWP standing working party
TA temporary agent
TDI treatment demand indicator
UK United Kingdom
UN United Nations
UNAIDS Joint United Nations Programme on HIV/AIDS
UNGASS United Nations General Assembly Special Session
UNODC United Nations Office on Drugs and Crime
VAT value added tax
WA Working arrangement
WHO World Health Organization
WP work programme
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I  Mission statement
Independent, science-based information is a vital resource to help Europe understand the nature 
of its drug problems and better respond to them. It was upon this premise, and in the face of 
an escalating drugs phenomenon, that the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) was established in 1993. Inaugurated in Lisbon in 1995, it is one of the 
European Union’s (EU’s) decentralised agencies.
Building on the EMCDDA’s founding regulation, which was recast in 2006, Strategy 2025 (1) 
defines the agency’s current mission and vision statements.
I Mission
The EMCDDA exists to support evidence-based decisions and actions at EU and national levels 
by providing factual, objective, reliable and comparable information concerning drugs and 
drug addiction, and their consequences. The EMCDDA’s mission is therefore grounded in the 
consensus that sound information is a prerequisite for developing effective policies in the drugs 
area.
I Vision
The EMCDDA’s vision is a healthier and a more secure Europe, achieved through better informed 
drug policy and action.
To do this effectively we must constantly strive to respond to the needs of our key stakeholders, 
who can be defined as:
■■ EU institutions;
■■ national decision-makers/policymakers; and
■■ professionals working in the drugs field.
Beyond meeting the information needs of our key stakeholders, to address our mandate we also 
need to engage with other stakeholders, which include academic institutions and researchers; 
the general public, civil society and those affected by drug problems; and international 
organisations and third countries.
I Values
The EMCDDA is committed to the EU and its values. Beyond these, we have identified a set of 
core values to inform all aspects of our work, inspire our staff in their professional performance, 
inform our future policies and guide our interactions with stakeholders and partners.
Our four core values are:
■■ scientific excellence;
■■ integrity and impartiality;
■■ customer focus and service orientation; and
■■ efficiency and sustainability.
(1) Available at http://www.emcdda.europa.eu/publications/work-programmes-and-strategies/strategy-2025_en
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Section I
General context
I Responding to EU needs in 2019–21
I Introduction
This programming document (PD) covers the period 2019–21. 
The document is fully aligned with the new EMCDDA Strategy 
2025, which was adopted by the Management Board in 
December 2016.
This is reflected in the new structure of the PD: while the 
document has been prepared in line with the provisions of 
Article 32 of the EMCDDA Financial Regulation, and in full 
compliance with the template provided by the European 
Commission (EC) in the guidelines for programming document 
for decentralised agencies, the presentation of the EMCDDA’s 
main areas of work has been entirely reshaped to mirror the 
Strategy 2025 (see Section II, Multiannual programming).
The concrete priorities of work are defined every year within 
these main areas, and they are presented in the annual work 
programme, which is part of the PD. For PD 2019–21, this is 
the 2019 work programme, which is presented in Section III of 
the document.
These annual priorities are embedded in the overall priorities 
defined in the EMCDDA recast regulation, which form the 
bedrock of this PD 2019–21. These are as follows: (a) 
monitoring the state of the drugs problem, in particular using 
epidemiological indicators, and monitoring emerging trends; 
(b) monitoring the solutions applied to drug-related problems, 
providing information on best practices in the Member 
States and facilitating information exchange among them; (c) 
assessing the risks of new psychoactive substances (NPS) and 
maintaining a rapid information system; and (d) developing 
tools and instruments to help Member States to monitor and 
evaluate their national policies, and the EC to monitor and 
evaluate EU policies.
I The role of the EMCDDA
As defined in the EMCDDA Strategy 2025, the agency’s main 
customers are its key stakeholders: the EU institutions (the 
European Parliament, the Council of the EU, the European 
Commission) and the policymakers and practitioners in the 
Member States.
The ultimate purpose of the work performed by the EMCDDA 
is therefore to inform sound decisions in the field of drugs, at 
the level of the EU and its Member States. The results of the 
data collection, monitoring and analysis process provide the 
evidence that policymakers and professionals from across the 
EU need to tackle the drugs phenomenon effectively.
This evidence is communicated by the EMCDDA through 
various means, depending on the needs of its customers. The 
most important means are the products and services that 
the agency provides to them. These are complemented by 
a range of knowledge exchange activities, which include the 
dissemination of best practice as well as capacity-building and 
training initiatives.
I Developments that will shape our work
Dynamic drug phenomenon
As our analyses show, the drug phenomenon is constantly 
evolving. Increasing numbers of overdose deaths, the 
continued availability of NPS and the rising health threat of 
highly potent synthetic opioids are only a few of the issues of 
growing concern, as highlighted by the EMCDDA’s most recent 
annual overview of the drug situation, European Drug Report 
2018: Trends and Developments (2).
New psychoactive substances (NPS/‘new drugs’), in particular, 
remain a considerable public health challenge in Europe. 
Not covered by international drug controls, they encompass 
a broad range of synthetic substances, including cannabinoids, 
cathinones, opioids and benzodiazepines. By the end of 
2017, the EMCDDA was monitoring more than 670 NPS 
(compared with around 350 in 2013). In view of these 
developments, the role of the EMCDDA in coordinating the EU 
Early Warning System on NPS (EWS) has been strengthened 
through the application, from 23 November 2018, of the new 
NPS legislation (see the later section on ‘Key institutional 
developments with an impact on the EMCDDA mandate’).
Innovations in drugs production are occurring in parallel with 
increasing sophistication of drug markets. As shown in the 
(2) Available at http://www.emcdda.europa.eu/publications/edr/trends-
developments/2018
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second joint EMCDDA-Europol strategic analysis EU Drug 
Markets Report (EDMR) (3), which was published in 2016, 
these markets now represent one of the key threats to the 
security of the EU. Use of the internet in this context creates 
particular concern. It provides not only new ways to access 
customers and suppliers, but also opportunities to enhance 
the efficiency and security of offline criminal activities.
A growing issue with a potential impact on drug use in Europe 
is the increasing migration flow into the EU. As presented 
in the first edition of Health and Social Responses to Drug 
Problems: a European Guide (4), which was published by the 
EMCDDA in October 2017, many migrants have lower rates 
of substance use than their host communities, but some may 
be more vulnerable to substance misuse for reasons such 
as trauma, unemployment and poverty, loss of family and 
social support, and the move to a normatively lenient setting; 
furthermore, these factors can be more severe in women and 
girls, as a result of experiences during migration (violence, 
sexual exploitation, loss of family members). These groups 
may be at risk of developing drug problems. There is a need 
therefore to increase awareness of vulnerabilities and reduce 
social exclusion of these people. Monitoring drug use among 
migrant groups may also become necessary in the future, to 
understand the situation and support formulation of adequate 
responses.
As this example shows, the drug problems facing Europe 
are increasingly influenced by developments occurring 
internationally, which makes understanding of the global 
context critical for our strategic analyses of the EU drug 
situation. A further example is the changes in the regulatory 
framework for cannabis that are taking place in parts of the 
Americas, which have generated interest among policymakers 
and the public in Europe. The extent to which developments 
occurring elsewhere are directly transferable to the European 
context is unclear; however, the EU drug monitoring system 
must remain alert to these developments and anticipate 
possible future scenarios.
Within this complex environment, a core challenge for the 
EMCDDA is to ensure that its tools and methods remain fit for 
purpose in relation to the changing nature of the European 
drug phenomenon and accompanying information needs. This 
requires regular review and revision of existing instruments, 
as well as the development of new approaches. Anticipating 
future challenges, thereby allowing the agency to develop 
a long-term plan for instrument development, will require 
investment. The agency also needs to develop more complex 
reporting and analytical models that reflect drug problems 
defined by the consumption of multiple substances, including 
medicines and a rising number of NPS carrying potentially 
(3) Available at http://www.emcdda.europa.eu/start/2016/drug-markets
(4) Available at http://www.emcdda.europa.eu/responses-guide
severe health risks. Furthermore, as mentioned above, the 
European drug problem is more and more linked to, and 
influenced by, global developments. Therefore, it will become 
increasingly important to identify trends and developments 
occurring in neighbouring countries, and internationally, which 
could have an impact on the European situation. In that regard, 
in 2019–21, the EMCDDA will enhance its activities with 
third countries which are a priority for the EU, namely in the 
framework of the European Enlargement and Neighbourhood 
policies, which will include scientific support and capacity-
building activities.
To achieve this, maintaining, consolidating and further 
developing the quality and comparability of the data and 
information collected through the Reitox network of national 
focal points (NFPs) and other sources of information remains 
a central priority for our work. This work will be guided by the 
Reitox Development Framework adopted in December 2017, 
which sets the direction of travel for the Reitox network for the 
period up to 2025, and describes how this will contribute to 
the goals defined in the EMCDDA Strategy 2025. Furthermore, 
to keep pace with developments and the needs of our 
stakeholders, the EMCDDA is committed to identifying and 
using appropriate complementary sources of information to 
keep its knowledge base up to date.
EU drug policy context
The need for factual, objective, reliable and comparable 
information reflects a European consensus that, in a sensitive 
and complex policy area such as drugs, effective actions have 
to be based on evidence of the nature of the problem and 
what has been shown to work, rather than on moral or value 
judgements. Moreover, cooperation, coordination and common 
action are facilitated by comparing, contrasting and sharing 
national experiences.
The EMCDDA is committed to providing the information 
resources necessary to meet these objectives and we are 
proud that, over the past two decades, our work has both 
helped to support the development of a more rational and 
effective approach to drug problems across the EU and 
facilitated a more cohesive policy dialogue on this complex and 
important issue.
In 2019–21, the EMCDDA will make an important contribution 
to implementing EU policy objectives and to providing ongoing 
high-quality expertise to its stakeholders, especially to the 
European Commission, other EU institutions and the EU 
Member States. At European level, the EMCDDA will contribute 
to the implementation of the EU Action Plan 2017–20, as 
required. The agency is also available to provide support to 
the European Commission in the final evaluation of EU Drug 
Strategy 2013–20. Technical support will be also provided, 
PROGRAMMING DOCUMENT 2019–21
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as requested, for reflection on the EU strategy on drugs post 
2013–20.
The EMCDDA, within its mandate and available resources, 
will contribute to European efforts to improve reporting at 
international level. Important developments in this area include 
the follow-up to the 2016 United Nations General Assembly 
Special Session (UNGASS) on drugs and processes towards 
the 2019 global drug policy review, also in view of the relevant 
links with the UN Sustainable Development Goals and support 
to relevant World Health Organization (WHO) strategies in the 
areas of human immunodeficiency virus (HIV) and hepatitis.
In terms of security, the agency will also fulfil the obligations 
arising from the EU Agenda on Security 2015–20 and it will 
contribute, as required, to the EU policy cycle for organised 
and serious international crime 2018–2021, which represents 
the framework within which the EU Member States coordinate 
common priorities and operational action.
Other relevant EU developments
This new programming period will see a change of leadership 
at the level of the EU institutions. In 2019, a new European 
Parliament will be elected and the European Commission will 
also have a new composition. These changes may affect where 
the drug phenomenon is placed on the EU policy agenda.
Another key development is the negotiation for withdrawal of 
the United Kingdom (UK) from the European Union in March 
2019. Although the possible consequences of this withdrawal 
are, to a large extent, currently unclear, some preliminary 
analysis carried out at the level of the agency suggests that, 
should the UK not retain its membership of the EMCDDA, our 
scientific work and operational capacity would undoubtedly be 
affected. The UK is a major contributor of data to the EMCDDA, 
and it also has a large pool of high-quality experts in areas 
relevant to our activities. Finally, the UK departure from the EU 
is expected to bring important financial implications (see the 
point on resources, below).
Key institutional developments with an impact on the 
EMCDDA mandate
In August 2016, the EC presented a legislative proposal for the 
amendment of the EMCDDA founding regulation to strengthen 
the EMCDDA’s role, tasks and procedures for the information 
exchange, early warning system and risk assessment on new 
psychoactive substances (COM(2016) 547 final of 29 August 
2016).
In November 2018, the resulting legislation — Regulation 
(EU) 2017/2101 of the European Parliament and of the 
Council of 15 November 2017 amending Regulation (EC) 
No 1920/2006 as regards information exchange on, and an 
early warning system and risk assessment procedure for, new 
psychoactive substances — will apply, thus replacing Council 
Decision 2005/387/JHA. This new legislation will strengthen 
the EU Early Warning System on NPS and the risk assessment 
mechanism. In addition to new tasks, it will entail shorter 
deadlines for the completion of the core obligations. It will also 
require additional information and new working procedures in 
the operation of the EWS and the risk assessment mechanism.
A key development with a significant impact on this 
programming period is the fourth external evaluation of the 
EMCDDA, which has been carried out by the EC in 2018. 
The purpose of this exercise has been to evaluate the 
agency’s success in implementing the three-year strategy 
and work programme for 2016–18, as well as the previous 
strategy and work programme for 2013–15, and to formulate 
recommendations for the future. The outcome of this external 
evaluation will shape the medium- to long-term work of the 
EMCDDA, including any possible extension of the agency’s 
mandate that may result from this important exercise.
Finally, a mid-term assessment of Strategy 2025 will take place 
in 2020. The exercise will measure the progress made by the 
EMCDDA in reaching the key milestones set up in Roadmap 
2020, and determine if the agency is on track to achieve its 
long-term strategic objectives. The findings of this review will 
inform the new roadmap, to 2025, and reshape, as needed, our 
work during the last year of this new programming period.
Resources
A key element of the implementation of this three-year 
programming document will be the resources available to 
the EMCDDA during this period, and also to our national data 
providers in the Member States. The Communication of the 
European Commission to the European Parliament and the 
Council on the programming of human and financial resources 
for decentralised agencies for 2014–20 (see COM (2013) 
519 final of 10 July 2013) provided a first estimate of the EU 
subsidy planned for the EMCDDA until 2020. Pursuant to this 
information, and without prejudice to the actual decision to 
be taken by the EU budget authority for the adoption of the 
EU annual subsidy to the EMCDDA and the establishment 
plan of the latter, as well as to the possible allocation of 
supplementary resources to cope with new tasks, at this stage 
it is estimated that by 2020 the EMCDDA will operate with an 
EU annual subsidy of around EUR 16 million.
The definition during the 2018–20 period of the next EU 
multiannual financial framework (MFF) for 2021–27 will 
affect the EMCDDA’s resources and activities, as well as the 
operations required for planning and managing the resources 
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available. No clear picture of this new framework was available 
at the time of preparing this PD 2019–21. Planning for 2021, 
the last year of this multiannual programming document, and 
the first year to be covered by the new MFF, has therefore been 
undertaken assuming a relatively stable EU subsidy.
Nevertheless, there is increasing concern that resources at 
EU level, and implicitly the EMCDDA budget beyond 2020, 
could substantially decrease as a result of the UK’s withdrawal 
from the EU. Should this scenario become reality, the 
EMCDDA would need to make important internal changes and 
significantly adjust its planning to cope with the situation.
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Section II
Multiannual programming 2019–21
l  Introduction: the EMCDDA’s strategic approach to 2025
The EMCDDA Strategy 2025 defines two ambitious long-term 
goals: first, to contribute to a healthier Europe and, second, to 
contribute to a more secure Europe. These core goals naturally 
form the two pillars on which the strategy is built: ‘health’ and 
‘security’. They also define the two core areas of work of PD 
2019–21.
Each of the two long-term goals is articulated through four 
strategic objectives (see Figure 1 and Section II, Multiannual 
objectives). These objectives identify at strategic level the main 
areas of focus for taking forward work in each pillar/main area 
of work. They were developed by bringing together an analysis 
of three key factors shaping the EMCDDA’s future work: first, 
the changing nature of the drug phenomenon; second, the 
challenges that these changes bring to our current business 
model; and, third, the implications of these changes for the 
needs of our customers.
FIGURE 1
The EMCDDA strategic approach
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In addition, four business drivers, with their corresponding 
objectives, have been established in Strategy 2025 and now 
form the third main area of work of PD 2019–21. These 
business drivers define the resources and processes that 
the EMCDDA must have in place, and the conditions that the 
organisation has to meet, to achieve our strategic objectives 
and attain our long-term goals. They are therefore core 
elements of our strategic approach because they pinpoint the 
key factors for successful delivery.
The long-term strategic priorities are translated into 
programmatic, operational priorities by means of the EMCDDA 
programming documents, which are prepared by the agency 
and adopted by the EMCDDA Management Board every year.
These PDs are informed by the key milestones set up in 
Roadmap 2020, which guides the medium-term planning 
efforts of the agency. The next roadmap, for 2021–25, will 
be developed and submitted to the Management Board for 
adoption in 2020. By taking stock of the progress made in 
implementing Roadmap 2020, the new roadmap will define the 
remaining key milestones that are necessary to be reached for 
the agency to accomplish its goals and objectives by 2025.
Together, the long-term strategy with its roadmaps, together 
with the PDs, constitute the EMCDDA’s integrated strategic 
and operational framework (see Figure 2). This architecture 
provides the Management Board with the assurance that the 
programming documents are fully grounded in the EMCDDA’s 
mandate and that they contribute to reaching the agency’s 
established long-term organisational objectives.
FIGURE 2 
The EMCDDA’s integrated strategic and operational framework
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l  Multiannual objectives
Core areas Strategic objectives
Health (H) H1. Maintain a state-of-the-art understanding of the extent, patterns and trends in drug use, and their 
impact on public health
H2. Identify new drug-related health threats and support rapid response from the EU and its Member 
States
H3. Support interventions to prevent and reduce drug use, drug-related morbidity, mortality and other 
harms, and support recovery and social reintegration
H4. Support the development, implementation, monitoring and assessment of policies aimed at addressing 
the health and social consequences of drug use
Security (S) S1. Provide a comprehensive, holistic and up-to-date understanding of the drug market in Europe
S2. Identify new drug-related security threats and support a rapid response from the EU and its Member 
States
S3. Improve understanding of the nature and consequences of drug-related crime
S4 Support policy and operational responses to the security challenges posed by drugs and drug markets 
at EU and national level
Business drivers (B) Business objectives
Institutional B1. Anticipate, and respond promptly to, institutional developments and needs
Partnership B2. Strengthen the European drug information system through effective and mutually beneficial 
partnerships and synergies with our data providers, communities of knowledge, and relevant European and 
international bodies
Scientific capacity B3. Have in place the scientific capacity (resources, processes and tools) to meet current analytical needs, 
and innovate to keep pace with changes in the drug situation and the corresponding institutional needs
Management B4. Ensure the optimal organisational structure and supporting processes, to deliver efficient and 
high-quality services
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l Multiannual programme
l Main area 1: Health
Core monitoring
Monitoring work in the health area is focused on two core 
dimensions: the drug situation and the responses to tackle 
it. These two dimensions are interlinked and they feed 
multi-area and cross-indicator analyses. These dimensions 
are complemented by the rapid information collected and 
analysed as part of the early warning and health threat 
assessment component.
Routine monitoring of the drug situation is based on the five 
key epidemiological indicators (KIs): GPS describes prevalence 
and patterns of drug use among the general population; PDU 
focuses on prevalence and patterns of high-risk drug use; TDI 
is the treatment demand indicator; DRD describes drug-related 
deaths and mortality among drug users; and DRID describes 
drug-related infectious diseases. As before, the knowledge 
base provided by the KIs will be supported by the EMCDDA’s 
Reitox NFPs and other networks of experts that contribute their 
national expertise to the agency’s European drug information 
and analysis system.
In the period 2019–21, analysis of the information collected 
systematically by the EMCDDA will be reinforced in the 
areas of both demand and demand reduction. A particular 
emphasis will be placed on multi-indicator analysis, building 
on the work carried out in previous years. The EMCDDA also 
envisages integrating new technologies (e.g. wastewater 
analysis, hospital emergency data, syringe residue analysis) 
into the framework of the general monitoring activities, with the 
purpose of making this monitoring more sensitive and timely.
The data collection efforts of the agency are supported by 
complex online instruments, namely Fonte, our main data 
collection tool; the data warehouse; and the European 
Database on New Drugs (EDND). Another information 
collection tool is the Reitox extranet, which supports the 
reporting by the NFPs of a structured commentary on the 
drug situation (the workbooks). In 2019–21, in addition to 
the ongoing work to maintain these critical instruments, the 
EMCDDA will also initiate a review of Fonte, to ensure that it 
is adapted to the growing demands of the EU drug monitoring 
system managed by the agency.
The EU Early Warning System and risk assessment of 
new psychoactive substances
The EMCDDA has been entrusted with a key role in monitoring 
and responding to NPS. In collaboration with our partners 
at national and EU level, the agency operates the EU Early 
Warning System on new psychoactive substances. This 
mechanism, established by the Joint Action from 1997 
concerning the information exchange, risk assessment and 
the control of new synthetic drugs, will operate in 2019–21 
under Regulation (EU) 2017/2101 of the European Parliament 
and of the Council of 15 November 2017 (5) amending 
Regulation EC No 1920/2006. Further to its adoption by the 
European Parliament on 24 October 2017, this new legislative 
framework started being applied on 23 November 2018, when 
it replaced Council Decision 2005/387/JHA. The EWS will be 
implemented by the EMCDDA and its partners in the Member 
States (the Reitox network) in cooperation with Europol, and 
with the active contribution of the European Medicines Agency 
(EMA), the European Chemicals Agency (ECHA), the European 
Food Safety Authority (EFSA), the European Centre for Disease 
Prevention and Control (ECDC) and the EC.
During 2019–21, in addition to undertaking the legal tasks 
assigned to the EMCDDA under the EU legal framework 
for NPS — which include the operation of the EWS and 
undertaking risk assessments — the work programme includes 
the delivery and integration of the following major systems into 
the EWS:
■■ the European Database on New Drugs — a new electronic 
information, monitoring and reporting system;
■■ open source information (OSI) monitoring system — 
hundreds of multilingual sources;
■■ toxicovigilance system — detects serious adverse events;
■■ signal management system — prioritise; and
■■ risk communication system— strengthens national and EU 
preparedness and response.
New trends and health threats
More generally, threat assessment and rapid reporting are 
likely to play a greater role in our work, reflecting the dynamic 
nature of the modern drug problem and the accompanying 
need for rapid and targeted health responses. Areas of concern 
here include new risk behaviours, outbreaks of drug-related 
infectious diseases or other adverse health events, and new 
consumption patterns with implications for public health. 
Improving capacity in this area requires greater attention to be 
given to the development of multi-source analytical models 
(5) http://eur-lex.europa.eu/legal-content/EN/TXT/
PDF/?uri=OJ:L:2017:305:FULL&from=EN
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and to the use of innovative approaches to identify, track 
and monitor new drug trends. In 2019–21, a new integrated 
framework for threat identification and reporting will be put 
in place, including rapid information assessment tools and 
a communication model for threat identification and rapid 
reporting.
Drug interventions
The EMCDDA also has an important responsibility to act as 
a catalyst for improving the quality and delivery of responses 
to reduce the health and social consequences associated 
with drug use. This requires the agency to keep abreast of 
new prevention, treatment and harm reduction approaches, 
and quality standards for implementation, including improving 
methods for estimating the cost of interventions. To that end, 
in 2019–21 the agency will put a particular emphasis on work 
in the areas of prevention of drug use, infectious diseases 
associated with drug use and drug-related mortality. These 
areas have been identified as having a major impact on the 
health of people in the EU; hence, the EMCDDA is committed 
to scaling up its work, in line with its mandate and within the 
available resources.
In that regard, the agency will continue the successful 
collaboration with its partners, in particular with the European 
Centre for Disease Prevention and Control (ECDC), the 
World Health Organization (WHO) and the Consumer, Health, 
Agriculture and Food Executive Agency (CHAFEA), in the 
prevention of infectious diseases among people who inject 
drugs (PWID). A major focus will be maintained on human 
immunodeficiency virus (HIV) and hepatitis C and B viruses; 
these remain important public health concerns, which have 
significant effects on the lives of individuals and place 
a considerable burden on society overall. By providing data 
for policymaking and intervention planning in the field of 
prevention of infectious diseases among PWID, the EMCDDA 
will help the European Commission in its efforts to support 
implementation of the Sustainable Development Goals, by 
monitoring, reporting and reviewing progress towards their 
delivery in the EU.
Drug prevention is an important topic for the agency, as it 
allows the identification and promotion of factors that can 
potentially reduce drug uptake at an early stage, or at least 
reduce its intensification or prevent escalation to high-risk 
drug use. Activities in this area will be further developed in 
2019–21. This includes providing support to the Member 
States (e.g. via capacity-building activities) and to key EU and 
international initiatives, and further analysis of the contextual, 
cultural and systemic determinants of implementing drug 
prevention. An important task will be the development of the 
databases on interventions in nightlife settings and evidence-
based prevention programmes, as part of the EMCDDA Best 
Practice Portal (BPP).
Facilitating the identification and adoption of best practices 
in drug responses will be an overall priority, which will be 
pursued through the development of practice-focused outputs 
on important topics. The agency will also help to achieve this 
through an improved understanding of what is necessary 
for successful implementation in diverse national contexts 
and settings. In 2019–21, special attention will be given to 
developing resources in areas where drugs have a significant 
impact on European public health, such as hepatitis C and 
overdose deaths. An initiative to encourage the provision of 
hepatitis C testing in drug treatment services was initiated 
in 2018 and will be further implemented in 2019–2020. This 
includes elements of country-level problem mapping, provision 
of best practice models of care and knowledge development.
In 2020, the agency will publish the second edition of Health 
and social responses to drug problems: a European guide (the 
European Responses Guide). Like the first edition, launched 
in 2017, the report will provide a state-of-the-art overview of 
responses to drug use and consequences across the EU and 
their effectiveness, as well as implications for action.
Finally, the EMCDDA will continue to fulfil its role as the 
repository of information on European and national research 
projects. Support to projects will be ensured (within the 
limitations of resources available), links to research findings 
will be provided and annually updated overviews of EU-funded 
and national drug-related research will be made available.
Drug policy
A priority for the agency is to provide support to those who 
define policy at both EU and national levels. In 2019–21 the 
EMCDDA will contribute to the implementation of EU policy 
objectives and to providing ongoing high-quality expertise to 
its stakeholders, especially to the EC, other EU institutions, and 
the EU Member States.
With regard to the EC, this work will mainly involve providing 
support to the Directorate-General for Migration and Home 
Affairs (DG HOME) in the field covered by the agency’s 
mandate, and in cooperation with other Directorates-General 
(DGs) as necessary (e.g. the Directorate-General for Health 
and Food Safety, DG SANTÉ, and the Directorate-General for 
Neighbourhood and Enlargement Negotiations, DG NEAR), 
through timely responses to requests and participation 
in events and EC processes (such as contributions to 
subcommittee meetings with third countries, EC conferences, 
steering groups, working groups, selection committees, 
contribution to the EU progress reports, etc.).
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The EMCDDA will contribute to the implementation of the 
EU Action Plan 2017–20, as appropriate. The agency is also 
available to provide support to the EC in the final evaluation of 
EU Drug Strategy 2013–20, as well as for reflection on the EU 
strategy on drugs post 2013–20. Another priority refers to the 
EU enlargement strategy and the transfer of EMCDDA know-
how. The agency will also continue to contribute to the work of 
the Council’s working groups, such as the horizontal working 
party on drugs (HDG) and support other relevant Council 
events where appropriate and required.
The EMCDDA, within its mandate and available resources, will 
support the European efforts to improve reporting at global 
level. Important developments in this area include the follow-
up to the UNGASS 2016 and processes towards the 2019 
global drug policy review, also in view of the relevant links 
with the UN Sustainable Development Goals, and support to 
relevant WHO strategies in the areas of HIV and hepatitis.
In 2019–2021, the EMCDDA will support policymakers in the 
development of evidence-based and effective drug policies 
through the provision of reliable and state-of-the-art drug 
policy analysis and the development of drug policy evaluation 
tools. This will include the production of briefings and guides 
focusing on cannabis policies, low-tetrahydrocannabinol (THC) 
cannabis products, drug consumption rooms and alternatives 
to coercive sanctions. The cannabis policy alert system and the 
web areas on drug laws and drug policies will also be further 
developed. Over this period, the EMCDDA will prepare an 
Insights publication addressing current and future challenges 
in the prison and drugs field.
The monitoring of national drug strategies, coordination 
mechanisms, public expenditures, policy evaluations, drug 
laws and the drugs and prison field will continue to be 
developed and the legal and policy correspondents network 
will be strengthened. The EMCDDA’s policy evaluation support 
package will be further developed over the 2019–21 period 
and will be able to provide both reactive responses to specific 
requests and proactive capacity-building activities. This 
will include the provision of thematic workshops organised 
around emerging topics of relevance to drug policymakers and 
planners.
The national authorities of the EU will be also provided with 
information about the drugs situation in candidate and 
potential candidate countries (CC and PCC) and countries 
from the European Neighbourhood Policy (ENP) area. Data 
from these countries will be further integrated in some 
EMCDDA outputs and reports, to facilitate a holistic analysis 
and to identify and anticipate threats (see also the business 
driver ‘Partnership’ in the later section of this PD and the 
Annex XII).
l  Main area 2: Security
Drug markets monitoring and identification of new 
threats
The EMCDDA collects routine drug supply data through a set 
of indicators which cover the following areas: drug seizures, 
drug law offences, drug prices, drug purity/potency and 
contents of tablets, drug availability (from population surveys), 
market size estimates, and drug production facilities (data 
collected by Europol). In the previous programming periods, 
these indicators have been revised in line with the Council 
Conclusions on improving the monitoring of drug supply in 
the European Union, adopted in 2013. In 2019–21, the focus 
will be on the continuous improvement of the availability and 
quality of the data provided by the Member States and hence 
of our analysis. A key output will be the third edition of the 
EMCDDA-Europol EU Drug Markets Report (EDMR), which will 
be released in 2019.
Depending on the needs and resources, capacity-building 
activities will be implemented to support the Member States. 
Furthermore, a closer working relationship is envisaged 
between the core data providers — the NFPs — and the 
representatives of the EMCDDA reference group on drug 
supply. Good practices from the Member States in improving 
data availability, in line with the revised supply indicators, will 
be also identified and promoted within the Reitox network of 
NFPs.
In addition to the routine monitoring, and to increase the scope 
and coverage of its analysis, in 2019–21 the EMCDDA will 
further develop new and innovative data collection approaches 
(non-routine sources of data). This will include open source 
information — from both surface-web and darknet markets — 
and key periodical reports issued by the EU or internal 
partners; the results of wastewater analysis; drug-related 
homicide data; information exchange with expert groups or 
individual experts; and EMCDDA-commissioned research (e.g. 
web surveys).
Such monitoring will allow the early identification of emerging 
threats, which once identified will also be tracked closely so 
that an appropriate response can be developed, and we will 
work with our partner Europol on this.
Also under the ‘security’ pillar, the EMCDDA will enhance 
its activities with third countries which are a priority for the 
EU, namely in the framework of the European Enlargement 
and Neighbourhood policies (see also the business driver 
‘Partnership’ in the later section of this PD and Annex XII).
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Understanding the nature and consequences of drug-
related crime
The trade in illicit drugs generates multibillion-euro profits for 
the groups involved in this criminal activity. The EU retail drug 
market is estimated to be worth at least EUR 24 billion a year. 
The immense profits generated from the trade in drugs fund 
various other criminal activities, allowing organised crime 
groups (OCGs) to thrive and develop their criminal enterprises 
at the expense of the health, prosperity and security of people 
living in the EU. The European security agenda highlights 
the need to understand the interactions that exist between 
drug-related crime and the operation of the drug market, on 
the one hand, and other areas of criminality, the activities of 
organised criminal groups and other serious security threats, 
on the other. This is a challenging area and one in which the 
EMCDDA needs to work closely with other European bodies 
with responsibilities in these areas, in particular Europol and 
Eurojust. Although some core monitoring tools exist, overall 
this remains a poorly developed area.
Improving performance in this field is important, however, 
and this was highlighted in the EMCDDA–Europol 2016 EU 
Drug Markets Report, which clearly suggests that threats in 
this area are increasing, in part due to the changing business 
models used by transnational organised crime groups. Europol 
estimates that some 65 % of OCGs involved in the drug trade 
are simultaneously involved in other criminal activities such as 
the trade in counterfeit goods, the trafficking of human beings 
and migrant smuggling. In addition to these major security 
threats, it is important to support the development of a broader 
understanding of the ramifications of the drug market, as 
these can represent significant hidden costs to society. In 
particular, monitoring tools focused on drug-related violence 
and acquisitive crime are needed.
Support EU responses to drug security challenges
One of the main contributions that the EMCDDA makes to 
a more secure Europe is that of supporting the EU policy 
cycle for organised and serious international crime. The 
second policy cycle runs from 2018 to 2021, and so this PD 
dovetails with this period. Therefore, in 2019–21, in line with 
the Council Conclusions on the continuation of the EU policy 
cycle for organised and serious international crime for the 
period 2018–21 (27 March 2017), and under the leadership 
of Europol, the EMCDDA will contribute as required to the 
following actions concerning the two priority areas addressing 
the drug threats identified by the Council of the EU’s Standing 
Committee on Operational Cooperation on Internal Security 
(COSI) (cocaine, heroin and cannabis; and synthetic drugs and 
new psychoactive substances):
■■ provision of methodological, analytical and administrative 
support to the EC for the drafting of the next multiannual 
strategic plan (MASP) (2022–25) and the operational 
action plans (OAPs) for 2020, 2021 and 2022;
■■ implementation of the ongoing MASP 2018–21 and of the 
relevant OAPs (2019, 2020, 2021).
Furthermore, the EMCDDA will prepare and launch, jointly 
with Europol, the 2019 EU Drug Markets Report (EDMR). This 
new strategic analysis will provide a comprehensive overview 
of new, changing or emerging threats, paying particular 
attention to the EU crime priorities decided in 2017. The 
recommendations made in the 2019 EDMR will be acted upon 
in the period 2019–21, and they will inform the 2021 Serious 
Organised Crime Threat Assessment (SOCTA) and influence 
the EU’s priorities in this area.
In 2019–21, the EMCDDA will also contribute as required to 
the EU Drug Strategy 2013–20 and its Action Plan 2017–20 
(the actions related to the supply area), and it will fulfil its 
obligations arising from the EU Agenda on Security 2020.
Transversal work — health and security
While the EMCDDA has clear objectives and priorities in 
each of the two main work areas, health and security, it is 
important to note that the multifaceted nature of the drugs 
problem means that these areas are interlinked and mutually 
complementary.
The agency produces timely and high-quality information, 
together with strategic and situational analyses and threat 
assessments, to inform policy and practice.
In 2019–21 a review of the current European Drug Report 
(EDR) package will be carried out. In 2019 and 2020, the 
agency will work on an updated concept for reporting on 
trends and developments reflecting contemporary needs and 
digital developments. The EDR will be developed as primarily 
an online publication with greater linkage to supporting data 
tables in the Statistical Bulletin, online graphical elements, 
and other web resources and country data. The Statistical 
Bulletin will be revised to provide greater complementarity with 
the EDR and better access to its data. In 2021, this revised 
package will be launched allowing greater synergy between the 
EMCDDA main reporting tools and also improving multilingual 
access and user interactivity.
Smaller, focused analyses based on emerging topics and the 
information needs of various stakeholder groups will be also 
produced and published in 2019–21.
Furthermore, the EMCDDA will produce prompt and focused 
products to immediately disseminate critical information 
relevant to safeguarding public health and security (threat 
assessment reports). These will include (as appropriate) 
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outputs related to the implementation of the applicable legal 
framework on NPS, in particular the EMCDDA initial reports 
and risk assessments; trendspotting case studies/reports; 
and joint analyses (with Europol and the ECDC). Other joint 
products will be produced, as appropriate, based on the most 
relevant topics and exploiting synergies with partners.
l  Main area 3: Business drivers
The success of the EMCDDA Strategy 2025 will rely on its 
capacity to provide stakeholders with services that match 
their evolving needs. This will be possible only if the agency is 
performing optimally, both substantively and operationally.
A set of four business drivers address external and internal 
factors critical for the EMCDDA’s performance: the institutional 
framework, effective partnerships, scientific capacity and the 
agency’s overall management capabilities.
These four business drivers are interlinked and jointly 
contribute to the successful delivery of our services (see 
Figure 3).
Business driver 1 (BD 1): Institutional
The EMCDDA operates in a complex institutional environment 
and its capacity to respond promptly to changing 
developments and needs is therefore a critical requirement for 
optimal performance.
The agency’s three main customer groups are: the EU 
institutions (European Parliament, Council of the EU, European 
Commission); national decision-/policymakers; professionals 
working in the drugs field.
EMCDDA-stakeholder relations are proactive and based on 
cooperation models aimed at generating mutual benefit. 
They have their roots in the agency’s core communication 
values, namely relevance, quality, efficiency, transparency and 
consistency. Understanding needs clearly, communicating 
effectively and using targeted delivery channels are central to 
serving our stakeholders successfully.
In recent years, the EMCDDA has streamlined its product range 
with a view to improving timeliness and offering better access 
to more pertinent information. This work will be continued in 
2019–21, with feedback taken on board from user satisfaction 
surveys and communication performance indicators.
FIGURE 3
The EMCDDA’s business drivers
Institutional Partnership
Scientic capacity Management
	e environment for the successful
delivery of the EMCDDA’s services
Services
Further exploration of the optimal approaches and channels 
for reaching policymakers will be undertaken and will include 
adapting product formats, expanding digital publication 
options, building on the impact of our social media approach 
and implementing a revised language policy.
Future reporting needs will be further identified through an 
EMCDDA ‘futures exercise’, which will lead to appropriate 
follow-up activities (for details, see Main area 1: Health).
As a result of this work, EMCDDA products and services will 
be analysed and adjusted as necessary to ensure that they 
are timely, delivered professionally, in line with the agency’s 
corporate identity, and coherent with our stakeholders’ 
needs. An EMCDDA framework for proactively identifying and 
responding to stakeholders’ needs will be put in place by 2020.
Importantly, during 2019–21 a strategic analysis of potential 
future changes in the EMCDDA Regulation will be carried out. 
This will be informed by the outcome of the fourth external 
evaluation of the EMCDDA (conducted by the EC in 2018), as 
well as by the results of the evaluations of the EU drug strategy 
and action plans.
Furthermore, as of November 2018, the new NPS legislation 
(Regulation (EU) 2017/2101 of the European Parliament and 
of the Council of 15 November 2017 amending Regulation 
(EC) No 1920/2006 as regards information exchange on, 
and an early warning system and risk assessment procedure 
for, new psychoactive substances) applies. This brings new 
responsibilities for the agency.
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Business driver 2 (BD 2): Partnership
The EMCDDA can be the leading EU provider of evidence 
on drugs if we develop our services in partnership with the 
national, European and international actors working in the 
drugs field. Consequently, in 2019–21 the agency will further 
strengthen its cooperation with partners, based on a few 
guiding principles, as follows:
■■ The EMCDDA’s work with partners will be guided by the 
priorities defined in Strategy 2025, and this work will be 
adjusted to reflect evolving EU priorities in the EMCDDA’s 
policy areas and any future changes in the agency’s 
mandate, as appropriate.
■■ In its work with partners, the EMCDDA will act in the 
spirit of transparency and clarity in respect of roles and 
responsibilities, aiming towards obtaining mutual benefit 
and maximising value from cooperation.
■■ Pursuing synergies and contributing to EU added value will 
remain a key driving factor in our activities with partners.
At national level, our key partners are the Reitox NFPs, an 
established network across the 28 EU Member States, Norway 
and Turkey that provides a direct link to national data and 
expertise, and which for more than 20 years has represented 
the backbone of the EMCDDA core monitoring system.
The main priorities of the network are being defined in the new 
Reitox Development Framework (RDF) 2018–25 (adopted 
by the heads of national focal points (HFPs) and presented 
to the EMCDDA Management Board at the end of 2017). The 
RDF will guide the network’s future work, allowing the NFPs to 
maximise their contribution to Strategy 2025. The EMCDDA 
will support the implementation of the RDF, with the aim of 
strengthening the capacity of the NFPs and enhancing their 
performance, both as core data providers for the agency, but 
also as reference points on drugs at national level.
In addition to Reitox, the EMCDDA needs to work directly 
with a number of specialist data providers and research 
collaborations, such as the European School Survey Project 
on Alcohol and Other Drugs (ESPAD) group, the Sewage 
analysis CORe group Europe (SCORE), and the European 
Drug Emergencies Network (Euro-DEN) (see also Main area 1: 
Health).
During 2019–21, existing synergies with EU agencies will 
be further intensified and new ones explored, delivering 
greater value from the joint work and providing the EC with 
an invaluable holistic analysis of the complex and interlinked 
issues in this area. In line with the priorities defined under the 
two strategic pillars, our main partners here are the agencies 
that are active in the health field, such as the ECDC, EMA, 
ECHA, EFSA and CHAFEA; and in the security area, namely 
the agencies from the Justice and Home Affairs (JHA) cluster, 
such as Europol, Eurojust, the European Agency for Law 
Enforcement Training (CEPOL), the European Union Agency for 
Fundamental Rights (FRA) and Frontex.
The EMCDDA will continue to monitor international 
developments and trends, including through strengthening 
information and knowledge exchange with global partners, the 
UN family in particular.
As regards third countries, activities will be guided by the 
EMCDDA International Cooperation Framework (adopted by 
the Management Board in December 2017), which updates 
the EMCDDA Strategy for International Cooperation which had 
been in place since 2007. When engaging in activities outside 
the EU, the EMCDDA will also follow the EU’s global strategy 
for the EU’s foreign and security policy, ‘Shared vision, common 
action: a stronger Europe’.
The EMCDDA has a long tradition of supporting the EC in 
implementing its technical assistance projects and develop 
capacity-building activities in priority third countries — 
especially CC, PCC and countries of the ENP area. During 
2019–21, the agency will complete its sixth project with 
six CC and PCC beneficiary countries funded by the 
Instrument for Pre-accession Assistance (IPA) and will start 
the implementation of the seventh IPA project (planned to 
start in 2019, subject to its approval for funding by the EC). It 
will also fulfil its obligations from the strategy for a ‘credible 
enlargement perspective for and enhanced EU engagement 
with the Western Balkans’ and the related flagships initiatives, 
as well as the EU global strategy for the EU’s foreign and 
security policies.
In the ENP area, the EMCDDA will implement its largest 
technical assistance project so far, EU 4 Monitoring Drugs 
(EU4MD), a major project funded by the EC, covering 15 
third countries (6), with a duration of three years (to be 
possibly extended for one additional year) and a budget of 
EUR 3 million, which will start in 2019 (see also Main area 1 
‘Health’, Main area 2 ‘Security’ and Annex XII). The EU4MD 
project will focus on the areas where the agency’s involvement 
can demonstrate significant added value, in particular: (1) to 
identify, analyse and report effectively on ongoing, emerging 
and future trends in the drug market and their implication 
for security and health; and (2) to increase monitoring and 
response capacity and enhance regional cooperation between 
ENP countries and between these and the EU. Focusing on 
both supply and health areas, the project will support improved 
monitoring of drug markets, the identification of new threats, 
the co-production of practical recommendations to respond 
(6) Algeria, Egypt, Israel, Jordan, Lebanon, Libya, Morocco, Palestine (this 
designation shall not be construed as recognition of a State of Palestine and is 
without prejudice to the individual positions of the Member States on this issue) 
and Tunisia (Southern Partnership); and Armenia, Azerbaijan, Belarus, Georgia, 
Moldova and Ukraine (Eastern Partnership).
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better to existing and emerging drug problems, and the wider 
dissemination of findings to support policies, practice and 
a more informed debate on drug problems in the participating 
countries.
The EMCDDA will also continue bilateral relations with partner 
countries with which the agency has signed Memoranda of 
Understanding (MoU) and working arrangements (WA). Ad 
hoc cooperation with other regions such as Central Asia or 
Latin America and the Caribbean will also continue, mainly in 
the framework of EU-funded projects such as the Cooperation 
Programme on Anti-Drugs Policies (COPOLAD) or the Central 
Asia Drug Action Programme (CADAP).
Business driver 3 (BD 3): Scientific capacity
The multifaceted nature of the drugs situation requires the 
EMCDDA to have both sufficient in-house expertise and 
access to experts working elsewhere to ensure adequate 
scientific capacity for this work. As the information needs of 
the agency are changing, this also implies that it must develop 
expertise in new areas that are required to fulfil its mandate. 
The agency will have to invest more in maintaining an ongoing 
dialogue with the research and scientific community, in both 
the drugs area and related disciplines, such as addiction 
science and criminology.
The EMCDDA’s Scientific Committee is an important resource 
in this respect. As guardian of the EMCDDA’s scientific 
excellence, the Scientific Committee plays a key role in 
assuring and improving the quality of our work. Ongoing 
support will be provided by the agency to ensure that the 
Committee’s work and regular meetings are successful and 
efficient. Furthermore, in June 2018 the Management Board 
decided on the publication, in 2019, of a call for expression 
of interest in membership of the Scientific Committee for the 
mandate 2020–22 and to use the results of this call to appoint 
the new members of the Scientific Committee and to establish 
a reserve list.
Strengthening the quality management of the scientific 
activities is one of the action areas defined in Strategy 2025. 
The ongoing commitment to improving the scientific quality 
of our work is a prerequisite for fulfilling our role as a centre 
of excellence for the collection, analysis and dissemination of 
drug-related information.
The EMCDDA is an information-intensive organisation, 
which bases its core tasks on adding value to data through 
an information value chain. This value chain — the way raw 
data are collected from different information sources and how 
they are stored, analysed and transformed for use in different 
types of information products — forms the framework for data 
quality management at the EMCDDA.
The work towards further implementing and integrating that 
data quality framework into the routine EMCDDA core data 
processes will continue in 2019–21. This will be in line with 
the action plan to follow on the recommendations of the EC’s 
Internal Audit Service (IAS) audits on the management of 
data collection, validation and quality assurance (2017) and 
publications management (2018).
In addition, the development of a project management culture 
at the EMCDDA will ensure a more coordinated and efficient 
allocation and use of scientific resources to produce pertinent 
and cost-effective results (see Business driver 4 for details).
Over the 2019–21 period, the EMCDDA will further strengthen 
dialogue and cooperation with the scientific community and 
centres of excellence in the drugs field. The EMCDDA will 
remain a main partner in the programme and organising 
committees of the Third European Conference on Addictive 
Behaviours and Dependencies, to take place in October 2019, 
and the Fourth European Conference on Addictive Behaviours 
and Dependencies, provisionally planned to take place in 
autumn 2021.
Business driver 4 (BD 4): Management
Optimal performance can be achieved only if it is supported 
by a healthy work environment and by good governance. The 
EMCDDA Strategy 2025 defines the priority actions to be taken 
at a management level to ensure that the organisation has the 
capacity to deliver high-quality services to its stakeholders, 
thereby achieving its strategic objectives.
These actions are focused on ensuring that the new 
organisational structure which was put in place in 2017 is 
fully operational, that the priorities defined in Strategy 2025 
are properly resourced, and that these resources are used 
efficiently. In addition, they aim to ensure that managerial 
performance is adequate at all levels, and that EMCDDA 
staff benefit from a sustainable training and development 
programme.
One crucial element for achieving corporate performance 
is the existence of a reliable planning and performance 
measurement and reporting system. This function will continue 
to play the fundamental role of ensuring that the core elements 
of the new strategy will be transposed to operational level. To 
that end, in 2019–21, the EMCDDA will continue to pursue the 
further development of the performance management system, 
ensuring that it provides senior management with sound and 
more timely performance information and analysis. Among 
other things, this will involve the implementation by the agency 
of the project management programme (PM-P) initiated in 
2018. This includes the application of a project management 
methodology for various areas of work, in line with the key 
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milestones set up in Roadmap 2020, and the implementation 
of a management information system (MIS) to enable more 
efficient planning, monitoring and reporting.
Corporate performance will also rely on effective and efficient 
management of available resources.
The expected definition during the 2019–21 period of the next 
EU MFF, for 2021–27, will influence the EMCDDA’s resources 
and activities as well as the operations required for planning 
and managing available resources. Efficient allocation and 
use of these resources will therefore remain critical. From 
a financial perspective, the objective will be to continue to 
ensure effective and timely planning, monitoring and execution 
of the EMCDDA budget, in line with organisational priorities 
and existing and foreseeable constraints.
The EMCDDA human resources (HR) remain nonetheless 
the agency’s main capital. The 100-plus staff members have 
a very rich professional and cultural background. The EMCDDA 
employs both recognised scientists and valuable specialists 
in various support areas, and all of them contribute to the 
accomplishment of the EMCDDA vision and mission. To 
further develop our human capital and maximise our staff’s 
contribution to Strategy 2025, a staff development programme 
will continue to be implemented in 2019–21.
Ensuring a safe working environment and the efficient use 
of available facilities, equipment, infrastructure and utilities 
will continue to be priorities, with special attention given to 
possible further synergies with our neighbour, the European 
Maritime Safety Agency (EMSA).
In line with the multiannual investment plan approved by the 
internal ICT Steering Committee, the ICT programmes and 
services will be developed and delivered to implement and 
support core business and corporate projects and processes, 
and to provide a continuously stable environment which 
supports existing basic and advanced services.
This is a key component of EMCDDA operations and relies 
heavily on the capacity to collect data through complex 
online instruments, such as Fonte and the EDND, and to 
ensure secure storage of these data in our databases. The 
ICT function is also critical for corporate projects such as 
the management information system (MIS) and the HR 
applications, as well as for the overall business continuity of 
the agency.
l  Human and financial resources outlook for 2019–21
l  Overview of the past and current situation
To fulfil its mission, the EMCDDA needs to stay abreast of the 
rapidly evolving drug phenomenon.
This requires the agency to increase its investments in 
acquiring complementary knowledge and new sources of 
information to keep pace with the innovations appearing 
constantly on an EU drug market that is estimated to be worth 
at least EUR 24 billion a year.
Within this complex business environment, however, the 
agency has for a few years been operating with resources that 
are decreasing in real terms. In terms of EMCDDA financial 
resources, in line with the EC Communication to the European 
Parliament and the Council on the programming of human and 
financial resources for decentralised agencies for 2014–20 
(COM(2013) 519 of 10 July 2013), a significant reduction 
in the budget was instigated in 2014, when the EU subsidy 
provided to the agency was cut by 5 %. This has had a direct 
impact on the EMCDDA’s operations, but also on the subsidy 
provided by the agency to its core data providers, the NFPs in 
the 28 Member States, Norway and Turkey.
In terms of staff, to comply with the abovementioned EC 
Communication, the EMCDDA has reduced the number of 
posts in its establishment plan by 5 %, i.e. from 80 posts 
authorised in 2015 to 76 posts authorised in 2018.
l Resources programming for 2019–21
Financial resources
The outlook for the budget/financial resources over the 
relevant period is built on the scenario resulting from the EC 
Communication to the European Parliament and the Council 
on the programming of human and financial resources for 
decentralised agencies for 2014–20 (COM(2013) 519 of 10 
July 2013), without prejudice to the possible revision of this 
programming and to the need for supplementary resources as 
required to cope effectively with additional and new tasks (see 
below).
The EMCDDA 2019 preliminary draft budget (PDB), as 
adopted by the EMCDDA Management Board in December 
2017, entered EUR 15 596 600 for the EU 2019 subsidy to 
the EMCDDA and provided for 76 authorised posts in the 
establishment plan for 2019. As a result, the EMCDDA 2019 
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PDB reflected an increase of EUR 151 188 in the EU subsidy 
compared to the EMCDDA 2018 budget. The aforementioned 
amount of the EU 2019 subsidy took into account the amount 
indicated for 2019 in the EC Communication COM (2013) 
519 of 10 July 2013 (EUR 15 090 000), as increased (by 
EUR 196 600) in accordance with the financial statement of 
Regulation (EU) 2017/2101 of 15 November 2017 (which 
amended the EMCDDA founding regulation to strengthen the 
role and tasks of the latter for the information exchange, early 
warning system and risk assessment on new psychoactive 
substances). Furthermore this amount encompassed the 
supplementary resources required in 2019 to cope with the 
additional needs and workload entailed by the increased role 
of the EMCDDA for the coordination and the development of 
the activities of the European School Survey Project on Alcohol 
and Other Drugs — ESPAD (EUR 310 000).
In May 2018, within the context of the EU 2019 draft budget, 
the European Commission (EC) proposed an amount of 
EUR 15 286 600 for the EU 2019 subsidy to the EMCDDA, 
while proposing 76 authorised posts in the EMCDDA 2019 
establishment plan (the same number as in 2018). This 
proposal entails a reduction by EUR 310 000 compared to the 
adopted EMCDDA 2019 PDB. This amount corresponds to the 
aforementioned supplementary resources required in 2019 to 
cope with the additional needs resulting from the increased 
role of the EMCDDA for the coordination and the development 
of ESPAD. Compared to the amount of the EU 2018 subsidy, 
the EC proposal for 2019 implies a reduction of EUR 159 000.
The two branches of the EU Budget Authority (Council and 
European Parliament) have endorsed the EC proposal, within 
the context of the EU 2019 budget procedure.
With regard to the above, and without prejudice to the final 
outcome of the EU 2019 budget procedure, the proposed 
EMCDDA 2019 budget enters EUR 15 286 600 for the EU 
2019 subsidy to the EMCDDA and provides for 76 authorised 
posts in the EMCDDA establishment plan for 2019.
Pursuant to the decision already taken by the relevant EU 
authorities, in 2019 the EMCDDA will receive some additional 
funds from the EU budget to be exclusively earmarked (as 
assigned appropriations of the EMCDDA budget) for the 
execution of the ‘EU 4 Monitoring Drugs project’ (see Main 
area 3: Business driver 2 ‘Partnership’ and annex XII ‘Technical 
assistance projects’). The execution of the project is planned 
to start on 1 January 2019 and will cover a period of 36 
months/3 years (to be possibly extended for one additional 
year). The appropriations allocated from the EU budget for the 
execution of the whole project amount to total EUR 3 000 000. 
They are going to be provided to the EMCDDA by annual 
instalments, in accordance with the financing agreement to be 
concluded between the EMCDDA and the EC for this purpose. 
The first instalment (concerning 2019) is expected to amount 
to EUR 1 197 414 and will be entered into the EMCDDA 2019 
budget as assigned appropriations.
Pursuant to the decision already taken by the relevant EU 
authorities, it is expected that in 2019 the EMCDDA will receive 
some further supplementary appropriations from the EU 
budget to be exclusively allocated (as assigned appropriations 
of the EMCDDA budget) to the execution of a new project 
for technical assistance to the beneficiary countries of the 
EU Instrument for Pre-accession Assistance (IPA 7). The 
appropriations to be allocated from the EU budget for the 
execution of the whole project amount to EUR 550 000.
The planning for 2021, the last year of this multiannual 
programming document, and the first year to be covered by 
the new EU MFF expected to operate from 2021, has been 
undertaken assuming a relatively stable EU subsidy. Should 
this assumption not be confirmed, the EMCDDA will need to 
adjust its planning accordingly.
More detailed data are provided in the tables in Annexes I 
and II.
Human resources
New tasks
The most dynamic and rapidly growing area of work for the 
EMCDDA is monitoring and responding to NPS (for details, 
see Main area 1: Health). Most of this work is focused on the 
development, management and coordination of the EWS 
and risk assessments — legal tasks for which the EMCDDA 
has been responsible since 1997. These two major activities, 
along with EU-level control measures, represent the pillars that 
underpin Europe’s response to these new substances, allowing 
the EU and the Member States to rapidly identify, understand, 
monitor and react to the public health and social harms that 
they can cause.
New legislation that strengthens the EWS and risk assessment 
(Regulation (EU) 2017/2101 of the European Parliament and 
of the Council of 15 November 2017 amending Regulation 
(EC) No 1920/2006 as regards information exchange on, and 
an early warning system and risk assessment procedure for, 
new psychoactive substances) was adopted on 24 October 
2017, and replaced Council Decision 2005/387/JHA starting 
from November 2018. The 2005 legal instrument set out well-
defined and tight deadlines for all the tasks covered therein; 
the deadlines imposed by the new regulation are even stricter 
and the times allowed have been reduced by more than half, 
i.e. to two weeks for collecting data from the Reitox national 
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focal points, to five weeks for drafting the initial report and to 
six weeks for preparing a requested risk assessment.
The new regulation allows for the inclusion of a few other 
concrete new tasks, additional information and new working 
procedures in the operation of the EWS and risk assessments.
Growth of existing tasks and additional tasks
As presented above, new tasks have been introduced by the 
legislation now in force in the NPS area. In addition, further 
growth of the existing tasks is expected to occur in this area. 
This is due to the increase in the number and availability 
of NPS appearing on the market. Alongside information on 
the appearance of NPS on the market, a key function of the 
EU EWS on NPS implemented by the EMCDDA and its EU 
partners is to identify signals of serious harms and respond 
as necessary. This requires monitoring each of the 600-plus 
substances that have been reported so far. A growing number 
of reports of serious harms, often related to acute toxicity and 
leading to hospitalisation and deaths, have been processed by 
the EWS in recent years. Since 2005, the EMCDDA has issued 
more than 130 public health alerts, of which close to 75 % 
have been in the past six years. Of great concern in this respect 
is that, during the past two years (i.e. between November 2015 
and November 2017), a record number of 11 risk assessments 
were requested by the Council of the EU (more than one third 
of the total number of risk assessments conducted).
Furthermore, in recent years the EMCDDA has scaled up its 
support to the ESPAD group. This is the largest cross-national 
research project on adolescent substance use in the world; 
it covers more than 40 European countries and provides 
a valuable source of longitudinal data on drug and alcohol 
trends.
Following an agreement endorsed by the EMCDDA 
Management Board in December 2011, the agency has been 
hosting ESPAD coordination since January 2013, and a joint 
EMCDDA–ESPAD work programme was developed in 2014. In 
2015, the Swedish Government addressed a formal request to 
the EMCDDA to fully assume the coordination of the project. 
Though the EMCDDA Management Board and the European 
Commission have acknowledged that the agency is an 
appropriate institutional home for the study, the EMCDDA does 
not have the sustainable financial means to fulfil that role on 
a permanent basis.
Nevertheless, the EMCDDA budget for 2018 provided 
some additional resources for data collection in a number 
of participating countries as well as for coordination tasks 
to support the next ESPAD cycle. This cycle will culminate 
in the 2019 data collection round and the production of 
the subsequent 2020 ESPAD Report; therefore, additional 
budget for the years to come will be required to successfully 
accomplish this important task. However, since the extra 
budget obtained in 2018 for these activities was not provided 
in the EU subsidy for the EMCDDA in 2019, the EMCDDA will 
strive to preserve essential tasks, but will not be able to provide 
full support.
Efficiency gains
As far as efficiency gains are concerned, and as they result 
from the EMCDDA past and present performance in the use of 
assigned resources, the EMCDDA is committed to constantly 
improving the effectiveness and efficiency of its activities and 
to maximising the use of its resources.
In this context, the EMCDDA has pursued action to further 
rationalise and reduce the running costs of its premises, 
namely through measures aimed at reducing energy 
consumption, to offset the impact of the extension of staff 
working time pursuant to the entry into force of the revised 
Staff Regulations (e.g. by installation of solar shading on glass 
areas, climate control switches on windows and an intelligent 
lighting system, or by optimisation of heating and cooling 
cycles at the EMCDDA premises). These measures have 
resulted in a substantial reduction in the energy consumption 
(of about 10 % in 2016 compared with previous years), which 
has been maintained.
Cooperation and synergies with EMSA have been intensified 
beyond those resulting from the implementation of the 
agreement in force between the EMCDDA and EMSA to 
share use of common areas in the compound where their 
headquarters are seated (namely the canteen, underground 
parking and conference facilities). Further cooperation 
and synergies have been developed, in a common effort 
to proactively exploit the opportunities provided by the 
geographical proximity of the two agencies, while safeguarding 
the autonomous legal personality and capacity assigned 
to each agency by the EU legislator. These developments 
concern in particular the joint procurement of shared services 
to increase critical mass and obtain better conditions (e.g. 
for the canteen and cafeteria, travel agency, interim staff and 
medical services), the joint organisation of training activities of 
common interest for the staff of both agencies, and the sharing 
of some services/bodies, such as the EMCDDA medical officer 
and the invalidity and disciplinary committees.
Further EMCDDA–EMSA synergies have been put in place 
in the ICT area, namely sharing infrastructures and costs for 
telecommunications and internet-based services. This has 
brought efficiency gains and savings of around EUR 35 000 
annually.
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Negative priorities/decrease of existing tasks
Starting in its 2014 work programme, the EMCDDA has 
introduced a prioritisation exercise, which is carried out 
annually in the context of the planning exercise. This is based 
on the classification of activities in the work programme across 
three priority levels, from level 1 (L1), the highest priority 
(‘must do’), to level 3 (L3), the lowest priority (see Section III, 
Executive summary). The work programme also sets different 
targets for these different levels: 100 % for L1 outputs/results; 
80 % for L2; and 50 % for L3.
Conclusion on evolution of resources compared to the 
Commission Communication 2014–2020
The EMCDDA considers that it has fully met the goals set in 
the Commission Communication 2014–2020.
The agency will do its best to deal with the growth of tasks 
and needs described above by maximising the use of existing 
resources. The request for necessary supplementary resources 
will target the residual supplementary needs that cannot be 
met through options for redeploying existing resources.
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Section III
EMCDDA work programme 2019
l Executive summary
This is the first annual work programme of the EMCDDA’s 
PD for 2019–21. Its structure mirrors the architecture of the 
EMCDDA Strategy 2025, as presented in Section II above.
The financial resources required for this work programme will 
be provided by the EMCDDA budget for 2019. In accordance 
with the relevant provisions, the EMCDDA budget becomes 
definitive when adopted by the Management Board and after 
final adoption of the general budget of the EU, in which the 
amount of the agency’s subsidy will be fixed. For planning 
purposes, the 2019 work programme has been drafted based 
on the parameters of the 2019 EMCDDA draft budget, taking 
into account the expected outcome of the EU 2019 budget 
procedure. This budget foresees that the EMCDDA will receive 
an amount of EUR 15 286 600 from the EU budget in 2019, 
and 76 authorised posts are assumed in the establishment 
plan for 2019. Should these figures not be confirmed in the 
final EMCDDA budget 2019, adjustments will be required to 
the activities proposed here.
The 2019 work programme applies a prioritisation approach 
for the expected outputs/results, which is based on three 
levels (level 1, L1; level 2, L2; level 3, L3) presented below:
L1 L1 tasks are ‘must do’ tasks, which are time-bound and critical 
for the agency to fulfil its institutional obligations. These tasks 
cannot be scaled down, removed from the work programme 
or postponed to future years without compromising the core 
performance of the agency. 
L2 L2 tasks are necessary to achieve the key commitments and 
fulfil the strategic objectives set out in Strategy 2025. In the 
event of resource constraints generated by external or internal 
factors, however, these tasks could potentially be scaled down 
or delayed without affecting the ability of the agency to deliver 
its L1 results in the current work programme.  
L3 L3 tasks are mostly developmental tasks, or new analyses, 
which are necessary for the agency to maintain an up-to-date 
understanding of the European drug situation in the medium 
term; however, in the event of resource constraints, they could 
potentially be scaled down or postponed without significant 
impact on the ability of the agency to deliver its L1 and L2 
results in the current work programme. Some L3 tasks also 
refer to desirable and valuable activities such as joint 
initiatives with third parties; these appear viable within the 
current planning framework, but could be postponed or 
cancelled if resources prove to be insufficient. 
l Activities
l Main area 1: Health
Goal: Contribute to a healthier Europe
Core monitoring
In 2019, ongoing work will be carried out to ensure annual core 
data collection and management activities. Key to achieving 
this will be the support provided, as required, to the main 
national data providers, the Reitox NFPs in the 28 Member 
States, Norway and Turkey. Central to this core monitoring 
are the five KIs (GPS, PDU, TDI, DRD, DRID). GPS describes 
prevalence and patterns of drug use among the general 
population; PDU focuses on prevalence and patterns of high-
risk drug use; TDI is the treatment demand indicator; DRD 
describes drug-related deaths and mortality among drug users; 
and DRID describes drug-related infectious diseases.
At the same time, the EMCDDA will work towards a new 
conceptual framework for data collection, to be put in place 
by 2020, in line with the roadmap. This will be informed by 
the results of the systemic review, which in turn will be fed by 
the review of the performance of individual tools and the gap 
analysis, which are planned to be carried out during the year.
In this context, the future of Fonte, the main online data 
collection instrument of the EMCDDA, will also be examined 
and preparatory work for a position paper will be conducted.
Analytical work will be further developed to inform key 
EMCDDA outputs, in particular the European Drug Report 
(EDR) package. The 2019 EDR will include the Trends and 
Developments report and the Statistical Bulletin, the repository 
of data for the regular monitoring of illicit drugs. National data 
will be published in the form of 30 online CDRs. A review of the 
EDR package will run in parallel.
Building on the preparatory work carried out in 2018 in close 
collaboration with ESPAD principal investigators, in 2019 the 
agency will be required to coordinate the activities necessary 
for the next round of ESPAD, which is planned to take place 
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during that year. The preparation of the 2019 ESPAD Report 
will also start, for publication in 2020. In addition, the EMCDDA 
will continue to support the development of ESPAD’s web 
presence. The scope of the agency’s work in this area will be 
more limited than initially planned due to the lack of availability 
of additional resources.
Support to EU priority third countries will continue under the 
framework of the technical assistance projects IPA 6, IPA 7 and 
‘EU 4 Monitoring Drugs’. For details, see Main area 3: Business 
driver 2, ‘Partnership’.
The EU Early Warning System and risk assessment of new 
psychoactive substances
In 2019, the EMCDDA, together with its partners in the 
Member States (the Reitox network of EWS correspondents), 
Europol and the EMA, and new EWS partners the ECHA, 
EFSA and ECDC, will carry on ensuring continuous and robust 
implementation of the EWS as provided for by Regulation (EU) 
2017/2101 of the European Parliament and of the Council 
of 15 November 2017 amending the Regulation (EC) No 
1920/2006 as regards information exchange, early warning 
system and risk assessment procedure on NPS which applies 
as of November 2018. The shorter deadlines stipulated by this 
new legislation will ensure even faster responses to emerging 
NPS and the harms associated with them.
In accordance with the new legal framework, the reporting and 
monitoring tools and instruments necessary for implementing 
the information exchange mechanism, including the reporting 
forms, the EWS progress and final reports, and the initial 
report, will need to be automated, interlinked and aligned. 
This will involve close cooperation with Europol. As a result of 
having structured data available, new trends analyses will be 
undertaken to inform the EU and international organisations. 
Adaptation to the new legislative instrument will also entail 
revision of the standard operating procedures, including the 
EWS and risk assessment operating guidelines.
In 2019, the toxicovigilance system will be fully implemented 
and integrated into the early warning systems, including the 
EDND. Coupled with the signal management system and 
risk communication system, this will allow both public health 
alerts and non-urgent information to be issued to the EWS 
network, and specific substances to be placed under intensive 
monitoring.
In addition, during 2019, the EMCDDA will implement and 
integrate the OSI monitoring and analysis system into the 
other EWS components relevant to proactive early detection 
of signals of potential public health relevance, including data 
related to the NPS markets, serious adverse events reported 
through the media, drug user forums, social media, and the 
scientific and medical literature.
Where requested, risk assessments on NPS will be 
conducted under the auspices of the EMCDDA’s extended 
Scientific Committee. This activity carries important resource 
implications and risks associated with the lack of such 
resources. In recent years, this concern has become more 
relevant as a result of the related amount of information 
generated by both the increased number of substances 
monitored and the increased number of reported serious 
adverse events and other harms to health.
Based on the experiences gained during the pilot of the risk 
communication system during 2017, the system will be revised 
as appropriate, and implemented and integrated into the EWS 
during 2019.
Another key task in this area will be to continue to maintain and 
further develop the next-generation replacement of the EDND. 
The EDND is the main information and monitoring system 
of the EU EWS — acting as Europe’s information hub on 
NPS — that allows secure electronic submission of data by the 
national early warning systems (NEWS) as well as advanced 
data management and search functionalities to users. It also 
supports communication and information exchange with 
partners. Building on the work undertaken during previous 
years, by the end of 2019 it is expected that a series of new 
modules will be operational, providing advanced technical 
functionalities to the EDND.
Provisions of Article 28(c) of the pharmacovigilance 
(PhV) legislation will continue to be implemented in close 
cooperation with the EMA, and information exchange and 
cooperation between the two agencies will be further 
strengthened.
New trends and health threats
To improve the timeliness of reporting, it is crucial that new 
and flexible monitoring tools complement the EMCDDA’s 
core monitoring system. In 2019, the agency will therefore 
further develop and strengthen its system for monitoring and 
understanding new and emerging trends in drug use and drug 
markets.
To that end, the EMCDDA will continue key activities aimed 
at better integrating new methods and tools within existing 
monitoring routines. This will include the publication of 
findings from two innovative projects, namely the 2018 SCORE 
(Sewage analysis CORe group Europe) wastewater monitoring 
campaign and the 2018 ESCAPE syringes project.
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Monitoring hospital emergencies data will also be further 
developed and the geographical coverage of the data will be 
improved. This will mainly involve consolidating and enlarging 
the sentinel European Drug Emergencies Network (Euro-DEN), 
making best use of the data provided by the workbooks, and 
carrying out cross-indicator analyses with the DRD indicator.
As regards the health threat assessment activities, 
rapid information assessment tools will be piloted and 
a communication model for health threat identification and 
rapid reporting will be conceptualised. These two elements 
will be part of the new integrated framework for threat 
identification and reporting, which is planned to be put in place 
by 2020.
Equally important are the EMCDDA’s joint risk assessments 
on emerging threats, including close collaboration between 
the EMCDDA and ECDC on the monitoring of all incoming 
information on the evolution and epidemiology of drug-related 
infectious diseases and outbreaks.
Drug interventions
Together with drug policymakers, professionals working in 
the drugs field are key EMCDDA customers. Activities in this 
area will thus be directed towards this important group. They 
will include identification and dissemination of best practice, 
training, production of targeted outputs and tools, and 
knowledge sharing via conferences and other practice-oriented 
events.
Identifying best practice and effectiveness of interventions 
across the EU and beyond is a key area for the EMCDDA, the 
main dissemination channel of which is the Best Practice 
Portal. In 2019, existing modules will be kept updated 
and new modules will be added, building on the thematic 
approach developed for the 2017 European Responses Guide. 
In addition, focused outputs will be developed to support 
practice on key areas. Better integration of criminal justice-
related issues such as alternatives to coercive sanctions and 
responding to drug problems within a prison setting will be 
pursued, further to the conceptualisation exercise conducted 
in 2018. In the prevention area, the BPP platform is being 
extended to include identification of effective programme 
examples. To that end, the databases on interventions in 
nightlife settings (Healthy Nightlife Toolbox) and the Xchange 
registry on evidence-based prevention programmes will be 
maintained and updated with new entries.
Another effective means of disseminating best practice is 
through training activities. These will include training for 
professionals, including Reitox academies in EU Member 
States and third countries, and adaptation of internationally 
developed training materials carried out in cooperation with 
other partners, e.g. in academia.
In 2019, the EMCDDA will continue to promote good practices 
in harm reduction including the integration of evidence-based 
practices, interventions and policies into routine health-care 
and public-health settings. Additional information resources 
will be developed and provided including practice-focused 
outputs on topics where innovations are becoming available 
or where the knowledge base is changing rapidly. The web 
resources will be further developed in areas of particular 
importance for public health, such as hepatitis C.
A significant effort will be invested in the preparation of the 
second edition of Health and Social Responses to Drug 
Problems: a European Guide, planned for publication in 2020.
Drug policy
The EMCDDA’s main institutional customers are its key 
stakeholders: the EU institutions and the EU Member 
States. These EU and national policymakers will be provided 
with technical support in areas covering both health and 
security aspects of the drug policies and initiatives. These 
two elements, which define the core pillars of the EMCDDA 
Strategy 2025, are closely interlinked in all aspects of the drug 
phenomenon, particularly so where policy development is 
concerned. While the EMCDDA support provided to general 
and health-related policy issues is presented here, the support 
provided to the security aspects of drug policies is presented in 
Main area 2: Security — Strategic objective S4.
At the level of EU institutions, in 2019 the agency will further 
support sound policymaking through high-quality technical 
input to requests, events, processes and relevant institutional 
meetings, as appropriate and when required. In particular, 
support will be provided to Romania and Finland, the hosts of 
the EU Presidency during 2019. Of particular importance is 
our responsibility with respect to the EU Drug Strategy and the 
Action Plan 2017–20 (an activity which is also important for 
the other pillar of our strategy). The EMCDDA will contribute 
to the implementation of the EU Action Plan 2017–20, as 
appropriate. The agency will be available in 2019 to provide 
support to the EC in the final evaluation of EU Drug Strategy 
2013–20, as well as for reflection on the EU strategy on drugs 
post 2013–20, if requested.
The EMCDDA will also provide technical support, upon 
request, to the EU institutions and the Member States for their 
activities in international fora (e.g. at UNGASS and the CND). 
Important developments in this area include the follow-up to 
the UNGASS 2016 and the process leading up to the UN 2019 
global policy review.
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In 2019, the EMCDDA will continue to provide reliable and 
timely drug policy analysis through a range of policy-relevant 
outputs. The policy alerts system will be further developed to 
better meet policymakers’ needs; as part of this system, the 
agency will continue to monitor news alerts related to policy-
relevant cannabis topics, analyse them, and produce and 
publish targeted messages and brief objective summaries. 
Furthermore, the agency will continue to produce high-level 
briefings and guides aimed at answering a wide range of 
policy-relevant questions in the fields of cannabis regulatory 
models, low-THC products and drug consumption rooms. In 
addition, the EMCDDA will prepare an Insights publication on 
addressing current and future challenges in the prison and 
drugs field (for publication in 2020).
In 2019, the EMCDDA will continue to monitor national drug 
strategies, public expenditure, coordination mechanisms 
and policy evaluations. Ongoing monitoring of drug laws will 
be also carried out, with a focus on emerging issues (e.g. 
cannabis, NPS), allowing the agency to proactively identify 
emerging drug policy trends. This will feed the policy alerts 
system implemented to inform EU and national policymakers 
in a prompt manner.
The European Legal Database on Drugs (ELDD) will be 
regularly updated and the annual meeting of the legal and 
policy correspondents will be organised, as way of further 
improving the sharing of knowledge and expertise among 
Member States. Topics addressed during the meeting will 
be driven by the pertinent needs of Member States or the 
EMCDDA, so as to maximise the practical value to the network 
as well as the agency.
The EMCDDA will continue to provide support to national drug 
policy evaluations in 2019, including both reactive responses 
to specific requests and proactive capacity-building activities. 
Thematic workshops will be organised around important 
emerging policy trends and the policy evaluation workshops, 
started in 2018 will be followed up proactively.
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Strategic objective H1:
Maintain a state-of-the-art understanding of the extent of drug use, its patterns and trends and their impact on public health
Expected outcomes
■■ Implementation of core monitoring tools optimised and new processes for monitoring drug demand developed, to respond to the needs of 
contemporary drug patterns
■■ Comprehensive understanding of the EU drug situation through improved quality and availability of data
■■ Improved ability to capture the developments in the international drug situation
KPIs
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA monitoring system
7. Work programme delivery
8. Efficient implementation of the technical assistance projects with third countries
9. Uptake of the EMCDDA evidence (knowledge) through a number of channels
10. Uptake of the EMCDDA evidence/knowledge by policymakers
Action areas Outputs/results
H1.1. Strengthen the core monitoring 
system: (a) critically review and develop, as 
needed, the data collection tools to ensure 
they remain fit for purpose; (b) support 
national reporting capacity necessary for 
routine reporting
■■ Annual core data available to inform analysis and outputs:
 – incoming data validated and processed in a timely manner (L1)
 – annual reporting package 2020 adopted by the NFPs (L1)
 – established reporting tools maintained and further developed (L2)
 – activities to support NFP data collection efforts, including quality assurance and appropriate 
follow-up to the 2018 five KI assessment exercise (L2)
■■ Annual overview of the European drug situation
 – European Drug Report 2019 (L1)
 – Statistical Bulletin 2019 published on the EMCDDA website (L1)
■■ 30 Country Drug Reports (web-based) (L2)
■■ Review of performance of individual reporting tools and gaps analysis (L1)
■■ Systemic review of tools (L1)
■■ Analysis of patterns, trends and consequences of drug consumption in Europe and related outputs 
(L2 or L3, as appropriate):
 – prevalence, incidence, estimates and trends of different forms of drug use (including general 
population and high-risk use estimates, and drug use among different groups and in different settings)
 – reporting and analysis of the main harms caused by or associated with the use of illicit drugs, 
and their public health impact at individual, community and population levels
 – multi-source and transversal analysis conducted to support products and services
 – polydrug use integrated into routine analysis
■■ Data submission and analytical expert meetings organised (L2)
■■ ESPAD data collection implemented (activities resource dependent):
 – support to the creation of a unified dataset (dependent on the completion of national data 
collection) (L2)
 – support to the preparation of the ESPAD Report (release in 2020) (L2)
■■ Data management tools (Fonte, data warehouse) operational:
 – Fonte and drugs data warehouse maintained to support the annual drugs data collection and 
analysis (L1)
 – preparatory work for a position paper on the future of Fonte (to be finalised in 2020) (L2)
H1.2. Identify and develop new flexible and 
timely monitoring tools and approaches to 
ensure the monitoring system reflects 
contemporary drug patterns and their 
implications for public health
■■ Results from the European Web Survey on Drugs disseminated — EMCDDA Insights drafted (for 
publication in 2020) (L2)
■■ Feasibility assessment of improving sensitivity and coverage of existing indicators (particularly 
DRID and DRD) in the context of changing patterns of drug use (L2)
■■ Analysis of the role of drug consumption rooms in monitoring new risk behaviours and market 
changes (outcome of the 2018 EMCDDA expert meeting) (L2)
■■ Feasibility assessment of extending monitoring activities to new settings or groups (e.g. cities, 
marginalised groups) (L3)
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Action areas Outputs/results
H1.3. Better understand the implications 
for public health of the developing 
international drug problem, with special 
attention to the countries bordering the 
European Union, and within the agency’s 
mandate
■■ National information maps of CC and PCC updated (L2)
■■ Updated Country Drug Reports for interested CC and PCC (L3)
■■ New datasets on drug-related issues produced in the CC and PCC (L3)
■■ ‘EU 4 Monitoring Drugs’ project outputs (Health area), in line with project logframe (L2)
■■ Exchange of information on emerging drug issues maintained and developed with monitoring 
centres outside the EU — topics here could include the resurgence of opioid misuse (prescription 
and other) and legislation on cannabis (L3)
H1.4. Identify future reporting needs 
through a ‘futures exercise’ and 
appropriate follow-up activities
■■ Draft technical report and supporting materials available (L2)
■■ Technical review at Lisbon Addictions 2019 (L2)
■■ Preparatory work for the 2020 policy workshop (L2)
Strategic objective H2:
Identify new drug-related health threats and support rapid response from the EU and its Member States
Expected outcomes
■■ Effective implementation of the EU Early Warning System on new psychoactive substances (EWS) and the EU risk assessment mechanism on 
NPS
■■ Health-related emerging trends and threats captured and reported in a timely manner
■■ Increased capacity of the EU and its Member States to rapidly respond to new drug-related health threats
KPIs
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA monitoring system
4. Implementation of the EWS and risk assessment mechanism on NPS
7. Work programme delivery
8. Efficient implementation of the technical assistance projects with third countries
9. Uptake of the EMCDDA evidence (knowledge) through a number of channels
10. Uptake of the EMCDDA evidence/knowledge by policymakers
Action areas Outputs/results
H2.1. Ensure the successful operation of 
the EU Early Warning System on new 
psychoactive substances (EWS)
■■ EWS and information exchange mechanism (supporting tools, processes and activities) operating 
under the new legal basis in place in 2019:
 – ongoing management of the EWS and information exchange mechanism, in compliance with the 
provisions of the applicable legislative framework (L1)
 – guidelines (procedures, processes and tools) relative to the EWS progressively adapted to the 
new legislative framework and implemented (as required) (L1)
 – initial reports prepared as required (L1)
 – EDND maintained and regularly updated (L1)
 – EDND infrastructure upgraded to reflect new reporting needs (L1)
 – EWS progress and final reports (L2)
■■ Annual meeting of the EWS network (L2)
■■ Toxicovigilance system, signal management system, OSI monitoring system and risk 
communication system implemented and integrated into the EWS (L2)
■■ Technical support to national early warning systems (NEWS) and forensic and toxicological 
networks (L2)
■■ Further develop OSI monitoring for EWS purposes (L2)
■■ Dissemination of knowledge on NPS, through publication of updates and issues in focus, 
organisation of, and participation in, scientific and technical events (L2)
■■ Sixth International Conference on Novel Psychoactive Substances (L2)
■■ Data exchange with international bodies (UNODC/SMART and WHO Expert Committee on Drug 
Dependence) to support prioritisation, scheduling discussions and information exchange activities 
(L2)
■■ Support to building EWS in third countries:
 – national EWS assessed in interested CC and PCC (L2)
 – national EWS profiles of interested CC and PCC published (L3)
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Action areas Outputs/results
H2.2. Ensure timely and high-quality 
implementation of the risk assessment on 
NPS
■■ RA mechanisms (supporting tools, processes and activities) operating under the new legal basis in 
place in 2019:
 – risk assessment reports prepared as required (L1)
 – guidelines, procedures, processes and tools relative to the risk assessment progressively 
adapted to the new legislative framework and implemented (as required) (L1)
■■ Effective information exchange with EMA, including formal notifications and public health-related 
risk communications, and responses to formal information requests, in line with Article 28(c) of the 
EU pharmacovigilance legislation (L1)
H2.3. Develop innovative approaches to 
identifying and reporting on new trends, 
and enhance the EMCDDA’s capacity for 
timely data collection and analysis
■■ Analysis of results of Euro-DEN network on hospital emergencies, focused on trends by 
substances, including NPS (L2)
■■ Findings from the 2018 SCORE wastewater monitoring campaign published (L2)
■■ Findings from the 2018 ESCAPE syringes project published (L2)
■■ Further integration of OSI data in core EMCDDA monitoring (L2)
■■ Feasibility studies of innovative future approaches for monitoring new drug trends (e.g. pill testing, 
hair testing) (L3)
H2.4. Conduct threat assessments and 
rapid reporting exercises of new drug-
related health threats in order to facilitate 
appropriate responses (in collaboration 
with partners, as appropriate)
■■ New integrated framework for threat identification and reporting in place (health pillar elements):
 – EU trendspotter studies prepared and national trendspotter studies supported as required (L2)
 – communication model for threat and rapid reporting conceptualised (for finalisation in 2020) 
(L2)
■■ Cooperation with ECDC, including risk assessment country missions in the EU Member States, 
upon request (L2)
■■ In-depth assessment of drug-related harms and responses (based on needs and resources) (L2)
■■ Publish and channel results of threat assessments and rapid reporting on health threats to 
interested groups (e.g. through alert services) (L2)
Strategic objective H3:
Support interventions to prevent and reduce drug use, drug-related morbidity, mortality and other harms, and support recovery and social 
reintegration
Expected outcomes
■■ Optimisation of tools to monitor drug interventions (established and new)
■■ Better and more informed policy and practice on effectiveness of interventions in drug demand reduction within the EU
■■ Increased availability of effective interventions to prevent and reduce drug use, drug-related morbidity, mortality and other harms
KPIs
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA monitoring system
7. Work programme delivery
9. Uptake of the EMCDDA evidence (knowledge) through a number of channels
10. Uptake of the EMCDDA evidence/knowledge by policymakers
Action areas Outputs/results
H3.1. Follow developments from basic 
research, applied research and 
implementation science to maintain 
state-of-the-art understanding of what 
constitutes effective interventions to both 
established and emergent drug-related 
problems
■■ BPP kept updated with new contents (L1)
■■ BPP — Evaluation Instruments Bank revamped and updated (L2)
■■ BPP — inventory of standards and guidelines revamped and updated (subject to resources) (L2)
■■ New toolbox introduced to support programme implementation for specific settings and target 
groups (L2)
■■ BPP interface improved to increase integration with other response topic areas and offer greater 
accessibility (L2)
■■ Tools for self-accreditation of quality standards collected (L2)
■■ Selected minimum quality standards operationalised (L2)
■■ Model approach for estimating the cost of providing drug-related health interventions, including 
European adaptation of toolkits for practice, developed (L2)
■■ Develop work in the area of treatment outcomes (L3)
PROGRAMMING DOCUMENT 2019–21
33 / 80
Action areas Outputs/results
H3.2. Strengthen, maintain and develop 
the monitoring tools required for describing 
the delivery of drug-related interventions: a) 
in established areas and settings; b) in new 
settings and developmental areas
■■ Reporting tools maintained and developed, for established areas (see objective H1 — Action area 
H1.1) (L2) and for new settings and developmental areas (e.g. naloxone, hepatitis C treatment, work 
places) (L3)
■■ Data analysis (state-of-the-art monitoring necessary for European-level assessment of the 
responses to the drug situation) (L2)
H3.3. Facilitate knowledge transfer, the 
adoption of best practice, and successful 
implementation, by developing state-of-
the-art resources for professionals and 
supporting and developing training and 
capacity-building activities
■■ State-of-the-art review of new challenges and opportunities for responding to drug problems 
(second European Responses Guide) in preparation (for publication in 2020) (L1)
■■ Reitox academies on selected practice topics implemented for the Reitox network and selected 
third countries, in line with resources (L2)
■■ Capacity development activities implemented for ‘EU 4 Monitoring Drugs’ beneficiaries, in line with 
project logframe (L2)
■■ European Drugs Summer School (L2)
■■ Knowledge transfer activities (e.g. face-to face workshop, online webinars) for selected 
interventions (L2)
■■ Appropriate follow-up of the Council Conclusions on minimum quality standards (L2)
■■ Databases on interventions in nightlife settings (HNT), club health and the Xchange registry on 
evidence-based prevention programmes maintained and updated with new entries (L2)
■■ EMCDDA contribution to key drug-related events to support practitioners (L2)
■■ Implementation of the second year of the multiannual harm reduction initiative (L3)
■■ Universal Prevention Curriculum adapted for European professionals in collaboration with key 
partners (L3)
■■ Comparative analysis of access, quality and prevention of diversion of opioid substitution treatment 
in Europe (L3)
■■ Analysis of practices of post-mortem toxicology of drug-related cases in Europe (L3)
H3.4. Provide additional information 
resources to support decision-making and 
programme development in areas 
particularly important for public health, or 
where innovations are becoming available 
or the knowledge base is rapidly changing 
(such as hepatitis C treatment, overdose 
prevention, new pharmacotherapies, 
e-health and interventions targeting 
hard-to-reach populations) or where new 
evidence reviews have become available
■■ Practice-focused outputs (L2 or L3, as appropriate)
■■ EMCDDA hepatitis C resource web pages available and maintained (L2)
■■ Existing and new consumer protection models (e.g. drug-checking models, their legal frameworks, 
risk communication strategies and protocols, or harm reduction models for cannabis users) 
identified and described (L2)
■■ Web resources on drug-related research updated (L2)
■■ Responses to emerging drug trends (e.g. NPS, chemsex) identified and communicated (L3)
■■ New technologies in the field of healthcare provision to drug users, specialists and non-specialists 
(e.g. e-learning, m-health) identified and communicated (resource dependent) (L3)
Strategic objective H4:
Support the development, implementation, monitoring and assessment of policies aimed at addressing the health and social consequences of drug 
use
Expected outcomes
■■ Optimisation of tools to monitor drug policies and legislation
■■ Increased capacity of EU and national policymakers to address the health and social consequences of drug use, with evidence provided by, and 
support from, the EMCDDA
KPIs
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA monitoring system
7. Work programme delivery
9. Uptake of the EMCDDA evidence (knowledge) through a number of channels
10. Uptake of the EMCDDA evidence/knowledge by policymakers
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Action areas Outputs/results
H4.1. Support as requested EU and 
national policy initiatives within the 
EMCDDA’s areas of competence, with 
particular attention given to the 
implementation of the EU drug strategy 
and its action plans
■■ Input to EU institution-related activities within established priorities and available resources:
 – support EU institutions related activities in the area of drug policy (HDG — horizontal working 
party on drugs, NDC — national drug coordinators, etc.) (L1)
 – support the EU in is policy dialogue with international bodies and third countries (L1)
 – support the implementation of the 2017–2020 EU Drug Action Plan (L1)
 – support final evaluation of the EU Drug Strategy 2013–2020 (L1)
 – support other policy initiatives within areas relevant to the EMCDDA (L2)
 – data exchange and technical cooperation with the UN system and appropriate technical 
backstopping to support the EU in external dialogues with international bodies and third 
countries (L2)
■■ Input to Member States-related activities within established priorities and available resources (L1)
■■ EMCDDA contribution to key drug-related events to support policymakers (L2)
H4.2. Monitor and report on key policy 
developments, occurring nationally, at EU 
level and internationally, to facilitate an 
informed and up-to-date dialogue
■■ Data collection system in place to ensure optimum EMCDDA data available for reporting for 
evaluation of 2017–2020 EU Drug Action Plan and EU Drug Strategy 2013–2020 (L1)
■■ Reporting tools in the policy area maintained and further developed for established areas (legal 
framework, national drug strategies, evaluation, coordination, public expenditures, prisons) (L2)
■■ Reporting tools in the policy area set up and improved for developmental areas (e.g. alternatives to 
coercive sanctions) (L3)
■■ Policy and law web areas maintained and regularly updated (L2)
■■ Policy alert system further developed (L2)
■■ Q and A policy briefings and guides (L2 or L3, as appropriate)
■■ In-depth review on current and future challenges in the prison and drugs field (EMCDDA Insights) 
prepared (for publication in 2020) (L2)
■■ Annual meeting of the legal and policy correspondents organised (L2)
■■ Thematic workshops organised around emerging trends in drug policies (L3)
H4.3. Maintain and develop resources to 
support policy formulation and evaluation 
(in close coordination with the support to 
policy provided in the supply area)
■■ Portfolio of tools and services to support policy development, implementation and evaluation in the 
Member States and priority third countries:
 – support provided to national drug policy evaluations, if requested and within available resources 
(L2)
 – workshop organised for national policymakers and planners on policy evaluation approaches 
(L2)
Resources necessary for the implementation of the activities  
in this area (7)
Budget (EUR) Human resources (FTE)
5 190 688.51 37.4
(7) This does not include the resources covered by the technical assistance  
projects with third countries (assigned appropriations).
PROGRAMMING DOCUMENT 2019–21
35 / 80
l Main area 2: Security
Goal: Contribute to a more secure Europe
Drug markets monitoring and identification of new threats
The drug-related market in Europe is continuously evolving, 
and providing a comprehensive understanding of this market 
requires ongoing effort to improve our core monitoring 
system, but also to modernise our data collection approaches. 
Importantly, the agency must keep abreast of developments 
in the international drug situation, for example cocaine 
production in Latin America, or heroin production and 
trafficking in Asia and in the Middle East, which have a direct 
impact on the EU drug phenomenon.
To that end, in 2019, work on improving the quality and 
availability of supply data will continue, in close collaboration 
with our data providers at national level and partner Europol.
A large amount of effort will go into preparing the launch of the 
third joint EMCDDA–Europol EU Drug Markets Report and its 
supporting digital information package. This will be a leading 
publication of the EMCDDA in 2019, building on the success of 
the previous two editions, published in 2013 and 2016.
In terms of new sources of data and innovative monitoring 
approaches, the agency will further develop its capacity for 
OSI monitoring, in particular of drug supply on the rapidly 
developing and dynamic darknet markets.
Concerning activities to monitor developments outside the 
EU, in 2019 the EMCDDA will enter the operational phase of 
the project ‘EU 4 Monitoring Drugs’, which aims to help 15 
ENP countries identify external drug-related threats (details 
to be provided at a later stage). Furthermore, similar to the 
work carried out under the health pillar, the EMCDDA will 
continue to support the transfer of its monitoring tools and 
methodologies to CC and PCC, on security-related issues, as 
well as gradual integration of supply-related data from these 
countries in EMCDDA publications, as the quality improves. 
This knowledge transfer will be undertaken in the framework 
of the technical assistance projects funded by the EC (namely 
IPA 6 and IPA 7 — subject to the approval of funding) and in 
line with the EMCDDA International Cooperation Framework 
adopted by the Management Board in December 2017 (see 
also Main area 3: Business driver 2, ‘Partnership’).
Identifying new drug-related security threats and transmitting 
this information rapidly so that appropriate responses can be 
developed is a key requirement if Europe is to keep pace with 
the growing security challenges emerging in this area. Threat 
assessments and ad hoc briefings on important security topics 
will be conducted in close collaboration with Europol. These 
will be self-initiated, at the request of stakeholders, or in the 
framework of the EU policy cycle for organised and serious 
international crime.
Understanding the nature and consequences of drug-
related crime
One of the strategic objectives of the EMCDDA in this area 
is to improve understanding of the drug-related crime 
phenomenon. This is a developmental area, and progress will 
be incremental and dependent on the availability of resources. 
In 2019, and following up on the knowledge gaps identified 
in the EU Drug Markets Report 2016, the agency will develop 
a framework for monitoring drug-related homicide and pursue 
synergies with partners (e.g. Eurostat) to improve our data 
collection in this area. The EMCDDA will also analyse links 
with other crime types, such as illegal firearms and terrorism, 
and study the societal impact of drug crime. The development 
of an EU-level model for estimating the costs associated 
with decontaminating the environment after the dumping 
of chemical waste from drug production activities is also 
foreseen.
Support EU responses to drug security challenges
In the EU policy area, the EMCDDA will contribute as required 
to the two priority areas addressing the drug threats set by the 
Standing Committee on Operational Cooperation on Internal 
Security of the Council: cocaine, heroin and cannabis; and 
synthetic drugs and new psychoactive substances. Specifically, 
the agency will provide methodological, analytical and 
administrative support to the EC for the drafting of the OAP for 
2020, and will implement its tasks under the OAP 2019.
This contribution will include the delivery of training for law 
enforcement in partnership with CEPOL and Europol, in line 
with the EU Strategic Training Needs Assessment, carried out 
by CEPOL. This knowledge transfer element is a key added 
value at EU level. In addition, the EMCDDA will continue close 
cooperation with key EU agencies active in the area of Justice 
and Home Affairs, in particular Europol, Eurojust and Frontex.
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Strategic objective S1:
Provide a comprehensive, holistic and up-to-date understanding of the drug market in Europe
Expected outcomes
■■ Implementation of supply-related monitoring tools optimised and new processes for monitoring drug supply developed, to respond to the needs 
of the contemporary drug market
■■ Comprehensive understanding of the EU drug market through improved quality and availability of data and analysis
■■ Improved ability to capture the developments in the international drug situation
KPIs
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA monitoring system
7. Work programme delivery
8. Efficient implementation of the technical assistance projects with third countries
9. Uptake of the EMCDDA evidence (knowledge) through a number of channels
10. Uptake of the EMCDDA evidence/knowledge by policymakers
Action areas Outputs/results
S1.1. Strengthen the core monitoring 
system: improve quality and coverage in 
the implementation of supply and supply 
reduction indicators in the Member States 
and their supporting tools, networks and 
processes
■■ Strategic overview of the European drug market: EU Drug Markets Report (EDMR) 2019 produced 
and launched jointly with Europol (L1)
■■ Analysis and outputs based on the available drug market data (L2 or L3, as appropriate)
■■ Activities to support NFP drug supply data collection efforts, in line with the Reitox Development 
Framework, including quality assurance and capacity building, and identification and promotion of 
good practices from/among the Member States (L2)
■■ Data on drug production — synthetic drugs and cannabis — available (tools revised as appropriate 
and training delivered with Europol and the European Multidisciplinary Platform against Criminal 
Threats (EMPACT)) (L2)
■■ Data on cocaine production (secondary extraction) available (tools revised as appropriate and 
training delivered with Europol and EMPACT) (L3)
■■ Work initiated for preparing the 2022 EDMR (planning of studies) (L3)
S1.2. Develop new and innovative data 
collection approaches to increase the 
scope and coverage of analysis, and 
provide a cost-effective and practical 
solution to supplement existing core data 
collection systems in this area (e.g. open 
source intelligence; internet monitoring; 
web surveys)
■■ Ongoing review of performance of individual drug supply reporting tools and gaps analysis (L2)
■■ Outputs of OSI monitoring integrated into EMCDDA analysis (L2)
■■ Ongoing monitoring of darknet implemented with the EC’s Joint Research Centre (JRC) (subject to 
resources) (L3)
■■ Utility of results of wastewater monitoring for application in supply monitoring and supply reduction 
measurement assessed (L3)
S1.3. Improve understanding of the impact 
on the European drug market of 
developments in the international drug 
situation, with particular attention given to 
the countries bordering the EU
■■ Strategic overview of the European and neighbouring countries’ drug markets: outputs from project 
‘EU 4 Monitoring Drugs’; and capacity-building activities, in line with project logframe (L2)
■■ Analysis of OSI carried out to improve understanding of the impact of drugs produced in the EU on 
the rest of the world, and the impact on the EU of drugs produced and seized outside the EU and 
destined for sale on the EU market (L2)
■■ New dataset on drug-related issues produced in the CC and PCC following EMCDDA supply 
indicators (L3)
S1.4. Support a better strategic 
understanding of the drivers of innovation 
in synthetic drug production and their 
impact, including routes of synthesis and 
source chemicals, and contribute to the 
European system on drug-precursor 
monitoring, together with the European 
Commission and Europol
■■ Analysis of synthetic drug production (from the European Reporting Instrument on Sites related to 
Synthetic Production (ERISSP) and seizures and stopped shipments of drug precursors) and 
results integrated into EMCDDA products (EDR and EDMR in particular) (L2)
■■ Information exchange and collaboration with partners (in particular with Europol and the EC) on 
drug precursors, and contribution to key activities in the drug precursor area, such as the synthetic 
drug production experts group established under EMPACT Synthetic Drugs and NPS priority (L2)
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Strategic objective S2:
Identify new drug-related security threats and support a rapid response from the EU and its Member States
Expected outcomes
■■ Security-related emerging trends and threats captured and reported in a timely manner
■■ Increased capacity of the EU and its Member States to rapidly respond to new drug-related security threats
KPIs
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA monitoring system
7. Work programme delivery
8. Efficient implementation of the technical assistance projects with third countries
9. Uptake of the EMCDDA evidence (knowledge) through a number of channels
10. Uptake of the EMCDDA evidence/knowledge by policymakers
Action areas Outputs/results
S2.1. Provide threat assessments related to 
transversal security threats linked to the 
production and supply of drugs
■■ Integrated framework for threat identification, assessment and reporting in place (security pillar elements):
 – threat assessment methodology/approach (developed by 2018 and tested by 2020) (L2)
 – communication model for threat and rapid reporting (2019-20) (L2)
■■ Joint threat assessments with Europol (L2)
■■ Briefing notes on emerging threats provided to European Commission services (as appropriate) (L2)
S2.2. Identify and communicate the threats 
associated with NPS with respect to 
sourcing, production, transit and marketing, 
and ensure vigilance and follow up on 
threats related to the emergence of newly 
controlled NPS on the drug market
■■ Results of monitoring of market-related information on NPS derived from the EU EWS analysed and 
integrated into EMCDDA outputs (L2)
S2.3. Improve capacity to monitor innovation 
in the drug market and its impact, with 
special attention given to the development of 
online drug markets and darknet drug sales
■■ Threat identification and analysis based on the results of the darknet monitoring (L2)
Strategic objective S3:
Improve understanding of the nature and consequences of drug-related crime
Expected outcomes
■■ Better understanding of drug-related crime and its link with other serious crimes such as terrorism, illegal firearms trafficking and illegal migration
■■ Improved comprehension of wider societal impact of drug markets and drug-related crime
KPIs
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA monitoring system
7. Work programme delivery
8. Efficient implementation of the technical assistance projects with third countries
9. Uptake of the EMCDDA evidence (knowledge) through a number of channels
10. Uptake of the EMCDDA evidence/knowledge by policymakers
Action areas Outputs/results
S3.1. Improve the monitoring of drug-
related crime and associated responses 
and countermeasures and their impact
■■ Framework for monitoring drug-related homicide/serious violence developed and published 
(non-routine data from selected countries) (L2)
■■ Information exchange with drug-related crime expert groups (L3)
■■ Feasibility assessment of collecting data on drug-related acquisitive crime, through creating 
synergies with partners (e.g. Eurostat) (L3)
S3.2. Contribute to an improved 
understanding of the links and interactions 
that exist between drugs and serious 
criminality, including security threats, such 
as illegal financial flows, corruption, 
trafficking in other illicit cargos and terrorism
■■ First analysis of links to other crime types such as terrorism (L3)
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Action areas Outputs/results
S3.3. Support the development of 
a broader conceptual framework on the 
wider societal impact of drug markets and 
drug-related crime, including 
environmental impact, implications for 
community safety and possible unintended 
negative consequences of interventions
■■ EU-level environmental cost estimation model developed based on findings of contract on 
synthetic drug production in the Netherlands and Belgium combined with data from ERISSP (L2)
■■ Study on societal impact commissioned and results integrated in EMCDDA products (L3)
Strategic objective S4:
Support policy and operational responses to the security challenges posed by drugs and drug markets at EU and national levels
Expected outcomes
■■ Improved law enforcement capacity to prevent and investigate drug-related crime, based on knowledge, skills and expertise acquired through 
training and sharing of best practices
■■ Enhanced capacity of policymakers at EU and national level to combat drug-related security threats
KPIs
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA monitoring system
7. Work programme delivery
9. Uptake of the EMCDDA evidence (knowledge) through a number of channels
10. Uptake of the EMCDDA evidence/knowledge by policymakers
Action areas Outputs/results
S4.1. Support the EU policy cycle for 
organised and serious international crime 
and provide expertise on the EMPACT drug 
priority areas (through threat assessments, 
provision of expertise and training). 
A priority task for the EMCDDA is to 
maintain an overview of EU drug markets, 
their ramifications and responses
■■ Support to the implementation of the 2017–20 EU Drug Action Plan (supply reduction actions) (L1)
■■ Expertise provided in support of the European Agenda on Security 2015–20 (L1)
■■ Support for the EU policy cycle for organised and serious international crime, in particular through 
appropriate tasks with the operational action plans on drug priorities and the development of 
multiannual strategic plans, as well as through contribution to the Serious Organised Crime Threat 
Assessment’ (L1)
■■ Delivery of training organised by CEPOL (L2)
■■ Participation in key events, such as SOCTA meetings (L2)
■■ EMCDDA SIENA system kept updated to support secure exchange of information with Europol (L2)
S4.2. Increase the effectiveness and the 
impact of EU actions in the security area 
including by a) strengthening/establishing 
networks of field experts, academics, 
law-enforcement officials, etc. and b) 
defining criteria for identifying, 
understanding and prioritising emerging 
threats (including external, current and 
future) stemming from drug market activity, 
integrating uncertainty, projected trends, 
and scenario planning
■■ Annual meeting and proceedings of the reference group on drug supply indicators (L2)
■■ Expert technical meetings held, building on network of supply experts and the reference group 
(subject to the availability of resources) (L2)
S4.3. Develop capacity for supporting the 
evaluation, upon request, of law 
enforcement responses to drug supply 
interventions (in close coordination with 
policy support provided to health 
interventions)
■■ Scoping exercise for better understanding the impact of supply reduction interventions (L3)
■■ Research on the utility of the results of wastewater monitoring for application in supply reduction 
measurement (L3)
Resources necessary for the implementation of the activities  
in this area (8)
Budget (EUR) Human resources (FTE)
3 080 533.93 13.35
(8) This does not include the resources covered by the technical assistance  
projects with third countries (assigned appropriations).
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l Main area 3: Business drivers
Business driver 1: Institutional
The year 2019 will mark the first year after the implementation 
of the fourth external evaluation of the agency; hence, steered 
by the EMCDDA’s Management Board and led by the Director, 
this will be a year of reflection and of reshaping our work in line 
with the outcome of this important exercise for the future of 
the EMCDDA.
It will be important, therefore, to align our efforts in all the 
areas, including core business and support activities, guided 
by Strategy 2025 and building on the solid organisational 
foundation established in 2017–18 via the internal 
reorganisation of the agency and the implementation of a new 
and stronger management structure.
To that end, a strategic analysis of consequences of potential 
future changes in the EMCDDA Regulation will be initiated (to 
be completed in 2020), to prepare the agency for ongoing and 
potential future revision of its mandate. This analysis will be 
carried out on the basis of the outcome of the fourth external 
evaluation of the EMCDDA, and it will be informed by the 
conclusions of the evaluations of the EU drug strategy and its 
action plans.
Furthermore, an action plan to follow up on the 
recommendations of the fourth external evaluation of the 
agency will be prepared and submitted to the Management 
Board for adoption in 2019, and necessary measures will start 
to be implemented, as appropriate.
The Regulation of the European Parliament and the Council 
amending Regulation EC No 1920/2006, which was 
adopted by the European Parliament on 24 October 2017, 
became applicable at the end of 2018, replacing Council 
Decision 2005/387/JHA. The new regulation sets out new 
working procedures in the operation of the EWS and the 
risk assessment mechanism, with shorter deadlines for the 
completion of the core obligations, but also allows for the 
inclusion of new tasks (see Main area 1: Health).
In this complex institutional context, the agency will seek to 
improve its understanding of the evolving needs of its key 
stakeholders. During the year, the agency’s ‘Customer needs 
project’ will be implemented using a range of methods to gain 
an understanding of these needs (such as detailed qualitative 
audience research, focus groups and analysis of customer 
feedback as well as of media monitoring and web and social 
media metrics).
On the basis of the outcome of this project, the EMCDDA 
portfolio of products and services will be analysed and 
adjusted as necessary. Communication and dissemination 
activities will be further optimised and measured for their 
effectiveness. Ongoing website developments will continue 
to offer the EMCDDA’s audiences access to new interactive 
products and tools. The agency’s digital transformation project 
will ensure that the changes and opportunities provided by 
developing digital technologies are leveraged in a strategic and 
prioritised way.
The agency will also endeavour to anticipate the developments 
in the EU drug situation, via the ‘futures exercise’ planned to be 
completed in 2020 (see Main area 1: Health).
These interlinked and mutually reinforcing efforts will allow 
the EMCDDA to prepare for future scenarios and position itself 
as a leading provider of evidence on drugs, for a healthier and 
a more secure Europe.
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Business objective B1:
Anticipate, and respond promptly to, institutional developments and needs
Expected outcomes
■■ Increased capacity of the EMCDDA to meet stakeholders’ needs through tailored products and services which are provided through optimised 
communication channels
■■ The EMCDDA is organised to respond to the recommendations emerging from the fourth external evaluation of the agency and other relevant 
institutional and political developments
KPIs
1. Budget execution
2. Staff capacity
6. Organisational efficiency
7. Work programme delivery
9. Uptake of the EMCDDA evidence (knowledge) through a number of channels
10. Uptake of the EMCDDA evidence/knowledge by policymakers
Action areas Outputs/results
B1.1. Continue to analyse the external 
environment and how it relates to current 
and future stakeholder needs
■■ Efficient support provided to the EMCDDA Management Board in performing its governance role 
(L1)
■■ ‘Customer needs project’ implemented and emerging results used to inform the preparation of the 
EMCDDA framework for proactively identifying and responding to stakeholders’ needs (to be put in 
place by 2020) (see B1.2) (L2)
B1.2. Configure services to ensure they 
are timely and are delivered professionally 
and in a form coherent with our 
stakeholders’ needs
■■ Draft framework and associated procedures for proactively identifying and responding to 
stakeholders’ needs (governance, workflows, tools) developed (see B1.1) (L2)
■■ Methods and instruments implemented to better understand the needs of drug professionals (e.g. 
stakeholder/focus group meetings; user testing) (L2)
■■ EMCDDA portfolio of products and services analysed and adjusted based on outcome of ‘Customer 
needs project’ (L2)
■■ Communication and dissemination activities (including through digital channels: website, social 
media, audiovisual) are optimised and measured for their effectiveness (L2)
■■ Web system functional and further developed as required (L2)
■■ Availability of multilingual products (subject to resources) (L2)
B1.3. Prepare the agency for ongoing and 
potential future revisions of its mandate, in 
line with the recommendations of the 
external evaluation to be performed in 
2018, and the conclusions of the 
evaluation of EU Drugs Strategy and 
Action Plan
■■ Action plan to follow up on the recommendations arising from the fourth external evaluation of the 
EMCDDA (‘follow-up action plan’) developed and submitted to the Management Board for adoption 
(L1)
■■ Set of measures implemented in line with the follow-up action plan (as appropriate and depending 
on the timeline of adoption of the follow-up action plan) (L1)
■■ Strategic analysis of consequences of potential future changes in EMCDDA Regulation on the basis 
of EMCDDA and EU Strategy and Action Plans evaluations initiated (to be completed in 2020) (L1)
■■ Regulation of the European Parliament and the Council amending Regulation EC No 1920/2006 
implemented (for substantive activities, see Main area 1: Health) (L1)
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Business driver 2: Partnership
In line with its strategic priorities, in 2019 the EMCDDA will 
continue to enhance information and knowledge exchange 
with its European and global partners.
The main partners of the EMCDDA in the Member States, 
Norway and Turkey, and the agency’s core data providers, 
are the Reitox NFPs. The substantive activities involving the 
contribution of the NFPs are presented in Main area 1: Health 
and Main area 2: Security.
As far as the network management is concerned, the work will 
be guided by the Reitox Development Framework 2018–25. 
The document, which was developed jointly by the EMCDDA 
and the NFPs was adopted by the HFPs and presented to 
the EMCDDA Management Board at the end of 2017. Its 
successful implementation by the NFPs, with support from the 
EMCDDA, will contribute to enhancing the visibility, usefulness 
and ultimately sustainability of the NFPs at national level, 
and as a network at European level. The annual planning of 
activities will be guided by the roadmap, which will be part of 
the document.
The accreditation system initiative will continue in 2019. The 
interested NFPs will be supported in the application of the 
self-assessment tool, which was piloted in 2017 through 
a collaborative effort coordinated by the EMCDDA, with input 
from the NFPs.
In addition to Reitox, the EMCDDA needs to work directly with 
a number of expert networks, as well as with specialist data 
providers and research collaborations (for details, see Main 
area 1: Health and Main area 2: Security). Furthermore, in 2019 
the EMCDDA will continue to contribute to the international 
coordination of ESPAD, in line with the existing working 
arrangements and the available resources (see also Section II, 
Human and financial resources outlook for 2019–21).
During the year the EMCDDA will also further enhance its 
cooperation with EU agencies working in the health area, 
such as the ECDC and EMA, as well as with agencies from the 
Justice and Home Affairs cluster, such as Europol, Eurojust, 
CEPOL and Frontex (see Main area 1: Health and Main area 2: 
Security).
Information and knowledge exchange will be also strengthened 
with global partners (mainly the UN family — the United 
Nations Office on Drugs and Crime (UNODC), the WHO and 
the Joint United Nations Programme on HIV/AIDS (UNAIDS) — 
but also other partners, such as the Pompidou Group), in line 
with the existing working arrangements and emerging annual 
priorities.
In 2019, the IPA 6 technical assistance project for six CC and 
PCC will be successfully completed, including the organisation 
of its closing conference and the dissemination of the final 
results. In parallel, the follow-up IPA 7 project proposal will be 
developed and submitted to the EC, and the project will start 
during the year (depending on the approval of funding by the 
EC).
The year 2019 will also mark the first year of implementation 
of the ‘EU 4 Monitoring Drugs’ project, the largest technical 
assistance project ever implemented by the EMCDDA, and the 
second such project in ENP-South and ENP-East countries. 
The EC-funded project (with a total budget of EUR 3 million for 
2019–21) aims to strengthen the capacity of 15 ENP partner 
countries, as well as to improve the EMCDDA knowledge base, 
by creating an analysis and response platform to tackle the 
dynamic links between drugs, security and health threats (see 
also Main area 1: Health and Main area 2: Security).
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Business objective B2:
Strengthen the European drug information system through effective and mutually beneficial partnerships and synergies with our data providers, 
communities of knowledge and relevant European and international bodies and cooperation with third countries
Expected outcomes
■■ Efficient coordination of the Reitox network to ensure improved reporting capacity of the NFPs and good performance in the implementation of 
the grant agreements
■■ Enhanced synergies with EU and international bodies working in the drug-related areas
■■ Increased EU capacity to address drug threats in EU priority third countries
KPIs
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA monitoring system
5. Implementation and management of the Reitox grant agreements
7. Work programme delivery
8. Efficient implementation of the technical assistance projects with third countries
9. Uptake of the EMCDDA evidence (knowledge) through a number of channels
10. Uptake of the EMCDDA evidence/knowledge by policymakers
Action areas Outputs/results
B2.1. Develop, jointly with the NFPs, and 
guided by EMCDDA Strategy 2025, the 
new Reitox Network Development 
Framework, and support its 
implementation by the NFPs
■■ Reitox network support and coordination
 – NFPs provided with support towards the implementation of the Reitox Development Framework 
2018–25, in line with its respective Roadmap for 2020, and the available resources (L2)
 – Biannual meetings of the HFPs (L1)
 – Technical meetings (as appropriate) (L2)
 – Interested countries supported in the implementation of the Reitox accreditation system (L2)
 – NFPs provided with quality feedback, technical assistance and institutional support (where 
required) (L2)
■■ Grant agreements management
 – 2019 grant agreements deliverables (financial and narrative reports) provided in line with the 
applicable rules and regulations (L2)
 – 2018 grant agreement final deliverables (financial and narrative reports) controlled and final 
payments executed (L2)
 – 2018 grant agreement audit reports (two or three reports, depending on budget availability) 
prepared, further to the audit missions carried out in selected countries, and made available to 
the European Court of Auditors (upon request) (L2)
B2.2. Strengthen national drug expert 
networks and develop, if necessary, new 
networks to ensure that the agency has 
sufficient expertise to accomplish the 
strategy’s objectives
■■ Drug expert networks maintained and developed, including in key indicators areas and other data 
collection sources (e.g. ESPAD, SCORE, Euro-DEN, Xchange) (L2)
■■ Reference paper on the articulation of different networks at EU and national level (update of the 
‘Charter of good communication between the EMCDDA, the NFPs and national experts’ adopted by 
the heads of national focal points in May 2010) (L3)
B2.3. Strengthen cooperation with EU and 
international partners in line with work 
priorities defined by Strategy 2025 and 
the emerging needs of stakeholders
■■ Joint work programmes with partner European and international organisations implemented in line 
with the EMCDDA strategic priorities for 2019 (L2)
■■ New working arrangements (e.g. with CEPOL, Frontex or FRA), as appropriate (L2)
■■ Active contribution to the work of the JHA network (L2)
■■ Active contribution to the subnetworks set up under the EU Agencies’ Network (EU AN) (e.g. the 
Performance Development network (PDN), the Heads of Communication and Information Network 
(HCIN), the Information and Communication Technologies Advisory Committee (ICTAC) (L2)
■■ IPA 6 project successfully completed and final results disseminated (L2)
■■ Efficient management of the project ‘EU 4 Monitoring Drugs’ (EU4MD) (overall administration and 
reporting, kick-off, steering committee and other meetings) (L2)
■■ IPA 7 project proposal developed and project launched (L2)
■■ Support to the EC (upon request and coverage of expenses by EU programmes) in the 
implementation of EU drug-related regional programmes, such as CADAP and COPOLAD (L2)
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Business driver 3: Scientific capacity
The multifaceted nature of the drugs situation requires the 
EMCDDA to have both sufficient in-house expertise and 
access to experts working elsewhere to ensure adequate 
scientific capacity for this work. In 2019, the agency will 
strengthen the ongoing dialogue with the research and 
scientific community, in both the drugs area and related 
disciplines, such as addiction science and criminology.
The members of the Scientific Committee will adopt a formal 
opinion on the EMCDDA PD 2020–22 and will continue to 
provide input on the agency’s main projects and scientific 
publications, in line with the guiding principles for the 
review of selected EMCDDA publications. They will also 
continue to engage actively in the EMCDDA Scientific Award 
and contribute to the HDG’s annual dialogue on research. 
The current Scientific Committee will end its mandate in 
2019 and therefore a new call for expressions of interest in 
membership of the EMCDDA Scientific Committee 2020–22 
will be launched in 2019. In addition, a call for expression of 
interest will be launched for the establishment of list of experts 
to extend the Scientific Committee for the purpose of risk 
assessments.
In 2019, the EMCDDA will continue to follow up on ways to 
further increase the quality of its analyses and outputs across 
all key areas of work. Efforts will focus on implementing 
the action plans that were put in place to address the 
recommendations of the IAS audits on the management of 
data collection, validation and quality assurance (2017) and 
publications management (2018).
The allocation and use of scientific resources will be optimised, 
including through the adoption of a project management 
approach for key scientific activities (see Business driver 4 for 
details).
During the year, the EMCDDA will also develop a framework 
to enhance cooperation with established scientific centres of 
excellence in the drugs field.
Last but not least, the EMCDDA will be one of the main 
partners in the programme and organising committees of 
the Third European Conference on Addictive Behaviours and 
Dependencies, which will take place from 23 to 25 October 
2019.
Business objective B3:
Have in place the scientific capacity (resources, processes and tools) to meet current analytical needs, and innovate to keep pace with changes in 
the drug situation and the corresponding institutional needs
Expected outcomes
■■ Scientific capacity optimised through efficient use of resources and improved coordination of core activities
■■ The scientific quality of the EMCDDA’s work is further enhanced through appropriate quality assurance measures, and provision of support and 
guidance by the Scientific Committee
■■ Communication and exchange with external monitoring and scientific bodies and centres of excellence are strengthened
KPIs
1. Budget execution
2. Staff capacity
6. Organisational efficiency
7. Work programme delivery
9. Uptake of the EMCDDA evidence (knowledge) through a number of channels
10. Uptake of the EMCDDA evidence/knowledge by policymakers
Action areas Outputs/results
B3.1. Maintain and develop the EMCDDA’s 
scientific capacity and ensure that it 
reflects the expertise required for the 
agency to fulfil its mandate
■■ Efficient support provided to the EMCDDA Scientific Committee in performing its advisory role (L1)
■■ Internal digital information service, updating on developments in the drugs field, in place (L2)
■■ Scientific articles in high-impact journals (L2)
B3.2. Optimise the allocation and use of 
scientific resources through clear 
prioritisation, adoption of more flexible 
working practices and the use of external 
resources where cost-efficient
■■ Project management approach progressively implemented for selected projects in scientific areas 
(see also Business driver 4) (L2)
■■ Internal scientific coordination mechanisms in place and communication tools maintained (L2)
■■ Improved coordination and planning of outputs (framework for standard products management 
implemented, taking into account the recommendations following the IAS audit carried out in 2018) 
(L2)
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Action areas Outputs/results
B3.3. Strengthen the quality management 
of scientific activities
■■ Quality assurance framework for scientific activities, including production of outputs, defined and 
implemented according to recommendations of audits (IAS audit follow-up action plans) where 
relevant (L2)
■■ Guiding principles for the drafting of EMCDDA scientific publications maintained and updated, as 
necessary (L2)
B3.4. Strengthen dialogue and 
cooperation with the scientific community 
and centres of excellence in the drugs 
field to ensure that the EMCDDA 
maintains a state-of-the-art understanding 
of developments in its areas of 
competence
■■ Lisbon Addictions 2019 successfully co-organised (L2)
■■ Support to the EU contribution to the revision and standardisation of reporting tools provided (L2)
■■ Participating and providing expertise in steering committees and advisory boards of external 
scientific partners (L2)
■■ Presentations and/or exhibition stands at scientific and technical events (L2)
■■ Active contribution to and follow-up of EU-funded drug-related research projects where relevant 
(resource dependent), including the Scientific Committee’s contribution to the HDG annual dialogue 
on research (L2)
■■ 2019 edition of the EMCDDA Scientific Award organised (L3)
■■ Development of a framework to enhance cooperation with established scientific centres of 
excellence in the drugs field (L3)
Business driver 4: Management
The EMCDDA will ensure that the optimal organisational 
structure and supporting processes are in place, and that their 
performance is regularly reviewed and developed to maintain 
a business environment corresponding with the long-term 
requirements of the EMCDDA Strategy 2025.
In 2019, one of the key objectives of this business driver will 
be to ensure that the implementation of the activities planned 
across the different areas of the annual work programme 
is supported by effective and efficient management of the 
available resources. The internal management mechanisms 
(e.g. the Strategic Committee, the Heads of Unit meetings, the 
Editorial Board meeting, the ICT Steering Committee) will be 
maintained to enable sound decision-making on the EMCDDA 
operational priorities and allocation of resources.
The EMCDDA will ensure the efficient implementation of the 
annual work programme, which is part of the PD 2019–21, and 
the timely delivery to the EMCDDA’s stakeholders of the next 
PDs: for 2020–22, and for 2021–23 (preliminary draft).
The performance management system will be further 
developed through the implementation of the project 
management programme (PM-P), including the establishment 
and implementation of a unified corporate project 
management methodology, supported by a management 
information system. This will be implemented in line with the 
phased implementation plan and the available resources.
The priorities concerning the budget and the financial 
management-related operations will focus on effective and 
timely planning, monitoring and execution of the EMCDDA 
budget, and on optimising all related processes. A key target will 
be to maintain the excellent level of performance achieved in 
the budget execution in previous years. Efficiency of all related 
processes will be pursued, namely by making increased use of 
digital solutions. Procedures and tools for sound management 
of financial resources will be adjusted in a timely fashion, in 
line with relevant financial rules, to contribute to ensuring 
the implementation of the EMCDDA Strategy 2025 and the 
operation of the organisational structure put in place in 2017.
The EMCDDA will continue to strengthen its internal control 
measures in line with the internal standards for effective 
management and control adopted by the Management Board 
in 2010. In 2019, the recommendations arising from the audits 
performed at the EMCDDA as well as from the fourth external 
evaluation (carried out in 2018) will be closely followed up on 
and implemented in line with the action plans adopted by the 
Management Board.
The management of human resources will encompass the 
sound management of existing processes, as required by 
the applicable Staff Regulations and their implementing 
rules. Special attention will be paid to the organisation of 
appropriate training for the agency’s staff to support the 
effective implementation of the EMCDDA Strategy 2025 and 
the achievement of the defined milestones.
In 2019, the agency will implement further measures to 
ensure a safe working environment as well as to guarantee 
the efficient use of the EMCDDA infrastructure, with special 
attention paid to controlling utilities-related costs and to 
building possible further synergies with EMSA. In line with the 
policy in place at the EMCDDA, this will be complemented by 
environmentally friendly measures (an internal environmental 
report will be delivered in 2019).
ICT programmes and services will continue to guarantee the 
smooth operation of all the services provided, and to support 
the agency’s core developmental objectives, in line with 
priorities set up by the ICT Steering Committee.
Synergies with EMSA will be further pursued in the areas 
related to staff training, infrastructure management and ICT.
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Business objective B4:
Ensure that the organisational structure and supporting processes are optimal, to deliver efficient and high-quality services
Expected outcomes
■■ Good performance by the EMCDDA in implementing the annual programming instrument
■■ Sound management of the EMCDDA’s resources, in compliance with applicable rules and procedures and in line with organisational needs
■■ Safe and environmentally friendly workplace, which prevents work accidents, promotes use of renewable energy and avoids waste of resources
■■ Optimal level of operability of the EMCDDA’s ICT systems
KPIs
1. Budget execution
2. Staff capacity
6. Organisational efficiency
7. Work programme delivery
Action areas Outputs/results
B4.1. Put in place the new organisational 
structure and other measures necessary 
for successful implementation of Strategy 
2025
■■ Management mechanisms (e.g. Strategic Committee, the Heads of Unit meetings, the Editorial 
Board meeting, the ICT Steering Committee) operational to enable sound decision-making on the 
EMCDDA operational priorities and allocation of resources (L2)
■■ Activities in the areas of data protection, internal control mechanisms and risk management 
implemented in line with the existing EU regulations and practices (L2)
■■ Preparatory work for the assessment of Roadmap 2020 (L2)
B4.2. Further improve cost-effectiveness 
and optimal allocation of resources, 
reflecting the priorities identified in 
Strategy 2025
■■ Planning instruments and processes
 – PD 2019–21 published (L1)
 – Draft PD 2020–22 finalised, taking into account the results of the consultation of key EMCDDA 
stakeholders and partners, and submitted to the Management Board for adoption (L1)
 – Preliminary PD document 2021–23 prepared and submitted to the Management Board for 
adoption (L1)
 – EMCDDA 2020 draft budget and 2021 preliminary draft budget prepared in a timely fashion and 
submitted for adoption by Management Board (L1)
 – 2019 management plan in place (L2)
 – Project management programme (PM-P) implemented in line with the phased implementation 
plan and available resources (L2)
■■ Financial resources management
 – Sound management of the EMCDDA’s financial resources, in compliance with applicable rules 
and procedures (L1)
 – Timely publication of report on the EMCDDA’s annual accounts (L1)
 – Annual procurement plan prepared in a timely fashion, successfully implemented and effectively 
monitored (L2)
 – Further development of financial and procurement-related electronic workflows (L3)
■■ Facilities support services
 – Efficiency in using available facilities, equipment, infrastructure and utilities (L2)
 – Provision of a safe, secure and environment-friendly working place, namely health and safety risks 
identified; security risk assessment delivered and followed up; and environmental report 
delivered (L2)
■■ ICT support services
 – Business continuity plan implemented (L1)
 – Technical changes implemented to provide a continuous stable environment and allow adequate 
reaction to risks and threats, in line with the approved ICT annual investment plan (L2)
 – Steering identification and evolution of business requirements, planning and delivery of technical 
services, processes and products supporting the implementation of the EMCDDA’s core 
objectives (L2)
■■ Synergies and efficiency gains
 – Synergies with other EU bodies, including through participation in interagency networks and 
interinstitutional framework contracts, and sharing technical services (with EMSA in particular) (L2)
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Action areas Outputs/results
B4.3. Strengthen performance 
management at all levels
■■ General Report of Activities (GRA) 2018 prepared, submitted to the Management Board for 
adoption, and published online by 15 June 2019, in line with the recast EMCDDA regulation (L1)
■■ Corporate performance mid-year monitoring review carried out, and results presented to inform 
sound management decisions (L2)
■■ End-term monitoring report of the 2016–18 strategy and WP (L2)
■■ High level of budget execution (commitment and payment appropriations), in line with annual 
targets (L2)
■■ Timely and effective follow-up to observations/recommendations from external audits, as required 
and agreed (L2)
■■ Timely report on measures taken in light of the observations accompanying the annual discharge 
(L2)
B4.4. Improve people management and 
implement a sustainable staff training and 
development programme to ensure the 
EMCDDA has the committed, skilled and 
motivated human resources it requires to 
achieve its long-term objectives
■■ Sound management of EMCDDA human resources, in accordance with applicable rules and in line 
with organisational needs (L1)
■■ Staff development programme in place, including 2019 training plan (L2)
■■ Adjustment of staff performance appraisal and promotion procedures and tools, as appropriate (L2)
■■ Definition and implementation of solutions for staff career progression/mobility (L2)
■■ Level of the vacancy rate below 5 % (in line with the KPI 2: Staff capacity — performance indicator 
2.1: Occupation rate (implementation of the establishment plan), and conditional upon resources 
(L2)
Resources necessary for the implementation of the activities  
in this area (9)
Budget (EUR) Human resources (FTE)
7 697 079.12 52.25
(9) This does not include the resources covered by the technical assistance  
projects with third countries (assigned appropriations).
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ANNEXES
l  Annex I Estimated budget allocation for the implementation of the EMCDDA 2019 work programme
The amounts indicated in the table below are based on the 
parameters of the 2019 EMCDDA draft budget, by taking 
into account the expected outcome of the EU 2019 budget 
procedure.
With regard to the above and without prejudice to the final 
official outcome of the EU 2019 budget procedure, the 
EMCDDA 2019 budget should rely on the following revenue:
■■ EUR 15 286 600 to be provided by the EU subsidy to the 
EMCDDA;
■■ EUR 407 997.93 to be provided by Norway for its 
participation in EMCDDA activities.
■■ EUR 273 703.63 to be provided by Turkey for its 
participation in EMCDDA activities, pursuant to the 
agreement concluded between the European Union and 
Turkey for this participation.
The table below presents the estimated allocation of the 
EMCDDA’s 2019 budget appropriations for the implementation 
of the agency’s 2019 work programme.
Main areas (MAs)
WP areas
Main actors for 
implementation/ 
cost objects
Allocated human resources (FTE/year)
Allocated budget resources — non-
assigned appropriations (EUR)
O TA CA SNE Total HR Total budget
MA 1: Health 2.55 23.1 11.75 0 37.4 5 190 688.51
MA 2: Security 0.5 8.9 2.95 1 13.35 3 080 533.93
MA 3: Business 
drivers
5.95 32 14.3 0 52.25 7 697 079.12
TOTAL 9 64 29 1 103 15 968 301.56
Abbreviations: FTE, full-time equivalents; WP, work programme; O, officials; TA, temporary agents; CA, contract agents; SNE, seconded national experts; HR, human 
resources.
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l  Annex II  Human and financial resources (tables 2019–21)
TABLE A1 
Expenditure
Expenditure
N (2018) N+1 (2019)
Commitment
appropriations
Payment
appropriations
Commitment
appropriations
Payment
appropriations
Title 1 10 359 903.62 10 359 903.62 10 809 640.41 10 809 640.41
Title 2 1 375 052.08 1 375 052.08 1 411 829.90 1 411 829.90
Title 3 4 436 437.63 4 436 437.63 3 746 831.25 3 746 831.25
Total expenditure 16 171 393.33 16 171 393.33 15 968 301.56 15 968 301.56
Expenditure
Commitment appropriations
Executed 
budget N−1 
(2017)
Budget 
N (2018)
Draft budget N+1 (2019) VAR 
N+1 / 
N
Envisaged N+2
(2020)
Envisaged N+3
(2021)Agency 
request
Budget 
forecast
Title 1
Staff expenditure
9 836 151.87 10 359 903.62 10 809 640.41 11 962 773.29 11 133 417.30
11 Salaries and allowances 9 633 741.22 10 202 651.21 10 710 740.41 11 805 520.88 11 088 417.30
- of which establishment plan posts 8 236 131.12 8 629 739.94 9 142 725.13 10 151 140.94 9 562 346.69
- of which external personnel 1 397 610.10 1 572 911.27 1 568 015.28 1 654 379.94 1 526 070.61
12 Expenditure relating to staff 
recruitment
36 423.56 14 000.00 3 500.00 14 000.00 0.00
13 Mission expenses
14 Socio-medical infrastructure
15 Training 127 894.33 100 000.00 45 000.00 100 000.00 45 000.00
16 External services 38 092.76 43 252.00 50 400.00 43 252.00 0.00
17 Receptions and events
Title 2
Infrastructure and operating expenditure
1 598 977.28 1 375 052.08 1 411 829.90 2 202 878.61 1 802 693.42
20 Rental of buildings and associated 
costs (1)
637 190.67 646 845.88 838 601.35 1 371 414.36 1 229 464.87
21 Information and communication 
technology
758 771.08 507 455.70 415 775.00 607 455.70 415 775.00
22 Movable property and associated costs 104 979.89 98 760.00 55 860.00 98 760.00 55 860.00
23 Current administrative expenditure 71 315.07 85 805.50 85 963.56 85 963.56 85 963.56
24 Postage/telecommunications 5 288.65 8 080.00 5 050.00 8 080.00 5 050.00
25 Meeting expenses
26 Running costs in connection with 
operational activities
27 Information and publishing
28 Studies
Other infrastructure and operational 
activities
21 432.92 28 105.00 10 580.00 28 105.00 10 580.00
Title 3
Operational expenditure
4 376 715.25 4 436 437.63 3 746 831.25 4 480 004.26 3 693 291.11
Information and publishing 636 437.26 580 000.00 430 000.00 580 000.00 430 000.00
Studies 647 550.19 675 784.23 387 844.34 675 784.23 383 485.94
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Expenditure
Commitment appropriations
Executed 
budget N−1 
(2017)
Budget 
N (2018)
Draft budget N+1 (2019) VAR 
N+1 / 
N
Envisaged N+2
(2020)
Envisaged N+3
(2021)Agency 
request
Budget 
forecast
Reitox grants 2 134 341.38 2 096 433.37 2 140 000.00 2 140 000.00 2 140 000.00
Mission expenses 293 227.08 318 220.03 260 000.00 318 220.03 240 000.00
Meeting expenses 662 595.65 762 500.00 525 486.91 762 500.00 496 305.17
Receptions and events 2 563.69 3 500.00 3 500.00 3 500.00 3 500.00
Expenditure IPA and LIN (2) projects, total 453 350.11 2 806.88 1 197 414.00 1 007 366.56 795 219.44
Expenditure related to IPA projects 453 350.11 (3) 2 806.88 0.00 0.00 0.00
Expenditure related to LIN (2) projects 0.00 0.00 1 197 414.00 1 007 366.56 795 219.44
TOTAL EXPENDITURE 16 265 194.51 16 174 200.21 17 165 715.56 19 653 022.72 17 424 621.27
(1) Including possible repayment of interest; detailed information as regards building policy provided in Table in Annex V.
(2) LIN stands for EU4MD.
(3) Includes IPA5 and IPA6 Projects and Commitment appropriations that were carried forward from 2016.
Expenditure
Payment appropriations
Executed 
budget N−1
Budget N
Draft budget N+1 VAR 
N+1 / 
N
Envisaged N+2 Envisaged N+3Agency 
request
Budget 
forecast
Title 1
Staff expenditure
9 768 601.63 10 359 903.62 10 809 640.41 11 962 773.29 11 133 417.30
11 Salaries and allowances 9 633 741.22 10 202 651.21 10 710 740.41 11 805 520.88 11 088 417.30
- of which establishment plan posts 8 236 131.12 8 629 739.94 9142 725.13 10 151 140.94 9 562 346.69
- of which external personnel 1 397 610.10 1 572 911.27 1 568 015.28 1 654 379.94 1 526 070.61
12 Expenditure relating to staff 
recruitment
31 153.40 14 000.00 3 500 14 000.00 0.00
13 Mission expenses
14 Socio-medical infrastructure
15 Training 72 654.45 100 000.00 45 000.00 100 000.00 45 000.00
16 External Services 31 052.56 43 252.41 50 400.00 43 252.00 0.00
17 Receptions and events
Title 2
Infrastructure and operating expenditure
999 823.91 1 375 052.08 1 411 829.90 2 202 878.61 1 802 693.42
20 Rental of buildings and associated 
costs (1)
507 001.96 646 845.88 838 601.35 1 371 414.36 1 229 464.87
21 Information and communication 
technology
332 120.85 507 455.70 415 775.00 607 455.70 415 775.00
22 Movable property and associated costs 69 606.01 98 760.00 55 860.00 98 760.00 55 860.00
23 Current administrative expenditure 67 028.94 85 805.50 85 963.56 85 963.56 85 963.56
24 PoStage/telecommunications 4 682.68 8 080.00 5 050.00 8 080.00 5 050.00
25 Meeting expenses
26 Running costs in connection with 
operational activities
27 Information and publishing
Other infrastructure and operational 
activities
19 383.47 28 105.00 10 580.00 28 105.00 10 580.00
28 Studies
Title 3
Operational expenditure
4 206 528.72 4 436 437.63 3 746 831.25 4 480 004.26 3 693 291.11
Information and publishing 586 483.81 580 000.00 430 000.00 580 000.00 430 000.00
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Expenditure
Payment appropriations
Executed 
budget N−1
Budget N
Draft budget N+1 VAR 
N+1 / 
N
Envisaged N+2 Envisaged N+3Agency 
request
Budget 
forecast
Studies 644 735.19 675 784.23 387 844.34 675 784.23 383 485.94
Reitox grants 2 068 473.26 2 096 433.37 2 140 000.00 2 140 000.00 2 140 000.00
Mission expenses 275 972.63 318 220.03 260 000.00 318 220.03 240 000.00
Meeting expenses 627 908.49 762 500.00 525 486.91 762 500.00 496 305.17
Receptions and events 2 955.34 3 500.00 3 500.00 3 500.00 3 500.00
Expenditure IPA and LIN (2) projects, total 379 757.63 (3) 2 806 88 1 197 414.00 1 007 366.56 795 219.44
Expenditure related to IPA projects 379 757.63 (3) 2 806 88
Expenditure related to LIN (2) projects 0.00 0.00 1 197 414.00 1 007 366.56 795 219.44
TOTAL EXPENDITURE 15 354 711.89 16 174 200.21 17 165 715.56 19 653 022.72 17 424 621.27
(1) Including possible repayment of interest; detailed information as regards building policy provided in Table in Annex V.
(2) LIN stands for EU4MD.
(3) Includes IPA5 and IPA6 Projects and Commitment appropriations that were carried forward from 2016
TABLE A2 
Revenue
Revenues
N (2018) N+1 (2019)
Revenues estimated by the agency Budget forecast
EU contribution 15 445 600.00 15 286 600.00
Other revenue 728 600.21 1 879 115.56
TOTAL REVENUES 16 174 200.21 17 165 715.56
Revenues General revenues
Executed 
budget 2017
Budget 2018 Draft budget 2019 VAR 
2019/ 
2018 (%)
Envisaged in 
2020
Envisaged in 
2021
Agency 
request
Budget 
forecast
1 Revenue from fees and charges
(including balancing reserve from 
previous years surplus)
2 EU contribution 15 135 600.00 15 445 600.00 15 286 600.00 17 839 040.00 15 900 000.00
- Of which assigned revenues deriving 
from previous years’ surpluses
54 436.49 215 188.58 189 763.80
3 Third countries contribution
(incl. EEA/EFTA and candidate 
countries)
674 487.34 691 393.59 681 701.56 806 616.16 729 401.83
- Of which EEA/EFTA  
(excl. Switzerland)
403 487.34 414 843.10 407 997.93 487 211.59 444 715.39
- Of which candidate countries 271 000.00 276 550.49 273 703.63 319 404.57 284 686.43
4 Other contributions 340 000.00 1 197 414.00 1 007 366.56 795 219.44
5 Administrative operations 18 301.84 37 206.62
- Of which interest generated by 
funds paid by the Commission by way 
of the EU contribution (FFR Art. 58), 
internal assigned revenue etc.
1 757 2 807.34
6 Revenues from services rendered 
against payment
7 Correction of budgetary 
imbalances
TOTAL REVENUES 16 168 389.18 16 174 200.21 17 165 715.56 19 653 022.72 17 424 621.27
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TABLE A3
Budget outturn and cancellation of appropriations
Budget outturn 2015 2016 2017
Revenue actually received (+) 18 632 222.81 15 481 464.63 16 168 797.96
Payments made (−) −17 626 446.15 −15 090 448.03 −15 370 324.15
Carry-over of appropriations (−) −1 180 476.44 −848 092.94 −968 942.02
Cancellation of appropriations carried over (+) 38 712.08 18 278.73 18 245.88
Adjustment for carry-over of assigned revenue appropriations from 
previous year (+)
185 447.51 651 383.96 342 257.97
Exchange rate differences (+/−) 4 976.68 2602.23 −271.84
TOTAL 54 436.49 215 188.58 189 763.80
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l  Annex III Human resources outlook and staff evolution
TABLE A4
Staff population and its evolution; overview of all categories of staff
Staff population
Actually filled in 
31.12.2016
Authorised 
under EU 
Budget 2017
Actually 
filled at 
31.12.2017 
(1)
Authorised 
under EU 
Budget 
2018
Actually 
filled in 
31.12.2018
In draft 
budget for 
year 2019
Envisaged 
in 2020
Envisaged 
in 2021
Officials AD 6 6 6 6 6 6 6 6
AST 3 4 3 4 3 4 4 4
AST/SC 0 0 0 0 0 0 0 0
TA AD 42 45 42 45 43 45 45 45
AST 22 22 21 21 21 21 21 21
AST/SC 0 0 0 0 0 0 0 0
Total 73 77 72 76 73 76 76 76
CA GF IV 3 7 4 8 5 8 8 8
CA GF III 9 10 9 10 9 10 10 10
CA GF II 13 13 13 13 12 13 13 13
CA GF I 3 3 3 3 3 3 3 3
Total CA 28 33 29 34 29 34 34 34
SNE 1 1 1 1 1 1 1
Structural service 
providers
0 0 0 0 0 0 0 0
TOTAL 101 111 102 111 103 111 111 111
External staff for 
occasional 
replacement
3 3 4 4 4 2 2
(1) Offer letters are counted as posts filled in.
PROGRAMMING DOCUMENT 2019–21
53 / 80
TABLE A5
Multiannual staff policy plan 2019–21
Category and 
grade
Establishment 
plan in EU 
budget 2017
Filled as of 
31.12.2017 
(1)
Modifications 
2017 in 
application of 
flexibility rule
Establishment 
plan in voted 
EU budget 
2018
Modifications 
2018 in 
application of 
flexibility rule 
(2)
Establishment 
plan in draft 
EU budget 
2019
Establishment 
plan 2020
Establishment 
plan 2021
officials TA officials TA officials TA officials TA officials TA officials TA officials TA officials TA
AD 16
AD 15 1 1 1 1 1
AD 14 1 1 1 1 1 1
AD 13 1 2 1 3 1 2 1 1 3 1 3 1 3
AD 12 4 11 3 4 4 11 −1 4 10 3 9 3 8
AD 11 1 11 7 1 11 1 11 1 10 1 9
AD 10 13 2 13 −1 12 1 11 1 9
AD 9 6 2 6 6 1 7 8 9
AD 8 11 1 3
AD 7 5 1 2
AD 6 1
AD 5 2
Total AD 6 45 6 42 6 45 0 0 6 45 6 45 6 45
AST 11 1 1 1 1 1 1 1 1 1
AST 10 3 1 3 −1 2 2 2
AST 9 1 7 3 1 7 1 7 1 6 1 5
AST 8 2 7 1 2 7 2 7 2 6 2 5
AST 7 5 1 3 −1 4 4 5 6
AST 6 6 1 2
AST 5 1 6
AST 4 1
AST 3
AST 2 1
AST 1
Total AST 4 22 3 21 −1 4 21 0 0 4 21 4 21 4 21
AST/SC 6
AST/SC 5
AST/SC 4
AST/SC 3
AST/SC 2
AST/SC 1
Total AST/SC
TOTAL 10 67 9 63 −1 10 66 0 0 10 66 10 66 10 66
(1) Offer letters are counted as posts filled in.
(2) The Article 38 of the Framework Financial regulation was applied following a screening exercise.
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l  Annex IV  Human resources policies
l Recruitment policy
The selection procedures applied by the EMCDDA comply 
with the relevant EU provisions, namely Article 12 of the CEOS 
for the recruitment of temporary and contract agents and the 
principles and standards laid down for officials in Annex III of 
the Staff Regulations.
The key phases of the selection procedure for the recruitment 
of temporary and contract agents can be summarised as 
follows:
■■ a vacancy notice is published on the EMCDDA website, on 
the EPSO website, and a communication is sent to all other 
EU institutions and agencies, to all focal points of the Reitox 
network, to all members of the EMCDDA Management 
Board and Scientific Committee and, where appropriate, 
advertisements are placed in the local and specialised 
press and web pages;
■■ the vacancy notice sets out eligibility and selection criteria, 
indicating type and duration of contract and recruitment 
grade;
■■ a Selection Committee is appointed, usually composed 
of five members. The Selection Committee includes 
a representative from the EMCDDA Staff Committee and 
takes into account gender balance and broad geographical 
representation. External members are invited in cases 
where specific expertise is required to carry out the 
selection process appropriately. The names of the Selection 
Committee members are now published in the vacancy 
notice in full respect of regulation 45/2001 as requested by 
the European Ombudsman;
■■ applicants are first screened on the basis of their 
application file (application form, CV and the further 
supporting documents required) in order to identify the 
candidates who best match the published requirements;
■■ selected candidates are interviewed on the basis of pre-
defined questions that are presented to all candidates 
interviewed. The procedure includes a compulsory 
written test. The interview and test cover: assessment of 
the specific competences and technical qualifications 
required for the selection process concerned; knowledge 
of European institutions and particularly of the EMCDDA’s 
activities; general skills and language abilities of the 
candidate;
■■ the Selection Committee drafts a list of the most suitable 
candidates together with a possible proposal to the 
Authority authorised to conclude the contract (AHCC) and/
or to establish a reserve list for recruitment purposes;
■■ a reserve list may be established by the AHCC who can, 
prior to this, choose to have a further interview with 
concerned candidates;
■■ the result of the selection process is communicated to the 
selected candidates;
■■ all steps of the procedure and all decisions made are 
reported and documented.
The procedures described above comply with the 
implementing rules on the recruitment and use of temporary 
and contract agents adopted by the EMCDDA with the 
agreement of the European Commission pursuant to Article 
110 of the Staff Regulations.
When recruiting officials, the EMCDDA complies with the 
relevant provisions of the Staff Regulations, namely with 
Article 29 and Annex III. The EMCDDA organised two internal 
competitions in 1999 and 2002. These competitions were 
carried out in cooperation with the European Commission.
Other EMCDDA vacant posts for officials have been filled 
through interinstitutional transfer processes according to the 
applicable provisions of the Staff Regulations.
The EMCDDA envisages that it will continue to draw on 
the assistance that the European Communities Personnel 
Selection Office (EPSO) can provide in this field, including 
using its reserve lists, as required. This has already been the 
case for hiring officials and contract agents.
Grade and function group corresponding to the tasks 
and level of the post
In line with the relevant provisions of the Staff Regulations 
and CEOS and within the limits set by the budget adopted and 
the establishment plan, the EMCDDA applies by analogy the 
rules applied by the European Commission for the grading of 
officials, temporary agents and contract agents. The EMCDDA, 
as a basic rule, recruits temporary agents at grades ranging as 
follows:
■■ from AST/SC 1 to AST/SC 2 for function group AST/SC;
■■ from AST 1 to AST 4 for function group AST;
■■ from AD 5 to AD 8 for function group AD.
Recruitment at grades AD 9 to AD 11, and in exceptional cases 
at AD 12, is limited to filling middle management positions or 
to particular cases where a higher grade is essential to ensure 
a recruitment of high quality. In the latter case, the grade must 
be justified by the high level of expertise required, the specific 
conditions of the labour market concerned and/or by the 
fact that a lower grade would not be attractive for the target 
population of potential candidates.
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Duration of employment
Upon recruitment, EMCDDA temporary and contract agents 
engaged to address long-term or permanent tasks are offered 
a contract of five years. In accordance with Articles 8 and 85 of 
the CEOS, this contract may be renewed for further five years. 
In case of second renewal, agents are engaged for an indefinite 
period.
EMCDDA temporary and contract agents on short-term 
employment recruited to address time-bound tasks or 
temporary needs are engaged for the period required to fulfil 
the tasks concerned. In principle, the contract may be renewed 
just once for a definite period.
The EMCDDA Director is employed as a temporary agent 
for a five-year term, this term being renewable. This is in 
accordance with the relevant provisions of the EMCDDA 
founding regulation.
Profile of staff, and type and duration of employment 
required to fulfil the agency’s mission and tasks
For the majority of its activities, the EMCDDA requires 
scientifically and/or technically qualified staff with highly 
specialised knowledge and extensive experience — particularly 
in those fields linked to its core activities. Specialisation is 
inherent to the agency. The EU skill base of available and 
competent staff is limited. In some areas of activity, only one 
staff member is involved in running the service.
Furthermore, given the ground-breaking nature of many of 
its activities, the agency needs to cultivate a workforce that 
combines sector knowledge and insight in its specialised field 
of expertise (drugs and drug addiction) with a track record of 
innovation, cooperation and knowledge transfer. Staff therefore 
need to be prepared to nurture agency-wide skills, and must 
possess the professional latitude and flexibility to work 
‘horizontally’ on other projects that might benefit from their 
area of expertise.
The EMCDDA’s staff policy must therefore rise to the 
challenges faced by all ‘centres of excellence’: to attract 
strong talent, to build on strong previous work, to retain valued 
expertise and, ultimately, to ensure business continuity. A key 
aspect in meeting these challenges is that the agency must 
have at its disposal the means to offer staff appropriate job 
security and career prospects, with a long-term or permanent 
outlook.
(a) Officials and temporary agents on long-term 
employment (long-term staff)
The EMCDDA employs officials and temporary agents on 
long-term employment to carry out its scientific, technical and 
administrative tasks of a permanent or long-term nature. These 
tasks can be summarised as follows:
■■ tasks directly relating to the implementation of the 
EMCDDA’s core activities as defined by its founding 
regulation;
■■ tasks relating to the management and functioning of the 
EMCDDA, aimed at providing technical and administrative 
support to its core business.
Temporary agents on long-term employment are offered a five-
year contract at the time they are contracted. In accordance 
with Articles 8 and 85 of the CEOS, this contract may be 
renewed for further five years. In case of second renewal, 
agents are engaged for an indefinite period.
The use of officials is necessary for a number of reasons:
■■ retaining proven talent and enhancing career opportunities 
for EMCDDA temporary staff;
■■ sourcing skills from other EU bodies: enabling the possibility 
for transfers of officials from other EU institutions and 
bodies, in order to fill posts of a sensitive character or 
requiring specific professional expertise which is available 
in these institutions and bodies. In particular, the option 
of official is important for sourcing the scientific, technical 
and administrative skills common to all EU institutions 
and bodies; it is also useful to attract suitably qualified 
candidates who are on reserve lists following successful 
completion of competitions at other EU institutions;
■■ expertise exchange to other EU bodies: that is, the 
possibility to offer options for external mobility, by way of 
secondment or transfer. This option takes into account the 
limited possibilities provided for temporary agents in the 
context of their current fixed-term contracts, while providing 
incentives to younger staff who are given the chance to plan 
their career in the wider context of all EU institutions and 
bodies;
■■ maximising resources: to profit from the specific experience 
and knowledge acquired for executing highly-specialised 
tasks.
All posts for officials and temporary agents authorised in the 
EMCDDA’s current establishment plan are posts of permanent 
or long-term nature (long-term employments), with the post of 
the Director being a specific case.
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(b) Temporary agents on short-term employment (short-
term staff)
The EMCDDA may also employ temporary agents on short-
term employment to fulfil specific scientific, technical and 
administrative operating needs of a limited duration. The 
duration of the contract is determined by the limited duration 
of the tasks. In principle, the contract may be renewed just 
once for a definite period:
■■ to ensure the delivery of time-bound tasks, that is for the 
execution of technical assistance projects financed by 
specific appropriations provided by EU programmes (for 
example, CARDS, IPA, ENI);
■■ to ensure the temporary replacement of staff in case of 
mid- or long-term absences;
■■ to cope with temporary peaks in workload;
■■ to fulfil highly specific temporary operational needs 
requiring highly specific and high-level technical or 
scientific expertise.
(c) Contract agents on long-term employment (long-term 
staff)
The EMCDDA employs contract agents on long-term 
employment for its scientific, technical and administrative 
tasks of a permanent or long-term nature. In accordance with 
the function groups (FGs) and grades defined by Article 80 of 
the CEOS, the EMCDDA’s contract staff are typically assigned 
to tasks aimed at providing administrative, linguistic, scientific 
and drafting support to the work of officials or temporary 
agents within the FGs I, II and III. The use of contract staff in FG 
IV is limited to those situations where it is necessary to recruit 
very specific and high-level technical or scientific expertise.
Currently the tasks that EMCDDA contract staff are requested 
to carry out under the supervision of officials or temporary 
staff entail a lower level of responsibility. Some restrictions on 
contract staff have been established with regard to:
■■ functions and tasks relating to the execution of the 
EMCDDA budget, where a large measure of discretion 
implying strategic choices is involved;
■■ functions relating to the representation of the EMCDDA 
in institutional relations with its partners, such as EU 
institutions, national authorities and international 
organisations, in accordance with the regulation 
establishing the EMCDDA.
Contract agents on long-term employment are offered a five-
year contract upon recruitment. In accordance with Articles 8 
and 85 of the CEOS, this contract may be renewed for further 
five years. In case of second renewal, agents are engaged for 
an indefinite period.
At the time of writing, all EMCDDA contract agent positions 
have been identified as long-term employment.
(d) Contract agents on short-term employment (short-term 
staff)
The EMCDDA may also employ contract agents on short-
term employment to cope with specific scientific, technical 
and administrative operating needs of a limited duration, 
similar to the one assigned to temporary agents on short-term 
employment. In principle, the contract may be renewed just 
once for a definite period.
Some restrictions apply to the use and the nature of the duties 
of the contract agents on short-term employment as detailed 
above.
(e) Seconded national experts (SNEs)
The objective the EMCDDA follows with the recruitment of 
SNEs is to benefit from the high level of their professional 
knowledge and experience, in particular in areas where such 
expertise is not readily available.
The complete legal framework for recruitment of SNEs at the 
EMCDDA is to be found in the Decision of the Management 
Board of the EMCDDA on the adoption of rules on the 
secondment of national experts at the EMCDDA (DEC/
MB/10/02) of 5 May 2010 (which adopts by analogy the 
European Commission Decision of 12 November 2008, laying 
down rules on the secondment to the Commission of national 
experts and national experts in professional training). SNEs 
are recruited following a similar procedure to the one used 
for the recruitment of temporary staff and the guidelines of 
such a procedure are publicly published in the EMCDDA job 
vacancies web page.
l  Appraisal of performance and reclassifications/promotions
Since 1998, the EMCDDA has carried out annual exercises 
for staff appraisal, promotion of officials, assignment of 
temporary agents to a post corresponding to a higher grade, 
and classification of contract agents in the subsequent higher 
grade. The rules and procedures applied by the EMCDDA 
comply with the relevant provisions of the Staff Regulations 
and the CEOS.
In this context, the EMCDDA applies tools and processes for 
its ‘long-term’ staff that reflect those applied by the European 
Commission. This means:
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■■ for staff appraisal: an annual exercise focusing on the staff 
member’s performance. This includes dialogue between the 
actors involved, possibility for appeal and definition of the 
staff member’s training needs;
■■ for promotion of officials, for assignment of temporary 
agents to a post corresponding to a higher grade and for 
classification of contract agents in the subsequent higher 
grade: a merit-based annual exercise with two years in the 
current grade as a minimum condition for eligibility. This 
includes a focus on the comparative assessment of the 
merits of eligible staff, mainly taking into account the result 
of the appraisal exercise.
The EMCDDA’s rules and procedures in this field were revised 
in 2009, by decision of the EMCDDA Management Board and 
with the agreement of the European Commission, on the basis 
of common model decisions resulting from preparatory works 
carried out by the agencies and the European Commission. 
After the entry into force on 1 January 2014 of the latest 
reform of the Staff Regulations/CEOS, the EMCDDA revised 
the appraisal of performance rules and procedures on the 
basis of common model decisions prepared by the standing 
working party (SWP) set up for this purpose by the EC’s 
relevant services and the network of the EU decentralised 
agencies. The EMCDDA Management Board adopted the rules 
that follow the model worked out by the SWP that has been 
adopted by ex-ante agreement by the EC and entered into 
force for the first time in 2016.
Taking into account the current policy at the EMCDDA for staff 
promotion and assignment to a higher grade (reclassification), 
the EMCDDA estimates a promotion and reclassification 
rate which is in line with Annex IB and Annex XIII of the Staff 
Regulations. Regarding the legal framework for promotions 
and reclassification, the SWP finalised the work and 
proposed a model to all agencies. The EMCDDA adopted 
the rules proposed by the EC and started applying them for 
the 2017 exercise. Below, the actual figures on promotion/
reclassification are presented for full information.
TABLE A6
Reclassification of temporary staff/promotion of officials
Category and 
grade
Staff in 
activity at 
01.01.2016
How many 
staff 
members 
were 
promoted/
reclassified in 
2017 (1)
Average no. of 
years in grade 
before 
reclassification/ 
promotion
officials TA officials TA
AD 16
AD 15
AD 14 1
AD 13 1 3
AD 12 3 5
AD 11 6 1 6
AD 10 2
AD 9 1 5 1 1 5
AD 8 1 8 4 3.25
AD 7 8 1 4.5
AD 6 2
AD 5 1
Total AD 6 41 1 7
AST 11
AST 10 1
AST 9 3
AST 8 1 1
AST 7 1 2 2 4
AST 6 8
AST 5 1 6
AST 4 1
AST 3
AST 2 1
AST 1
Total AST 4 22 0 2
AST/SC 1
AST/SC 2
AST/SC 3
AST/SC 4
AST/SC 5
AST/SC 6
Total AST/SC
TOTAL 10 63 1 9
(1) Number of staff reclassified/promoted at the new grade.
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TABLE A7
Reclassification of contract staff
Function 
group
Grade
Staff in 
activity at 
01.01.2016
How many 
staff members 
were 
reclassified in 
2017 (1)
Average 
number of 
years in grade 
of reclassified 
staff members
CA IV
18
17 1 2
16 1
15
14 1
13
CA III
12 1
11 2 1 5
10 3
9 2
8
CA II
7 5 2 4
6 5
5 1 1 3.5
4 1
CA I
3 3
2
1
TOTAL 25 5
(1) Number of staff reclassified at the new grade.
l Mobility policy
(i) Mobility within the EMCDDA
So far, mobility of staff members within the EMCDDA has been 
achieved using the following:
■■ internal publication of calls for expression of interest;
■■ external publications of calls for selection which also 
welcome applications from internal candidates;
■■ redeployment or reassignment of staff in the interest of the 
service;
■■ mutual exchange of staff between different units, where 
there is agreement between the heads of unit concerned.
(ii) Mobility among EU agencies
Most of the EMCDDA’s staff is composed of temporary agents, 
as is the case with the staff of most other EU agencies. Inter-
agency mobility has to date been achieved via the recruitment 
of staff previously employed at other agencies by applying 
the standard selection procedures used for all candidates. So 
far, the EMCDDA has recruited seven temporary agents who 
were previously engaged by other EU agencies. Seven of the 
EMCDDA’s former temporary agents have been engaged by 
another EU agency.
As from 2014 and with the entry into force of the new Staff 
Regulations the legal framework has changed. Due to the 
introduction of a new category of temporary agents (upon 
Article 2f of the Conditions of Employment of other Servants 
of the EU (CEOS) and the introduction of Article 55 CEOS, 
the continuity of career for temporary agents is ensured. The 
EMCDDA has already recruited the first temporary agent from 
another agency using the abovementioned articles.
(iii) Mobility between the EMCDDA and the EU 
institutions
So far, mobility of staff members between the EMCDDA and 
the EU institutions has been achieved through:
■■ transfer of officials from the institutions to the EMCDDA 
(seven officials from the European Commission and one 
from the Council were concerned so far);
■■ transfer of officials from the EMCDDA to the EU institutions 
(six officials to the European Commission and one official 
to the Committee of the Regions);
■■ engagement as temporary agents of officials on 
secondment from EU institutions who have been successful 
in an EMCDDA selection process for temporary agents (12 
officials from the European Commission; two officials from 
European Parliament).
l Gender and geographical balance
The gender balance among EMCDDA overall staff in 2016 was 
once again slightly positive towards women. The illustration 
below provides a visual representation of the number of female 
and male staff per contract type (officials/temporary agents/
contract agents) with an indication of the function group (AD/
AST). The same information is provided regarding seconded 
national experts.
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Gender balance at 31/12/2017
Female Male Total
Officials
AD 0 6 6
AST 3 0 3
Sub-total 3 6 9
Temporary agents
AD 21 21 42
AST 10 11 21
Sub-total 31 32 63
Contract agents
CA IV 3 1 4
CA III 6 3 9
CA II 12 1 13
CA I 0 3 3
Sub-total 21 8 29
SNE 0 1 1
Sub-total 0 1 1
TOTAL 55 47 102
Management gender balance at 31/12/2017
Positions (HoU upward only) Female Male % of female
Senior management (Director) 1 -
Middle management (Heads of unit) 2 6 25 %
Geographical balance at 31/12/2017
Officials Temporary 
agents
SNE Contract agents Total
Nationality AD AST AD AST CA I CA II CA III CA IV Nationality %
Belgian 1 3 3 2 1 10 Belgian 9.8 %
British 8 1 1 10 British 9.8 %
Bulgarian 3 1 4 Bulgarian 3.9 %
Dutch 1 1 Dutch 1.0 %
French 5 1 1 7 French 6.9 %
German 1 3 2 6 German 5.9 %
Greek 1 1 Greek 1.0 %
Irish 3 1 4 Irish 3.9 %
Italian 1 4 1 4 10 Italian 9.8 %
Latvian 1 1 Latvian 1.0 %
Luxembourgish 1 1 2 Luxembourgish 2.0 %
Polish 1 1 1 1 4 Polish 3.9 %
Portuguese 1 3 6 8 3 8 4 1 34 Portuguese 33.3 %
Romanian 1 1 2 Romanian 2.0 %
Spanish 2 2 2 6 Spanish 5.9 %
TOTAL 6 3 42 21 1 3 13 9 4 102 100 %
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l Schooling
There is no European or accredited school that can be 
attended free of charge in the area where the EMCDDA has 
its seat, and education is available only in English, French, 
German, Spanish and Portuguese on a private basis which is 
more expensive than the cost staff members can cover with 
the double education allowance foreseen under Annex VII of 
the Staff Regulations. Because of this, staff members of the 
EMCDDA are penalised for not being able to give their children 
an education in their mother tongue.
It is evident that the staff of the EMCDDA are not treated 
equally to other EU personnel when one considers that: (i) the 
staff members of EU institutions, including some agencies, 
enjoy free access to European Schools (school fees and 
transport included), where available, under the condition they 
have a contract of at least one year; (ii) the average annual 
costs covered by the EU budget per pupil attending a European 
school is approximately EUR 11 840 (10) while the maximum 
reimbursement for education allowance, foreseen by the Staff 
Regulations for covering the costs of attendance of a pupil 
per year of any school where no European school is available, 
is approximately EUR 5 953; (iii) European Schools provide 
multilingual tuition in all languages of the EU 15 and most of 
the EU 27 and offer the European Baccalaureate recognised in 
all Member States.
Given that the EMCDDA is called upon to recruit officials 
and temporary staff of the highest ability, efficiency and 
integrity from the broadest possible geographical basis among 
nationals of Member States, as laid down in Article 27 of the 
Staff Regulations and Articles 12 and 82 of the Conditions 
(10) Annual Report of the Secretary-General to the Board of Governors of the 
European Schools — Presented to the Board of Governors of the European 
Schools at its meeting 8, 9 and 10 April 2014, in Sofia. Ref.: 2014-01-D-23-fr-2.
of employment for temporary officials and contract staff, 
a measure is needed to match the unequal working conditions 
to which the staff of the EMCDDA are subject compared to 
other staff working for the European Union in a location where 
European Schools exist. Local solutions based on existing best 
practice should have been found to school staff children — 
solutions that reconcile the work and private life of EMCDDA 
staff by facilitating the schooling of their children.
While awaiting a more structural solution resulting from the 
work performed by the management of the European Schools 
and in line with the ‘Guidelines on staff policy in the European 
regulatory agencies’ as adopted by the European Commission 
on 16 December 2005 (C(2005)5304), since the school year 
2009/2010 the EMCDDA has negotiated and concluded 
agreements with educational establishments in the area of 
Lisbon to provide schooling services for the children of its 
staff and ensure the direct payment of the eligible costs for 
educational services as described in the Staff Regulations.
The staff member who benefits from this system does not 
receive the education allowance provided for in Article 3 of 
Annex VII to the Staff Regulations, and the relevant rights/
entitlements are suspended for the period where he/she 
benefits from the system. The payment of expenses incurred 
by EMCDDA staff for the abovementioned eligible education 
costs is limited to a maximum ceiling of EUR 11 076 per child, 
per annum, which is, as mentioned above, the annual average 
cost covered by the EU budget per pupil attending a European 
school. The ceiling mentioned shall be revised annually 
pursuant to the relevant information provided by the Annual 
Report of the Secretary-General to the Board of Governors of 
the European Schools.
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l  Annex V Buildings
l Current building(s)
EMCDDA headquarters: Praça Europa 1, Cais do Sodré, Lisbon
Other comments
Type of building Office building, rented Pursuant to an agreement with the Portuguese State, in 2009 an area of 
673.25 square metres (located in the ‘Relogio’ building of the EMCDDA 
premises) was sublet to the latter for the use of the Jaques Delors European 
Information Centre (JDEIC since 2009). This sublease covered the period 
between May 2009 and March 2012, when the CIEJD left the areas occupied 
pursuant to the decision taken by the relevant Portuguese authorities.
Since 2012, some private and public entities have expressed an interest for 
the sublease but they were not able to present any offer.
Finally in early 2016 the company Bensaude presented an offer for this 
sublease which would allow the EMCDDA to sublet the areas previously used 
by the CIEJD and neutralise the budget impact entailed by the departure of 
the latter. On this basis the EMCDDA and the company Bensaude S.A. 
concluded the contract for the sublease of these areas. The date of effect of 
this contract is 1 May 2016 and it will have an initial duration of five years, 
which may be extended for further period of five years.
Surface area (in square 
metres)
Of which office space
Of which non-office space
6 520 + 61 parking spaces
5 846
674
643 square metres of office space are subleased.
Annual rent (in EUR) 305 421.96 Pursuant to the agreement reached in 2015 with the landlord for the payment 
of the rent for the lease of the current premises in the following years, the 
annual amount of this rent was adjusted as follows:
EUR 272 085.96 for 2017 EUR 305 421.96 for 2018 EUR 589 689.96 for 
2019 EUR 955 889.96 for 2020 EUR 1 072 089.96 from 2021 until the end of 
the 25 years lease contract in force.
Type and duration of rental 
contract
Lease for 25 years with option to 
buy
Host country grant or support The host county supported the 
installation by providing the office 
furniture for the headquarters.
Present value of the building Not applicable
l Building project in the planning phase
No new building projects have been planned.
l  Building projects submitted to the European Parliament and the Council
No further building projects have been submitted to the 
European Parliament and the Council.
PROGRAMMING DOCUMENT 2019–21
62 / 80
l  Annex VI  Privileges and immunities
Agency privileges Privileges granted to staff
Protocol of privileges and immunities/
diplomatic status
Education/day care (1)
The Portuguese Government granted the 
EMCDDA with diplomatic status by means of 
the conclusion of a seat agreement on 26th 
June 1996 (Protocol between the Portuguese 
Government and the EMCDDA regarding the 
functioning of the agency in Portugal and the 
installation of its headquarters in Lisbon). 
Through this Agreement, which entered into 
force in May 1998, the Portuguese 
Government applies the Protocol on the 
Privileges and Immunities of the European 
Communities to the EMCDDA, exempting the 
agency from payment of all national, regional or 
municipal rates and taxes as regards the fixed 
assets it owns or rents, as well as from 
customs duties and from any other taxes, 
prohibitions or restrictions on goods of any kind 
which it imports or exports in the exercise of its 
official business (VAT, etc.).
Protocol on the Privileges and Immunities of the 
European Communities is applicable to 
EMCDDA staff. The Protocol concluded 
between the Portuguese Government and the 
EMCDDA regarding the functioning of the 
agency in Portugal and the installation of its 
headquarters in Lisbon, grants the EMCDDA 
staff the privileges and immunities, exemptions 
and facilities recognised by the Portuguese 
State to members of a comparable category of 
the diplomatic corps in Portugal. As 
a consequence, EMCDDA staff members are 
entitled to purchase furniture and/or household 
aids VAT-free. This exemption does not cover 
expenditure for food supplies and beverages, 
property works, including materials, water, gas, 
electricity, food and beverages services, hotels 
or similar services, fixed line telephone services. 
Limited exemption is granted from the payment 
of the Portuguese tax and VAT on the purchase 
and registration of vehicles.
There is no European or accredited school that 
can be attended free of charge in the area 
where the EMCDDA has its seat. As per the 
Memorandum of Understanding signed in 2004 
by the Portuguese Government, the EMCDDA 
and EMSA concerning the common premises 
of the two agencies in Lisbon, the Portuguese 
Government committed itself to do its utmost 
(jointly with EMSA and EMCDDA) to find the 
best possible solution for providing schooling 
for the children of EMSA and EMCDDA staff. In 
this context it agreed to pursue either the 
establishment of a European School in Lisbon 
or the signature of partial agreements between 
the European School Board and the main 
international schools in the Lisbon area. 
However, difficulties have been encountered for 
the implementation of this solution.
(1) See also Annex IV, Section Schooling
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l  Annex VII Monitoring and evaluation
l External evaluations
In line with Article 23 of the EMCDDA founding regulation 
recast, the European Commission shall initiate an external 
evaluation of the agency every six years and forward the 
evaluation report to the European Parliament, the Council and 
the Management Board of the EMCDDA.
The last external evaluation of the agency was completed in 
June 2012 and the result can be found at the following web 
link: http://www.emcdda.europa.eu/html.cfm/index184823EN.
html.
The final report contained 15 recommendations and the 
agency prepared an action plan to implement them. This 
action plan was adopted by the Management Board at its 
meeting of 5–6 July 2012.
With a view to monitoring the implementation of the 
follow-up action plan, an annual internal assessment 
exercise was put in place and the results were presented 
in the General Report of Activities for 2013 and 2014 
(available at: http://www.emcdda.europa.eu/publications/
searchresults?action=list&type=PUBLICATIONS&SERIES_
PUB=w8).
All the actions which were under the control of the 
EMCDDA had been implemented by the end of 2014. On 
this ground, a decision was adopted by the Management 
Board in September 2015 to consequently close all these 
recommendations.
The fourth external evaluation of the EMCDDA has been 
carried out by the European Commission during 2018. The 
exercise has evaluated the success of the implementation of 
the three-year strategy and work programme for 2016–18, 
as well as of the previous strategy and work programme 
for 2013–15. The Final report will be presented to the 
EMCDDA Management Board in December 2018, further 
to which a follow-up action plan will be developed by the 
agency in 2019 (see also the Main area 3: Business Drivers, 
‘Institutional’).
l Internal monitoring and evaluation system
In 2017, the EMCDDA started an important exercise to align 
its strategic planning activities with the recently adopted 
Strategy 2025 and ensure they fit within the new integrated 
strategic and operational framework of the agency (see 
Section II, Multiannual programming 2019–21, Introduction: 
the EMCDDA’s strategic approach to 2025, Figure 2).
As part of this process, a redefinition of the areas of work 
within the EMCDDA’s Programming Document 2019–21 was 
performed, so that it reflects the structure of the Strategy 
2025. In this context, a review of the performance framework 
of the agency was initiated. The process benefitted from an 
exchange of experience with Eurofound, an EU agency similar 
to the EMCDDA in terms of mandate and size of its operations.
As a result, and following the ‘theory of change’ approach, 
a new model has been designed (see Figure A1). It identifies 
a limited number (ten) of key performance indicators (KPIs) 
which will be used to measure the effectiveness in delivering 
the desired outputs and the efficiency in using the resources 
allocated to that end.
They will be complemented by higher level KPIs, at outcome 
and impact levels respectively. While the EMCDDA will ensure 
high-quality delivery of its products and services, in line with 
its mandate and resources, their uptake by the agency’s key 
stakeholders (outcome) and any consequent changes to EU 
drug policies and legislation (first-level impact) are, however, 
beyond the control of the EMCDDA.
In Figure A1, this is reflected by means of the ‘accountability 
ceiling’, which shifts gradually from ‘high’ in the area of inputs, 
processes and outputs, to ‘low’, as we approach the ‘impact’ 
area.
In order to measure the ten composite KPIs, smaller and 
more specific performance indicators (PI) and additional 
performance data (metrics) will be put in place (see Table A9). 
They will build on the experience and knowledge gained in 
implementing the EMCDDA performance framework to date 
and will be further refined in order to make sure they are fit for 
purpose in the new framework.
Therefore, the framework presented in this PD 2019–21 
represents work in progress and it will be further elaborated, 
fine-tuned and tested in 2019. For a comprehensive picture, 
an overview of the main areas, strategic objectives, high-
level expected results (outcomes) and KPIs included in this 
programming document is provided in Table A8.
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FIGURE A1
The new EMCDDA performance model
Input
Activities
(process) Output Outcome
1st level
impact
Accountability ceiling
Highest Lowest
1. Budget 
execution
2. Sta	 
capacity
3. Implementation
of the EMCDDA
monitoring system
A healthier and 
more secure 
Europe through 
better-informed 
drug policy and 
action
EMCDDA
Vision
EMCDDA
Mission
4. Implementation
of the EWS and
risk assessment
mechanism
5. Implementation
and management
of the RTX grant
agreements
6. Organisational
eciency
7. Work
programme
delivery
8. Ecient
implementation
of the technical
assistance 
projects with
third countries
9. Uptake of the 
EMCDDA evidence 
(knowledge)
through a number 
of channels
10. Uptake of the 
EMCDDA evidence 
(knowledge)
by policymakers 
To provide the
EU and its
Member States
with a factual
overview of
European 
drug problems
and a solid
evidence base
to support
the drugs 
debate
TABLE A8
Overview of the main areas, strategic objectives, high-level expected results (outcomes) and KPIs
Strategic objectives Action areas Outcomes KPIs
Main area 1: Health
1. Maintain 
a state-of-the-art 
understanding of the 
extent, patterns and 
trends in drug use, 
their impact on 
public health
1.1. Strengthen the core monitoring 
system: a) critically review and develop, 
as needed, the data collection tools to 
ensure they remain fit for purpose; b) 
support national reporting capacity 
necessary for routine reporting
1.2. Identify and develop new flexible 
and timely monitoring tools and 
approaches to ensure the monitoring 
system reflects contemporary drug 
patterns and their implications for 
public health
1.3. Better understand the implications 
for public health of the evolving 
international drug problem, with special 
attention to the countries bordering the 
European Union, and within the 
agency’s mandate
1.4. Identify future reporting needs 
through a ‘futures exercise’ and 
appropriate follow-up activities
Implementation of core monitoring 
tools optimised and new processes for 
monitoring drug demand developed, to 
respond to the needs of contemporary 
drug patterns
Comprehensive understanding of the 
EU drug situation through improved 
quality and availability of data
Improved ability to capture the 
developments in the international drug 
situation
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA 
monitoring system
7. Work programme delivery
8. Efficient implementation of the 
technical assistance projects with third 
countries
9. Uptake of the EMCDDA evidence 
(knowledge) through a number of 
channels
10. Uptake of the EMCDDA evidence/
knowledge by policymakers
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Strategic objectives Action areas Outcomes KPIs
2. Identify new 
drug-related health 
threats and support 
rapid response from 
the EU and its 
Member States
2.1. Ensure the successful operation of 
the EU Early Warning System on new 
psychoactive substances (EWS)
2.2. Ensure timely and high-quality 
implementation of the risk assessment 
on new psychoactive substances 
(NPS)
2.3. Develop innovative approaches to 
identifying and reporting on new 
trends, and enhance the EMCDDA’s 
capacity for timely data collection and 
analysis
2.4. Conduct threat assessments and 
rapid reporting exercises of new 
drug-related health threats in order to 
facilitate appropriate responses (in 
collaboration with partners, as 
appropriate)
Effective implementation of the EU 
Early Warning System on new 
psychoactive substances (EWS) and 
the EU risk assessment mechanism on 
NPS
Health-related emerging trends and 
threats captured and reported in 
a timely manner
Increased capacity of the EU and its 
Member States to rapidly respond to 
new health-related drug-related threats
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA 
monitoring system
4. Implementation of the EWS and 
risk assessment mechanism on NPS
7. Work programme delivery
8. Efficient implementation of the 
technical assistance projects with third 
countries
9. Uptake of the EMCDDA evidence 
(knowledge) through a number of 
channels
10. Uptake of the EMCDDA evidence/
knowledge by policymakers
3. Support 
interventions to 
prevent and reduce 
drug use, drug-
related morbidity, 
mortality and other 
harms, and support 
recovery and social 
reintegration
3.1. Follow developments from basic 
research, applied research and 
implementation science to maintain 
state-of-the-art understanding of what 
constitutes effective interventions to 
both established and emergent 
drug-related problem
3.2. Strengthen, maintain and develop 
the monitoring tools required for 
describing the delivery of drug-related 
interventions: a) in established areas 
and settings; b) in new settings and 
developmental areas
3.3. Facilitate knowledge transfer, the 
adoption of best practice, and 
successful implementation, through 
development of state-of-the-art 
resources for professionals and 
supporting and developing training and 
capacity-building activities
3.4. Provide additional information 
resources to support decision-making 
and programme development in areas 
particularly important for public health, 
or where innovations are becoming 
available or the knowledge base is 
rapidly changing (such as HCV 
treatment, overdose prevention, new 
pharmacotherapies, e-health and 
interventions targeting hard-to-reach 
populations) or where new evidence 
reviews have become available
Optimisation of tools to monitor drug 
interventions (established and new)
Better and more informed policy and 
practice on effectiveness of 
interventions in drug demand reduction 
within the EU
Increased availability of effective 
interventions to prevent and reduce 
drug use, drug-related morbidity, 
mortality and other harms
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA 
monitoring system
7. Work programme delivery
9. Uptake of the EMCDDA evidence 
(knowledge) through a number of 
channels
10. Uptake of the EMCDDA evidence/
knowledge by policymakers
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Strategic objectives Action areas Outcomes KPIs
4. Support the 
development, 
implementation, 
monitoring and 
assessment of 
policies aimed at 
addressing the 
health and social 
consequences of 
drug use
4.1. Support as requested EU and 
national policy initiatives within the 
EMCDDA’s areas of competence, with 
particular attention given to the 
implementation of the EU drug strategy 
and its action plans
4.2. Monitor and report on key policy 
developments, occurring nationally, at 
EU level and internationally, to facilitate 
an informed and up-to-date dialogue
4.3. Maintain and develop resources to 
support policy formulation and 
evaluation (in close coordination with 
the support to policy provided in the 
supply area)
Optimisation of tools to monitor drug 
policies and legislation
Increased capacity of EU and national 
policymakers to address the health and 
social consequences of drug use, with 
evidence provided by, and support 
from, the EMCDDA
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA 
monitoring system
7. Work programme delivery
9. Uptake of the EMCDDA evidence 
(knowledge) through a number of 
channels
10. Uptake of the EMCDDA evidence/
knowledge by policymakers
Main area 2: Security
1. Provide 
a comprehensive, 
holistic and 
up-to-date 
understanding of the 
drug market in 
Europe
1.1. Strengthen the core monitoring 
system: improve quality and coverage 
in the implementation of supply and 
supply reduction indicators in the 
Member States and their supporting 
tools, networks and processes
1.2. Develop new and innovative data 
collection approaches to increase the 
scope and coverage of analysis, and 
provide a cost-effective and practical 
solution to supplement existing core 
data-collection systems in this area 
(e.g. open source intelligence, internet 
monitoring and web surveys)
1.3. Improve understanding of the 
impact on the European drug market of 
developments in the international drug 
situation, with particular attention given 
to the countries bordering the EU
1.4. Support a better strategic 
understanding of the drivers of 
innovation in synthetic drug production 
and their impact, including routes of 
synthesis and source chemicals, and 
contribute to the European system on 
drug-precursor monitoring, together 
with the European Commission and 
Europol
Implementation of supply-related 
monitoring tools optimised and new 
processes for monitoring drug supply 
developed, to respond to the needs of 
contemporary drug patterns
Comprehensive understanding of the 
EU drug market through improved 
quality and availability of data and 
analysis
Improved ability to capture the 
developments in the international drug 
situation
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA 
monitoring system
7. Work programme delivery
8. Efficient implementation of the 
technical assistance projects with third 
countries
9. Uptake of the EMCDDA evidence 
(knowledge) through a number of 
channels
10. Uptake of the EMCDDA evidence/
knowledge by policymakers
2. Identify new 
drug-related 
security threats and 
support a rapid 
response from the 
EU and its Member 
States
2.1. Provide threat assessments related 
to transversal security threats linked to 
the production and supply of drugs
2.2. Identify and communicate the 
threats associated with NPS with 
respect to sourcing, production, transit 
and marketing, and ensure vigilance 
and follow up on threats related to the 
emergence of newly controlled NPS on 
the drug market
2.3. Improve capacity to monitor 
innovation in the drug market and its 
impact, with special attention given to 
the development of online drug 
markets and darknet drug sales
Security-related emerging trends and 
threats captured and reported in 
a timely manner
Increased capacity of the EU and its 
Member States to rapidly respond to 
new drug-related security threats
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA 
monitoring system
7. Work programme delivery
8. Efficient implementation of the 
technical assistance projects with third 
countries
9. Uptake of the EMCDDA evidence 
(knowledge) through a number of 
channels
10. Uptake of the EMCDDA evidence/
knowledge by policymakers
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Strategic objectives Action areas Outcomes KPIs
3. Improve 
understanding of the 
nature and 
consequences of 
drug-related crime
3.1. Improve the monitoring of 
drug-related crime and associated 
responses and countermeasures and 
their impact
3.2. Contribute to an improved 
understanding of the links and 
interactions that exist between drugs 
and serious criminality, including 
security threats, such as illegal financial 
flows, corruption, trafficking in other 
illicit cargos and terrorism
3.3. Support the development of 
a broader conceptual framework on the 
wider societal impact of drug markets 
and drug-related crime, including 
environmental impact, implications for 
community safety and possible 
unintended negative consequences of 
interventions
Better understanding of drug-related 
crime and its link with other serious 
crimes such as terrorism, illegal 
firearms trafficking and illegal migration
Improved comprehension of wider 
societal impact of drug markets and 
drug-related crime
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA 
monitoring system
7. Work programme delivery
8. Efficient implementation of the 
technical assistance projects with third 
countries
9. Uptake of the EMCDDA evidence 
(knowledge) through a number of 
channels
10. Uptake of the EMCDDA evidence/
knowledge by policymakers
4. Support policy 
and operational 
responses to the 
security challenges 
posed by drugs and 
drug markets at EU 
and national level
4.1. Support the EU policy cycle for 
organised and serious international 
crime and provide expertise on the 
EMPACT drug priority areas (through 
threat assessments, provision of 
expertise, and training). A priority task 
for the EMCDDA is to maintain an 
overview of EU drug markets, their 
ramifications and responses
4.2. Increase the effectiveness and the 
impact of EU actions in the security 
area including through: a) 
strengthening/establishing networks of 
field experts, academics, law-
enforcement officials, etc.; and b) 
defining criteria for identifying, 
understanding and prioritising 
emerging threats (including external, 
current and future) stemming from 
drug market activity, integrating 
uncertainty, projected trends, and 
scenario planning
4.3. Develop capacity for supporting 
the evaluation upon request, of 
law-enforcement responses to drug 
supply interventions (in close 
coordination with policy support 
provided to health interventions)
Improved law enforcement capacity to 
prevent and investigate drug-related 
crime, based on knowledge, skills and 
expertise acquired through training and 
sharing of best practices
Enhanced capacity of policymakers at 
EU and national level for combatting 
drug-related security threats
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA 
monitoring system
7. Work programme delivery
9. Uptake of the EMCDDA evidence 
(knowledge) through a number of 
channels
10. Uptake of the EMCDDA evidence/
knowledge by policymakers
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Strategic objectives Action areas Outcomes KPIs
Main area 3: Business drivers
B1. INSTITUTIONAL
Anticipate, and 
respond promptly to, 
institutional 
developments and 
needs
B1.1. Ongoing analysis of the external 
environment and how it relates to 
current and future stakeholder needs
B1.2. Configure services to ensure they 
are timely, are delivered professionally 
and in a form coherent with our 
stakeholders’ needs
B1.3. Prepare the agency for ongoing 
and potential future revisions of its 
mandate, in line with the 
recommendations of the external 
evaluation to be performed in 2018, 
and the conclusions of the evaluation 
of EU drugs Strategy and Action Plan
Increased capacity of the EMCDDA to 
meet stakeholders’ needs through 
tailored products and services which 
are provided through optimised 
communication channels
The EMCDDA is organised to respond 
to the recommendations emerging 
from the fourth external evaluation of 
the agency and other relevant 
institutional and political developments
1. Budget execution
2. Staff capacity
6. Organisational efficiency
7. Work programme delivery
9. Uptake of the EMCDDA evidence 
(knowledge) through a number of 
channels
10. Uptake of the EMCDDA evidence/
knowledge by policymakers
B2. PARTNERSHIP
Strengthen the 
European drug 
information system 
through effective 
and mutually 
beneficial 
partnerships and 
synergies with our 
data providers, 
communities of 
knowledge, and 
relevant European 
and international 
bodies
B2.1. Develop, jointly with the national 
focal points, and guided by EMCDDA 
Strategy 2025, the new Reitox Network 
Development Framework, and support 
its implementation by the NFPs
B2.2. Strengthen national drug expert 
networks and develop, if necessary, 
new networks to ensure the agency has 
sufficient expertise to accomplish the 
strategy’s objectives
B2.3. Strengthen cooperation with EU 
and international partners in line with 
work priorities defined by Strategy 
2025 and emerging stakeholders’ 
needs
Efficient coordination of the Reitox 
network to ensure improved reporting 
capacity of the NFPs and good 
performance in the implementation of 
the grant agreements
Enhanced synergies with EU and 
international bodies working in the 
drug-related areas
Increased EU capacity to address drug 
threats in EU priority third countries
1. Budget execution
2. Staff capacity
3. Implementation of the EMCDDA 
monitoring system
5. Implementation and management 
of the Reitox grant agreements
7. Work programme delivery
8. Efficient implementation of the 
technical assistance projects with 
third countries
9. Uptake of the EMCDDA evidence 
(knowledge) through a number of 
channels
10. Uptake of the EMCDDA evidence/
knowledge by policymakers
B3. SCIENTIFIC 
CAPACITY
Have in place the 
scientific capacity 
(resources, 
processes and tools) 
to meet current 
analytical needs, 
and innovate to keep 
pace with changes 
in the drug situation 
and the 
corresponding 
institutional needs
B3.1. Maintain and develop the 
EMCDDA’s scientific capacity and 
ensure it reflects the expertise required 
for the agency to fulfil its mandate
B3.2. Optimise the allocation and use 
of scientific resources through clear 
prioritisation, adoption of more flexible 
working practices and the use of 
external resources where cost-efficient
B3.3. Strengthen the quality 
management of scientific activities
B3.4. Strengthen dialogue and 
cooperation with the scientific 
community and centres of excellence 
in the drugs field to ensure that the 
EMCDDA maintains a state-of-the-art 
understanding of developments in its 
areas of competence.
Scientific capacity optimised through 
efficient use of resources and improved 
coordination of core activities
The scientific quality of the EMCDDA’s 
work is further enhanced through 
appropriate quality assurance 
measures, and provision of support and 
guidance by the Scientific Committee
Communication and exchange with 
external monitoring and scientific 
bodies and centres of excellence are 
strengthened
1. Budget execution
2. Staff capacity
6. Organisational efficiency
7. Work programme delivery
9. Uptake of the EMCDDA evidence 
(knowledge) through a number of 
channels
10. Uptake of the EMCDDA evidence/
knowledge by policymakers
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B4. MANAGEMENT
Ensure the optimal 
organisational 
structure and 
supporting 
processes, to deliver 
efficient and 
high-quality services
B4.1. Put in place the new 
organisational structure and other 
measures necessary for successful 
implementation of Strategy 2025
B4.2. Further improve cost-
effectiveness and optimal allocation of 
resources, reflecting the priorities 
identified in the Strategy 2025
B4.3. Strengthen performance 
management at all levels
B4.4. Improve people management and 
implement a sustainable staff training 
and development programme to ensure 
the EMCDDA has the committed, 
skilled and motivated human resources 
it requires to achieve its long-term 
objectives
Good performance by the EMCDDA in 
implementing the annual programming 
instrument
Sound management of the EMCDDA’s 
resources, in compliance with 
applicable rules and procedures and in 
line with organisational needs
Safe and environmentally friendly 
workplace, which prevents work 
accidents, promotes use of renewable 
energy and avoids waste of resources
Optimal level of operability of the 
EMCDDA’s ICT systems
1. Budget execution
2. Staff capacity
6. Organisational efficiency
7. Work programme delivery
Note: the core KPIs for each strategic objective are presented in bold text
TABLE A9
KPI architecture
Category Key performance indicators 
(KPI)
Performance indicators (PI)
and metrics
PI targets /
Metrics definition
Strategic 
objectives
Input 1. Budget execution 1.1. Commitment appropriations Minimum 95 % of the total commitment 
appropriations
All
1.2. Cancellation rate of payment 
appropriations
Maximum 5 % cancelled payment 
appropriations
2. Staff capacity 2.1. Occupation rate (implementation 
of the establishment plan)
At least 95 % of the establishment plan 
posts (officials, temporary agents) filled at 
the end of the year (in line with resources)
All
2.2. Staff turnover Maximum 4 % of staff leaving EMCDDA 
during the year, out of the total number of 
staff (officials, temporary agents, contract 
agents)
2.3. Average number of training days 
per staff member
Minimum of three days
Activities 
(process)
3. Implementation of the 
EMCDDA monitoring 
system
3.1. Input to the monitoring system 
via national reporting
National reporting guidelines agreed at the 
HFP meeting each autumn
H1, H2, H3, H4, 
S1, S2, S3, S4, 
B2
3.2. Availability of statistical outputs Statistical Bulletin published on the public 
website annually alongside the EDR
3.3. Feedback provided to NFPs on 
workbooks
Feedback by the HFP meeting in spring
Activities 
(process)
4. Implementation of the 
EWS and risk assessment 
mechanism on NPS
4.1. Formal notifications on NPS and 
public health related warnings issued to 
the EWS network
In line with the deadlines and criteria defined 
by Regulation EU 2017/2101 (amending 
Regulation EC 1920/2006) and the applicable 
standard operating procedures
H2
4.2. Formal reports (EMCDDA initial 
reports on NPS, and risk assessment 
reports) submitted to stakeholders (as 
appropriate)
PROGRAMMING DOCUMENT 2019–21
70 / 80
Category Key performance indicators 
(KPI)
Performance indicators (PI)
and metrics
PI targets /
Metrics definition
Strategic 
objectives
5. Implementation and 
management of the Reitox 
grant agreements
5.1. Quality organisation of the HFP 
meetings
a) 100 % of the supporting documents made 
available to the NFPs two weeks prior to the 
meetings (except for documents related to 
events occurring within this timeframe)
B2
b) Conclusions and action points disseminated 
within four weeks after the closing of the 
meetings
5.2. Execution rate (commitments) of 
the grant agreements budget
95 % of the available funding is committed for 
NFP grants
5.3. Timeliness of processing of the 
payment requests
85 % of the balance payment requests, 
submitted complete and on time, are 
successfully checked and paid by 30 June of 
year N+1
6. Organisational efficiency 6.1. Effectiveness of the Director in 
providing support to the Management 
Board (MB) for performing its tasks
a) 100 % of the supporting documents for the 
MB meetings uploaded on the MB extranet at 
least two weeks before the meetings (except 
for documents related to events occurring 
within this timeframe)
B1, B3, B4
b) Draft minutes sent to the Chair within 
a maximum of twenty working days from the 
close of the MB meetings
6.2. Effectiveness of the Director in 
providing support to the Scientific 
Committee (SC) in performing its tasks
a) 100 % of the supporting documents for the 
SC meetings uploaded on the SC extranet at 
least two weeks before the meetings (except 
for documents related to events occurring 
within this timeframe),
b) Draft minutes of the meetings sent to the 
Chair within maximum two weeks of the close 
of the meetings
6.3. Timely delivery of the documents 
supporting the strategic planning and 
programming cycle (programming 
documents and General Report of 
Activities) (as required by the EMCDDA 
founding recast Regulation)
All documents delivered within deadline
6.4. Average time of recruitment 
processes
Maximum of four months from the expiry date 
of the vacancy notice to appointment decision
6.5. Number of accidents at workplace No accidents
6.6. Efficiency in using available 
facilities, equipment and infrastructure
No increase in utility costs (as compared to 
2018)
6.7. Availability of the ICT systems a) Office supporting infrastructure availability: 
system availability superior to 95 %, office 
hours (maximum of 103 hours of accumulated 
down time over the year)
b) Corporate supporting infrastructure 
availability (web sites, web applications, Fonte, 
databases, email, security): system runs on 
a 24x7 basis with an overall availability annual 
target of minimum 99 % availability (maximum 
of 88 hours of annual accumulated down time)
6.8 Efficiency in implementing ICT 
projects
Deviation between planned and consumed 
ICT resources (defined as FTEs of ICT staff) for 
core projects
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Category Key performance indicators 
(KPI)
Performance indicators (PI)
and metrics
PI targets /
Metrics definition
Strategic 
objectives
Output 7. Work programme 
delivery
7.1. Degree of implementation of the 
2019 work programme
a) 100 % of the expected outputs/results 
listed as Level 1 priority (L1) achieved
All
b) 80 % of the expected outputs/results 
listed as Level 2 priority (L2) achieved
c) 50 % of the expected outputs/results 
listed as Level 3 priority (L3) achieved
8. Efficient implementation 
of the technical assistance 
projects with third 
countries
8.1. Efficient implementation of the 
IPA 6 project
a) Minimum 80 % of the project expected 
results are achieved (in line with the 
commitments expressed by the partner 
countries)
B2, H1, H2, S1, 
S2, S3
b) Minimum 85 % of the total budget 
committed
8.2. Efficient implementation of the 
EU 4 Monitoring Drugs
a) Minimum 80 % of the annual milestones 
achieved
H1, H2, S1, S2, 
S3, B2.
b) Minimum 70 % of the annual budget 
committed
Outcome 9. Uptake of the EMCDDA 
evidence (knowledge) 
through a number of 
channels
9.1. Audience reached through the 
website
Number of unique visitors H1, H2, H3, H4, 
S1, S2, S3, S4, 
B1, B2, B39.2. Responsiveness of the EMCDDA 
to the needs of key institutional 
stakeholders (EU institutions and 
Member States)
a) Number of institutional meetings 
attended
b) Number of requests for input/advice from 
key institutional stakeholders responded to
c) Number of the requests to visit the 
EMCDDA received from EU institutions and 
national authorities from EU Member States 
fulfilled
9.3. Contribution to major scientific 
and practice drug events
a) 100 % of the events attended (resource 
dependent)
b) 75 % of presentations delivered
9.4. Publishing of scientific articles in 
peer-reviewed journals
Impact score 30 or higher (impact score = 
the journal impact factor X the number of 
scientific articles published in 2019)
9.5. Training provided by the 
EMCDDA
Number of people trained (by categories of 
training: Reitox academies; Summer school; 
training with partners – e.g. CEPOL)
Minimum 80 % satisfaction rate (average 
score calculated based on all the training 
evaluation reports) with the Reitox 
academies
9.6. General public requests Number of public enquiries answered
9.7. Audience reached through social 
media
a) At least 5 % increase in social media 
followers
b) An average engagement rate above the 
industry standard
9.8 Audience reached through 
newsletters
a) At least 5 % increase in subscribers to 
email lists
b) An average opening and click rate above 
industry standard
9.9 Audience reached through 
videos:
a) At least 5 % increase in subscribers
b) Audience retention rate above 50 %
c) Increase of 5 % in total video views
9.10 Media reached Number of media requests answered
9.11 Visitors at the EMCDDA Number of visitors received (by categories: 
policy; practice; academia; general public)
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Category Key performance indicators 
(KPI)
Performance indicators (PI)
and metrics
PI targets /
Metrics definition
Strategic 
objectives
Impact 10. Uptake of the EMCDDA 
evidence/knowledge by 
policymakers
10.1. Council implementing decisions 
to subject NPS to control measures 
and criminal penalties throughout the 
EU (within the mechanism 
established by the Regulation EU 
2017/2101)
Defined by needs H1, H2, H3, H4, 
S1, S2, S3, S4, 
B1, B2, B3
10.2. EU policy cycle for organised 
and serious international crime for 
the period 2018–21: implementation 
OAP 2019; support to the EC and the 
Member States for formulating OAP 
2020
10.3. EU SOCTA informed by the 
EMCDDA (including through EDMR 
2019)
Defined by needs
10.4. Other EU and national policies 
and legislation, and UN documents, 
informed by the evidence produced 
by the EMCDDA
Defined by needs
10.5. Other evidence of uptake of the 
EMCDDA knowledge by policymakers 
(to be defined)
Defined by needs
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l  Annex VIII  Risks 2019
Risk factors identified for delivery of the 
2019 work programme
Likelihood of risk and respective impact on the 2019 work programme
External risks with a direct link to specific fields of the annual work programme
1. Insufficient funding of the 2019 EMCDDA 
budget
Freezing of EU funding for the EMCDDA budget was implemented for 2014, 2015 and 2016, at the 
level of EUR 14 794 000; this amount was some EUR 756 000 lower than for 2013. For 2017 and 
2018, an aggregate increase of around EUR 651 000 has been granted. Therefore, all in all, the 
value of the EU subsidy for 2018 is EUR 105 000 lower than for 2013.
In line with the EMCDDA draft budget for 2019, the value of the EU subsidy for 
2019 is EUR 15 286 600. Compared to the amount of the EU 2018 subsidy, the EC proposal for 
2019 implies a reduction of EUR 159 000. The expected amount of the EU 2019 subsidy (which 
reflects a reduction by EUR 310 000 compared to the amount entered into the EMCDDA 2019 
PDB) poses risks for resourcing some planned operational activities, such as the activities entailed 
by the required enhancement of the EMCDDA role for the coordination and development of 
ESPAD.
The budgetary situation presents a medium to high level of risk to the EMCDDA’s activities, as it 
encompasses an erosion in real terms of the value of its budget, thereby affecting the agency’s 
capacity to cope effectively with the increasing operational needs and the resulting pressure on 
the agency’s resources (see risks 2 to 5, below). This risk is compounded by the uncertainty 
surrounding the prospective UK withdrawal from the EU, in that the UK is an important net 
contributor for the EU budget.
2. Lack of adequate resources for national focal 
points (NFPs) in the Member States, which will 
impact their capacity to comply with reporting 
obligations towards the EMCDDA. This risk 
could be compounded by insufficient funding 
for core data collection in Member States (see 
3, immediately below)
All core monitoring activities could be affected, with the following main consequences: (a) 
lessened capability to identify new drug threats and developments; (b) undermining of established 
and valid time series data; and (c) reduced ability to properly report to the EMCDDA’s key partners.
The EMCDDA’s own budget constraints have led to a decrease in its grants to the NFPs. A review of 
the present national reporting package has been carried out and should continue, involving regular 
reviews of core data needs, timely feedback to the NFPs on their performance and compliance 
with reporting obligations towards the EMCDDA.
The budgetary situation in certain Member States has also led to cuts in funding of the respective 
NFPs. In particular, budget revisions performed by certain national authorities during the last 
quarter of 2016 and kept for 2017 could trigger corresponding reductions of the co-financing 
provided by the EMCDDA, which would have obvious negative consequences for the NFPs in 
question. This risk can therefore be assessed as medium to high, depending on the concrete 
situation in Member States.
3. Reduction of the reporting capacity of 
Member States, due to either lacking or 
reduced availability of core data with adequate 
quality levels
The timeliness and comprehensiveness of reporting by Member States on new threats and drug 
developments have been affected; moreover, some comparative data has been unavailable, which 
has not allowed useful analysis at European level.
The impact of this risk can be considered as medium to high and should in principle be confined to 
some Member States. Closer attention ought to be paid to reporting biases and statistical 
approaches adopted across the Member States, in order to ensure the credibility of data received. 
Additionally, monitoring of and feedback to the Member States on their reporting performance is 
ongoing and should be further developed in order to allow corrective action to be taken, wherever 
required.
4. Supplementary specific requests from EU 
institutions to provide technical support for the 
implementation of EC programmes and 
actions, particularly regarding implementation 
of Council Decision 2005/387/JHA on NPS
Supporting drug policy and technical cooperation (with EU institutions) could be affected. The 
same applies regarding the undertaking of prompt action aimed at addressing issues arising from 
harmful NPS.
In view of the high impact of harms related to NPS appearing over a short time period, monitoring 
through the EWS and, in particular, risk assessments have placed a disproportionate burden on 
the work programme; yet, legal obligations regarding performance of risk assessments along the 
lines established by Regulation (EU) 2017/2101 of the European Parliament and of the Council of 
15 November 2017 amending Regulation (EC) No 1920/2006 as regards information exchange on, 
and an early warning system and risk assessment procedure for, new psychoactive substances 
need to be complied with.
Although not legally binding, concerns also exist for requests related to new activities in the 
security area.
For the reasons above, the risk level is within the medium to high range.
5. Supplementary requests from Member 
States and third parties to provide expertise in 
specific domains
Supporting drug policy and technical cooperation (with EU institutions) could be affected.
It has been increasingly demanding to deal with the level of requests. Further increase in demand 
for this type of expertise would need additional scientific resources dedicated to it and to be 
considered in view of other work programme priorities; in this respect, there is a serious concern 
over the work overload being created in response to the number of requests addressed to the 
EMCDDA.
The risk level is presently seen as medium although on the rise.
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Risk factors identified for delivery of the 
2019 work programme
Likelihood of risk and respective impact on the 2019 work programme
External events that might have an impact on the implementation of the annual work programme as a whole
6. Natural disasters: earthquakes (leading to 
possible tsunamis), landslides or floods
The location of the EMCDDA facilities, bordering the Tagus river, raises a potential risk of being 
affected by any of these natural disasters. The likely consequences of a major earthquake are 
hardly predictable and appropriate measures would have to be taken in order to deal with the 
resulting damages. A landslide of the building caused by earthquakes, although not very likely, 
cannot be ruled out.
As regards Tagus flooding, some information available leads us to believe that the potential risk 
here would be low. On the other hand, it is conceivable that a combination of heavy rain with Tagus 
high tides could cause flooding of the underground car park. Further mitigating measures to deal 
with this risk ought to be agreed with and taken by the landlord of the EMCDDA buildings.
A very comprehensive insurance contract covering, inter alia, adverse effects from earthquakes, 
landslides and floods has been signed and renewed in 2017.
A business continuity plan (BCP) for the agency as a whole was approved in 2013 (latest update 
made in November 2017): this will help mitigate these risks and respective consequences. 
Moreover, intensive one-day earthquake emergency training was provided to security wardens; 
also, all staff have been informed on how to act if an earthquake were to occur.
7. Terrorist attacks Any activity of the EMCDDA could be affected. Recent events in some European countries, while 
isolated, raise serious issues concerning possible collateral effects of ISIS activities both in North 
Africa and the Middle East (notably, radicalisation of youngsters and further home-grown 
terrorism). A series of mitigating measures have been taken, notably: adequate insurance policies 
of premises; reinforced building protection against bomb blasts and small calibre bullets; and 
scanning of suspicious mail. Moreover, the main entrances at the EMCDDA premises have been 
redesigned in order to create a second barrier to possible intruders; the security level at the 
immediate entrance area to the garage was upgraded in order to prevent or deter entrance by 
a vehicle of would-be terrorists.
Further risk mitigation measures were implemented in 2017, notably: setting up of an access 
card-based system allowing pre-selection of persons enabled to enter the buildings; installation of 
bullet-proof glass entrances; and, equipment of outside windows with mirror film.
Installation of vehicle blockers or bollards at the entrances of ‘Praça Europa’, in order to prevent 
unverified access of vehicles, is currently under consideration.
All in all, the risk of terrorist attacks is presently assessed as medium.
Internal risks
8.1 Information technology (IT) governance 
risks, notably linked to:
a) suboptimal investment decisions in IT;
b) certain weaknesses in the management of IT 
projects; and
c) suboptimal licensing and assets 
management procedures
A large number of mitigating measures to deal with these risks have been implemented, namely:
a) elaboration of the ICT Strategy 2025, fully aligned the EMCDDA 2025 Strategy; setting up of 
a register with a categorisation of ICT investments; elaboration of detailed reports on ICT activities 
from 2010 onwards; setting up of a project and service catalogue for ICT; creation of an ICT 
investments steering committee, which reviews and controls investments in this area; 
implementation of a project portfolio management process; improved documentation of 
procedures leading to decisions taken on IT investments; coordinated set of actions to actively 
reduce the telecommunications costs; and, setting up of a shared high-speed internet access (in 
cooperation with EMSA);
b) participation of the EMCDDA in interinstitutional framework contracts; adoption of a ‘turn-key’ 
approach to projects; selection of a suitable enterprise architecture for the EMCDDA; selection of 
a fit-for-purpose project management methodology; and, definition of business and technical 
requirements for a project management platform;
c) use of suitable tools in supporting sound assets management and reliability of licensing; 
implementation of the services catalogue on the basis of the new services request management 
tool.
A wide range of additional measures and actions is expected to further reduce the existing 
medium risk levels: (a) implementation of a framework targeting investment optimisation; (b) 
implementation of ongoing contracts focusing on specialised project management roles; better 
alignment, in the light of the ICT Strategy 2025, of IT projects with our core business needs; 
implementation of the selected fit-for-purpose project management methodology; adoption and 
design of an enterprise architecture management framework; definition of a process for 
requirements management; and (c) to enhance planning and control of license and assets 
utilisation.
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Risk factors identified for delivery of the 
2019 work programme
Likelihood of risk and respective impact on the 2019 work programme
8.2 Information technology (IT) technical risks, 
notably linked to:
a) software configuration management 
problems resulting from installations of 
software not being properly planned;
b) inconsistent application of patching 
procedures, compounded by insufficient 
documentation of interventions and system 
updates;
c) difficulties in ensuring business continuity 
and swift recovery in cases of incidents or 
disasters, due to both governance related and 
technical risks; and
d) security violations, due to some lack of 
adequate procedures, policies and 
documentation in the IT area
Most relevant mitigating measures have already been implemented, such as:
a) setting up of an automatic monitoring system to deal with installed configurations; configuration 
audit exercises; implementation of technical tools addressing management of software 
configuration issues; and, conception of a ‘documentation tree’ as the basis for a future 
documentation set covering risk management, security and governance in IT;
b) ‘ad hoc’ testing of potential consequences emerging from patching procedural weaknesses and 
systematic registration of interventions performed; setting up of a definitive software library (DSL), 
indicating software versions in use and patches installed; and, extension of the scope of Windows 
7 in order to include the configuration of patching capabilities. Documentation of the processes 
used for patching in desktops has been produced;
c) adoption of an EMCDDA business continuity plan (BCP) as a whole (thus also covering IT); 
implementation of an external facility for backup tape storage; use of a framework contract for the 
backup consolidation project supporting business continuity; procurement of specialised 
assistance services in cases of emergency or disaster; documentation of key technical 
dependencies in ICT; and, completion of the first phase of the setting up of the EMCDDA business 
continuity and disaster recovery (BCDR) in Madrid (the second and final phase, dealing with the 
deployment of enterprise and corporate applications, is under way).
d) installation of network management software combined with an update of the firewall software; 
introduction of modules for intrusion detection and prevention; increased protection against 
malware and virus threats; definition of a process to control the creation, modification and 
revocation of user accounts and access profiles; approval of an information system security policy 
framework aimed at articulating the different levels of regulation on information security; review of 
user generic accounts; and, enhancement of the information security policy in key areas such as 
network security, change management and applications.
Furthermore, a comprehensive set of additional measures has been planned in order to further 
reduce present risk levels: (a) establishment of standard documentation on the EMCDDA ICT 
technical infrastructure; (b) definition of specific guidelines for patching in servers; and, alignment 
of software configurations and use of patching capabilities also on Citrix servers; (c) finalisation of 
the work started in implementing the business continuity and disaster recovery plans (BCDR 
centre in Madrid); to continue investment in documenting dependencies among key technical 
components of the EMCDDA ICT infrastructure; and (d) contracting and carrying out of telecom 
security related services, as well as external audits on sensitive areas of the EMCDDA’s core 
business (for instance, Fonte data collection application); implementing further security best 
practices regarding, inter alia, diffusion of system administrator passwords; and, periodical review 
of user access rights.
In view of the above, these IT technical risks are presently within the medium to high range.
9. Unexpected departure of key members of 
staff, which could have a negative impact on 
the quality of the scientific output of the 
EMCDDA
Given the highly specialised and technical nature of much of the agency’s work, finding suitable 
replacements can be a time-consuming task. Redeployment could prove to be unfeasible, as it 
would require the existence of a pool of staff members with very comprehensive skills and 
expertise in the areas at stake.
The present organisation of the Scientific Division has provided some back-up arrangements for all 
staff concerned, while allowing a wider decentralisation of responsibilities in this key area. Even so, 
these might turn out to be insufficient, notably in the event of long-term absence of key staff, which 
could hinder the EMCDDA’s core operations.
Investment in human resources ensures that arising needs are treated with minimum delay in 
most cases; a recruitment tool was developed by the EMCDDA with a view to further accelerating 
recruitment procedures. Job profiles have been designed with a view to recruiting staff for 
transversal tasks and facilitating sharing of knowledge and expertise within small working groups. 
A stable contracts policy with key staff, notably in scientific areas, has been pursued and ought to 
be reinforced.
In view of the mitigation measures already taken and planned, the risk level could be assessed as 
low to medium; however, this risk might be compounded by the prospective UK withdrawal from 
the EU, in that the UK is a relevant contributor for the agency staffing and ‘in house’ expertise.
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l  Annex IX  Procurement plan 2019
Pursuant to the applicable financial regulation, this annex 
indicates the procurements for non-administrative activities 
that have been envisaged for the implementation of the 
EMCDDA 2019 work programme the value of which is equal to 
or greater than EUR 60 000, to be covered by appropriations 
entered into Title 3 of the relevant EMCDDA budget.
Two procurements have been envisaged for the 
implementation of the 2019 work programme, as follows:
1) Framework service contract (open procedure) – 
Interpretation services:
Amount EUR 180 000 (4 years)
Budget line 3171-Statutory meetings
Contract to be signed in April 2019
2) External FRAMEWORK contract (specific contract under 
framework contract – European Parliament ITS14) - EDND ll 
‘European database on new drugs’:
Amount EUR 80 000
Budget line 3141-Studies-ICT
Contract to be signed in February 2019
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l  Annex X  Organisation chart 2019
Director
Alexis Goosdeel (DIR)
(TOTAL 2: 2 TA)
Unit
Public health
(HEA)
(TOTAL 5: 1 O, 2 TA, 
2 CA) 
Unit
Risks to public safety 
and security (SAS)
(TOTAL 3: 1 TA, 2 CA)
Unit
Reitox and
external partners (RTX)
(TOTAL 6: 4 TA (1 TA 
shared with HEA), 1 CA 
and 1 O (the 
EMCDDA DPO)) 
Unit
Communication
(COM)
(TOTAL 9: 1 O, 7 TA, 
1 CA)
Unit
Information and
communication
technology (ICT)
(TOTAL 5: 3 TA, 2 CA)
Unit
Resources management
and administrative 
services (ADM)
(TOTAL 5: 1 O, 3 TA, 
1 CA)
Sector
Support to policy
(TOTAL 6: 5 TA (1 TA 
shared with RTX), 1 CA)
Sector
Trends and analysis
(TOTAL 10: 6 TA, 4 CA)
Sector
Support to practice
(TOTAL 6: 1 O, 4 TA, 1 CA)
Sector
Infrastructure and
logistics
(TOTAL 4: 2 TA, 2 CA)
Sector
Financial management
(TOTAL 7: 1 O, 5 TA, 1 CA)
Sector
Human resources
management
(TOTAL 5: 2 TA, 3 CA)
Sector
Markets, crime and
supply reduction
(TOTAL 5: 3 TA, 1 CA, 
1 SNE)
Sector
International cooperation
(TOTAL 4: 1 O, 2 TA, 
1 CA shared with ADM)
Sector
Media relations
and marketing
(TOTAL 2: 1 TA, 1 CA)
Sector
Service delivery
(TOTAL 4: 4 TA)
Sector
Action on new drugs
(TOTAL 6: 3 TA, 3 CA)
Executive oce (EXO) 
TOTAL 7: 1 O, 3 TA, 3 CA 
Data Protection Ocer
(1 O shared with RTX)
Scientic coordination (SDI)
(TOTAL 4: 1 O, 3 TA)
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l  Annex XI  List of the beneficiaries of Reitox grants (national focal points)
■■ AUSTRIA: Gesundheit Österreich GmbH (Austrian Public 
Health Institute), Vienna.
■■ BELGIUM: Institute of Public Health — (IPH), Brussels.
■■ BULGARIA: National Centre for Addictions (NCA BG), Sofia.
■■ CROATIA: Vlada Republike Hrvatske — Ured za suzbijanje 
zlouporabe droga (Office for Combating Drugs Abuse of the 
Government of the Republic of Croatia), Zagreb.
■■ CYPRUS: Cyprus National Addictions Authority— CNAA), 
Nicosia. CZECH REPUBLIC: Úřad vlády České republiky 
(Office of the Government of the Czech Republic), Prague.
■■ DENMARK: Danish Health Authority, Copenhagen.
■■ ESTONIA: Tervise Arengu Instituut (National Institute for 
Health Development — NIHD), Tallinn.
■■ FINLAND: Terveyden Ja Hyvinvoinnin Laitos (National 
Institute for Health and Welfare — THL), Helsinki.
■■ FRANCE: Observatoire Français des Drogues et des 
Toxicomanies (French Monitoring Centre for Drugs and 
Drug Addiction), Saint-Denis.
■■ GERMANY: Institut für Therapieforschung (Institute for 
Therapy Research), Munich.
■■ GREECE: Εθνικό Κέντρο Τεκμηρίωσης και Πληροφόρησης 
για τα Ναρκωτικά — ΕΚΤΕΠΝ (University Mental Health 
Research Institute), Athens.
■■ HUNGARY: EMMI, Emberi Erőforrások Minisztériuma 
(Ministry of Human Capacities), Budapest.
■■ IRELAND: Health Research Board (HRB), Dublin.
■■ ITALY: Presidenza del Consiglio dei Ministri — Dipartimento 
per le Politiche Antidroga (Presidency of the Council of 
Ministers — Department for Antidrug Policies), Rome.
■■ LATVIA: Slimību profilakses un kontroles centra (Centre for 
Disease Prevention and Control of Latvia), Riga.
■■ LITHUANIA: Narkotikų, Tabako ir Alkoholio Kontrolés 
Departhamentas (Drug, Tobacco and Alcohol Control 
Department), Vilnius.
■■ LUXEMBOURG: Ministère de la Santé, Direction de la 
Santé, Service Epidémiologie et Statistique, Luxembourg.
■■ MALTA: Ministry for the Family and Social Solidarity (MFSS), 
Valletta.
■■ NETHERLANDS: Stichting Trimbos Instituut, Utrecht.
■■ POLAND: Krajowe Biuro Do Spraw Przeciwdziałania 
Narkomanii (National Bureau for Drugs Prevention), 
Warsaw.
■■ PORTUGAL: Serviço de Intervenção nos Comportamentos 
Aditivos e nas Dependências (SICAD), Lisbon.
■■ ROMANIA: Agenţia Natională Antidrog (National Anti-drug 
Agency), Bucharest.
■■ SLOVAKIA: Ministerstvo zdravotníctva Slovenskej 
republiky — MZ SR (Ministry of Health of the Slovak 
Republic), Bratislava.
■■ SLOVENIA: Inštitut za Varovanje Zdravja Republike 
Slovenije — NIJZ (National Institute of Public Health of the 
Republic of Slovenia), Ljubljana.
■■ SPAIN: Delegación del Gobierno para el Plan Nacional 
sobre Drogas (Government Delegation for the National Plan 
on Drugs — GDNPD), Madrid.
■■ SWEDEN: Folkhälsomyndigheten (Public Health Agency of 
Sweden), Östersund.
■■ UNITED KINGDOM (to be confirmed): Public Health 
England, Alcohol and Drug, London.
Full contact details are available at: www.emcdda.europa.eu/
about/partners/reitox-network
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l  Annex XII Technical assistance projects
l  IPA 6 project
The contract for the IPA 6 technical project was signed on 30 
June 2017 and the project started on 1 July 2017. It will run 
for a period of 24 months, i.e. until June 2019. The beneficiary 
countries are Albania, Bosnia and Herzegovina, the Republic of 
North Macedonia, Kosovo*, Montenegro and Serbia. The total 
budget is EUR 340 000.
l  EU 4 Monitoring Drugs project (European Neighbourhood Policy (ENP) South and East countries)
The EU 4 Monitoring Drugs project will start in 2019 and run 
for a period of 3 years (2019–21). The beneficiary countries 
are 15 out of the 16 Eastern and Southern neighbourhood 
countries of the EU: Morocco, Algeria, Tunisia, Egypt, Lebanon, 
Jordan, Libya, Palestine (**), Israel, Armenia, Azerbaijan, 
Georgia, Ukraine, Belarus, Moldova. The grant agreement 
for implementation of the respective technical proposal is 
expected to be signed in the first half of 2019 (DG NEAR). The 
total budget is EUR 3 million.
l Other projects
During 2019, the EMCDDA will submit to the European 
Commission a technical proposal for a new project to 
be funded through the EU Instrument for Pre-accession 
Assistance (IPA). This project (identified as EMCDDA-IPA7) 
aims at further integrating the IPA beneficiaries (Albania, 
Bosnia and Herzegovina, Republic of North Macedonia, 
Kosovo*, Montenegro and Serbia) into the activities of the 
EMCDDA and the Reitox network. It is estimated that the 
execution of the project will start on 1 July 2019 and will cover 
a period of 24 months. The appropriations to be allocated from 
the EU budget for the execution of the whole project amount to 
EUR 550 000.
(*) This designation is without prejudice to positions on status, and is in line with 
UNSCR 1244 and the ICJ Opinion on the Kosovo declaration of independence. It 
applies to all mentions of Kosovo in this document.
(**) This designation shall not be construed as recognition of a State of Palestine 
and is without prejudice to the individual positions of the Member States on this 
issue.
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